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Abstract 
Osteoarthritis affects millions of people globally, with damage to articular cartilage causing pain 
and altered mechanics during articulation. The treatment for late stage osteoarthritis is surgical 
intervention ultimately leading to total joint replacements. These treatments are not ideal for 
younger or more active patients so there is a clinical need for an early stage intervention 
treatment to reduce or stop the progression of osteoarthritis. It has been reported that there 
is a correlation between the loss of glycosaminoglycans (GAGs) from within osteoarthritic 
cartilage and the changes in biomechanics of the cartilage. It is hypothesized that the re-
introduction of GAGs into early stage osteoarthritic cartilage through the use of permanent 
linkage and integration into a self-assembling peptide hydrogel matrix which could penetrate 
the cartilage tissue would potentially restore the resistance to deformation observed in 
osteoarthritic cartilage. 
Initially synthetic self-assembling peptide-chondroitin sulfate (CS) conjugates were synthesized 
through utilizing copper-catalyzed click chemistry and subsequently characterized.  
The chosen peptide-CS conjugates were then incorporated into self-assembling peptide 
hydrogels and the morphologies and gel properties were investigated and evaluated in terms 
of the closest resemblance to the natural properties of the surrounding cartilage into which the 
hydrogels would be eventually injected.  
The best hydrogel candidates were then taken forward to be injected into a GAG depleted early 
stage osteoarthritic porcine cartilage model developed by Andres Barco (University of Leeds) 
where a severely GAG depleted state had been produced through a succession of surfactant 
and phosphate buffered saline washes. The hydrogels were doped with fluorescently labelled 
material which integrated into the hydrogel matrix, then injected into the cartilage tissue in a 
monomeric state. The hydrogels then self-assembled in situ and the deformation of the tissue 
was measured through creep indentation. The introduction of the peptide-CS conjugate 
showed significant restoration of resistance to deformation. 
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Chapter 1  
Introduction 
1. General Introduction 
Cartilage is a connective tissue, which is found throughout the body, in particular surrounding 
hard tissues such as bone. The tissue has a sparse cell distribution of chondrocytes, contributing 
only a small volume within adult tissue (Foundation, 2002), which are found within an 
extracellular matrix (ECM) mainly comprised of collagen, proteoglycans (PGs) such as aggrecan, 
glycosaminoglycans (GAGs) such as chondroitin sulfate (CS) and hyaluronan and water. It can 
be described as a “stiff, inelastic tissue” (Fisher, 2013). Unlike other tissues, it is avascular, 
alymphatic and aneural and thus it has a low nutrient influx which is maintained through 
physical processes such as diffusion and mechanical stimulation – compression and expansion. 
This lack of blood supply gives rise to the low regenerative nature of cartilage after injury and 
damage (Jahn et al., 2016). 
There are different types of cartilage: hyaline, elastic and fibrocartilage (Lee, 2007).  Hyaline 
cartilage is found in the endplates of vertebrae, intervertebral discs and articulating joints – 
where it is known as articular cartilage. Elastic cartilage is found within tendon and ligament 
insertion sites such as found around the knee and the outer ear. Fibrocartilage is the type of 
cartilage found within the annulus fibrosis of interverterbral discs as well as the menisci in the 
knee joint, but as discussed later on it can form after trauma and surgery to articular cartilage. 
Each type of cartilage has a different basic function and thus has a different composition in 
terms of the components found within the ECM (Eslahi et al., 2016). Hyaline or articular 
cartilage is mainly responsible for providing the near frictionless surface necessary for 
diarthrodal joints to function correctly and efficiently. The function of elastic cartilage is to 
support and maintain the shape and form of the tissue surrounding it. The function of 
fibrocartilage is to provide a very flexible and compressible basis for other tissue types to form 
around, in the case of the annulus fibrosis for example. 
In terms of extracellular components, hyaline cartilage consists of mainly collagen and PGs such 
as aggrecan, while elastic cartilage incorporates elastic fibres such as elastin. Fibrocartilage is 
similar to hyaline cartilage in consisting predominately of collagen and PGs but the proportions 
of each differ, in that it has a lower proteoglycan and higher collagen content (Verma, 2001, 
Bhattacharjee et al., 2015).  
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1.1 Hyaline articular cartilage 
1.1.1 Function of hyaline articular cartilage 
Hyaline articular cartilage is the predominant type of cartilage found within articulating joints 
such as the knee. It provides protection between the two articulating surfaces of the bones 
from abrasion due to its near frictionless properties thus ensuring a smooth movement of the 
bones over one another and helps minimise the impact damage experienced by the joint during 
situations such as jumping and/or falling by distributing the weight evenly over the joint instead 
of on a specific point of the joint (Pearle, 2005, Sophia Fox, 2009). 
1.1.2 Composition and structural features of hyaline articular cartilage 
Articular cartilage comprises two different components in essence: a solid component and a 
fluidic component, where the interactions between these two components are paramount in 
determining the mechanical properties and in turn the function of articular cartilage. 
The fluidic component is water at physiological pH ~ 7, along with physiological concentrations 
of ionic solutes such as Na+, K+, Ca2+ and Cl- which are summarised in Table 1.1 (Kienle et al., 
2015, Boettcher et al., 2016). 
Species Concentration in 
Superficial Zone (mM) 
Concentration in Deep 
Zone (mM) 
Ref. 
Na+ 210-230 260-320 (Kienle et al., 
2015, Urban, 
1994) 
K+ 7 9-11 
Ca2+ 4-6 8-15 
Cl- 100-110 70-90 
Table 1.1: The concentration ranges for various ionic solutes found within the superficial and deep zones of 
articular cartilage. 
This contributes to 75-80% of the wet weight of articular cartilage (Maroudas, 1979). The solid 
component consists of approximately 1-2% chondrocytes but depending on the source 
chondrocytes may contribute up to 10%, up to 95 % collagen – mainly type II, 3-10% PGs, ~10% 
lipids and small amounts of glycoproteins – which are polypeptide chains functionalised with 
carbohydrate groups typically found on cellular membranes (2004, Saltzmann, 2004). 
1.1.3 Collagen 
Collagen is the most abundant structural protein found in articular cartilage and accounts for 
approximately 90 – 95 % of the dry weight of cartilage. There are various types of collagen with 
different structures depending on the tissue location. 
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The various types of collagen all have the same fundamental unit within the structure: a triple 
helical motif that forms through the molecular interactions between three polypeptide chains. 
Each of the polypeptide chains consists of ~1000 amino acid residues, and each type of collagen 
has a specific set of three polypeptide chains within its makeup (Pearle, 2005, Ofek et al., 2008, 
Saltzmann, 2004). There are no fewer than 29 different polypeptide chains which make up the 
15 distinct types of collagen found within cartilage including types I, IV, V, VI, IX and XI in small 
amounts (< 5%) and type II. Each polypeptide chain consists mainly of glycine and proline 
residues and hydroxyproline helps stabilise the structures (Saltzmann, 2004, Hunziker et al., 
2015). 
Collagen is produced by chondrocytes. The cells secrete procollagen molecules which undergo 
enzymatic cleavage within the extracellular environment to form a triple helix. The triple helices 
can undergo further organisation via inter and intra molecular bonds such as hydrogen bonding 
from hydroxyproline residues and disulfide bridges from cysteine residues to form fibrils and 
fibres, which are stabilised by crosslinking between lysine residues (Ofek et al., 2008, Pearle, 
2005). A schematic showing the production of collagen and the various intermediates is shown 
in Fig 1.1. 
 
Fig 1.1: A schematic showing the various intermediate structures during collagen production, as well as typical 
dimensions. 
Fibril forming types of collagen include type I, II and III. Type II is the collagen predominately 
found in articular cartilage accounting for 60 % of the dry weight. It is made up of three α1 (II) 
polypeptide chains and consists of high levels of 4-hydroxylysine and carbohydrate. These fibrils 
are thinner than those formed by type I collagen (Ofek et al., 2008, Pearle, 2005). Type I collagen 
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consists of two α1(I) chains and one α2(I) chain, and features low levels of 5-hydroxylysine and 
carbohydrate and the fibrils formed are broad. Type III collagen differs from the previous two, 
in that it is made up of three α1(III) chains but has high levels of 4-hydroxyproline and low levels 
of 5-hydroxylysine and carbohydrate but this type is not found within articular cartilage tissue 
and is found mainly in elastic cartilage within skin, blood vessels and internal organs (Pearle, 
2005, Hosseininia et al., 2016). 
Articular cartilage also contains other collagen types that form fibrils and globular like structures 
such as types V, VI, IX and XI (Pearle, 2005, Saltzmann, 2004, Hunziker et al., 2015). The roles of 
these types of collagen are still not fully understood but hypotheses have been put forward to 
suggest that they play a role in interactions between molecules and help modulate the 
macrostructure of collagen type II (Saltzmann, 2004) Type X, which is found predominately 
within calcified cartilage (see below), appears to be involved in the process of cartilage 
mineralisation at the interface between the cartilage and the underlying subchondral bone 
(Ofek et al., 2008, Pearle, 2005, Saltzmann, 2004).  
1.1.4 Glycosaminoglycans and proteoglycans 
Glycosaminoglycans (GAGs) are high molecular weight polysaccharides which, due to being 
heavily sulfated, are negatively charged. Every GAG is a poly (disaccharide) of two regularly 
repeating sugar residues which are characteristic of the GAG (Fajardo et al., 2014). The different 
sugar residues of the GAGs found within articular cartilage as well as other characteristics 
associated with each GAG are summarised in Table 1.2. 
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GAG MW (kDa) Residue A Residue 
B 
Sulfated Covalently 
Linked to 
proteins 
Contains 
other sugar 
residues 
Tissue 
Hyaluronic 
Acid 
4 – 8,000 D-
glucuronic 
acid 
N-acetyl-D-
glucosamine 
- - - Cartilage, 
synovial fluid, 
connective 
tissue, 
vitreous 
body, skin 
Chondroitin 
Sulfate 
5 – 50 D-
glucuronic 
acid 
N-acetyl-D-
galactosamine 
+ + + Cartilage, 
skin, cornea, 
bone, 
arteries 
Keratan 
Sulfate 
4 - 19 D-galactose N-acetyl-D-
glucosamine 
+ + + Cartilage, 
intervertebral 
discs, cornea 
 
Table 1.2: The different types of GAGs found in articular cartilage and their associated characteristics,  where 
residue A and B refer to the repeating units within a polysaccharide chain and where +/- indicates the presence 
or absence of the described characteristic (Adapted from Saltzmann, 2004 with permission from Oxford 
University Press). 
Most sulfated GAGs contain other sugar residues, which creates further complexity in the linear 
chemical structure. GAGs are unbranched, inflexible but very soluble in water, allowing 
adoption of a random coil conformation. This conformation allows the GAGs to occupy a large 
volume in aqueous media. Each GAG chain extends within the space and interacts with other 
GAG chains to form further structures, thus causing the formation of highly hydrated gels at 
relatively low concentrations of GAGs. In physiological aqueous media, counter ions such as Na+ 
surround the sulfated GAG chains, creating an osmotic pressure which pulls further water 
molecules into the gel. Due to this action, tissues such as cartilage which are high in sulfated 
GAGs have high resistance to compression (Athanasiou, 2009, Pearle, 2005, Saltzmann, 2004). 
With the exception of hyaluronic acid, GAGs covalently bind to a core protein forming 
macromolecular structures called proteoglycans. 
Proteoglycans are one of the largest groups of macromolecules in the ECM, representing 
between 10-15% of the wet weight. Each proteoglycan can consist of one or more GAG types, 
such as aggrecan which consists predominately of chondroitin sulfate and a smaller quantity of 
keratan sulfate that are covalently bound to a core protein through linker proteins. Aggrecan 
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consists of ~ 130 GAG chains, and the molecular weight of the core protein is 210kDa 
(Athanasiou, 2009, Pearle, 2005, Saltzmann, 2004). The global structure of aggrecan, in a 
schematic form, is shown in Fig 1.2. 
 
Fig 1.2: A schematic representation of aggrecan, G1, G2 and G3 represent globular domains involved in 
chondrocyte apoptosis, binding of hyaluronan, cell adhesion and aggregation.  
Aggrecan is the most abundant and largest proteoglycan found within articular cartilage, and it 
is characterised by the ability to further assemble by aggregating with hyaluronic acid through 
linker proteins to form large proteoglycan aggregates. 
Aggrecan fills the interfibrillar space of the articular cartilage ECM, and due to the negative 
charge on the GAG chains and the counter ions, the osmotic pressure formed – called the 
Donnan osmotic pressure, is critical to the compressive resistance of articular cartilage. This 
negative charge is called a “fixed charge density” when applied to the cartilage ECM, and the 
osmotic pressure imbibes fluids into the tissue to help maintain equilibrium (Athanasiou, 2009, 
Pearle, 2005, Saltzmann, 2004). The equilibrium is between the swelling of the tissue by the 
influx of fluids and the restraint imposed by the inelastic nature of the collagen network. When 
the cartilage is loaded, after the load has been displaced the fluid within cartilage is restored to 
equilibrium and this helps dissipate the force throughout the entire tissue. This is explained by 
the biphasic theory which will be discussed in later sections (Athanasiou, 2009, Pearle, 2005, 
Saltzmann, 2004). 
This equilibrium is also important to the functional properties of cartilage when under pressure 
since function is highly dependent on the fluid pressure within the tissue (Athanasiou, 2009, 
Pearle, 2005, Saltzmann, 2004). Due to the fact that GAGs give rise to this osmotic pressure, a 
loss of GAGs would result in a loss of fluid pressure within the tissue, therefore impairing the 
mechanical function of the cartilage (Saltzmann, 2004; Pearle et al., 2005; Athanasiou et al., 
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2009). This breakdown in function has been reported in advancing stages of diseases such as 
osteoarthritis which will be discussed in later sections (Athanasiou, 2009, Pearle, 2005, 
Saltzmann, 2004). 
Articular cartilage contains other proteoglycans which do not form aggregates, and are 
characterised by the ability to interact with the collagen network. These proteoglycans include 
decorin, biglycan and fibromodulin, which are all smaller than aggrecan but are present in 
similar molar quantities to aggrecan (Athanasiou, 2009, Pearle, 2005, Saltzmann, 2004). These 
all have similar protein structures, only varying in the GAG composition and the function of the 
proteoglycan. Biglycan and decorin possess 2 and 1 dermatan sulfate, another type of GAG, 
respectively, while fibromodulin possesses multiple keratan sulfate chains (Athanasiou, 2009, 
Pearle, 2005, Saltzmann, 2004). The function of each differs; decorin and fibromodulin interact 
with type II collagen fibrils in the ECM and are involved in fibrillogenesis and the interactions 
between fibrils. Biglycan on the other hand is found around chondrocytes and interacts with 
collagen type VI (Athanasiou, 2009, Pearle, 2005, Saltzmann, 2004). 
1.1.4.1 Chondroitin sulfate 
Chondroitin sulfate is the most abundant GAG in articular cartilage, which, as shown in Table 
1.2,  is made up of two repeating saccharide molecules: D-glucuronic acid and N-
acetylgalactosamine. The two saccharides are linked through an α(1→3) covalent bond, where 
the 1 and 3 represent the carbon bearing the oxygen through which the bond forms. Each of 
the repeating disaccharide molecules are linked through either a β(1→4) or β(1→3) covalent 
bond (Bali, 2001). The core structure of chondroitin sulfate is shown in Fig 1.3. Chondroitin 
sulfate gains the sulfate part of its name from the fact the galactosamine residues are sulfated 
in one of two places; position 4 or position 6 giving rise to two different isomers of chondroitin 
sulfate – chondroitin 4 sulfate and chondroitin 6 sulfate. The ratio of these two isomers is 
different depending on the type of cartilage as well as the age and health of the cartilage. As 
cartilage ages, the amount of these saccharide molecules that are sulfated in the two positions 
changes. In adolescent cartilage, there is up to a four times greater concentration of the 4- 
sulfated chondroitin sulfate in the deeper regions of the cartilage compared to the upper 
residues. This changes as the cartilage matures and ages with the predominant residue 
becoming chondroitin 6 sulfate rather than chondroitin 4 sulfate (Bali et al., 2001, Bayliss, 
1999).  
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Fig 1.3: The basic structure of chondroitin-6-sulfate. 
1.1.5 Other molecules 
Articular cartilage, in addition to collagen, GAGs and proteoglycans contains small amounts of 
noncollagenous proteins such as fibronectin, tenascin, cartilage oligomeric protein, 
chondrocalcin, superficial zone protein, thrombospondin and matrix-GLA (glycine, leucine, and 
alanine) protein (Athanasiou, 2009, Pearle, 2005, Saltzmann, 2004), lipids, phospholipids, 
glycoproteins and inorganic crystal compounds such as hydroxyapatite within calcified cartilage 
(Athanasiou, 2009, Pearle, 2005, Saltzmann, 2004, Bhattacharjee et al., 2015). The functions of 
these components are unclear currently, but theories exist speculating that they are involved 
in organising and maintaining the macromolecular structure of the ECM.  
1.1.6 Microstructure and extracellular matrix of articular cartilage 
As discussed above, the make-up of articular cartilage ECM consists of a varying amount of 
collagen, proteoglycans and non-collagenous proteins (Fisher, 2013). The biomechanical 
properties of articular cartilage are aided by organisation of the tissue structure which 
comprises of the pericellular, territorial and inter-territorial matrices. The force being exerted 
upon the tissue is transmitted throughout the three matrices before reaching the chondrocytes, 
thus assisting in regulating the strains observed at the cellular level (Athanasiou, 2009).  
1.1.6.1 Pericellular matrix 
The pericellular matrix is a thin layer encapsulating the cell membrane of chondrocytes within 
articular cartilage. It comprises fine collagen fibres, a high concentration of proteoglycans, some 
glycoproteins, other noncollagenous proteins, and a small amount of fibronectin and collagen 
type VI (Athanasiou, 2009, Sophia Fox, 2009, Wilusz et al., 2014). The precise function of the 
matrix is currently unknown but evidence indicates it may have two functions: 
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1. Protect the physical integrity of the articular chondrocytes during compressive loading 
(Athanasiou, 2009). 
2. Play a functional role of initiating  signal transduction within articular cartilage when 
load bearing (Sophia Fox, 2009). 
1.1.6.2 Territorial matrix 
The territorial matrix surrounds the pericellular matrix and is thicker and comprises similar 
molecular components to the surrounding extracellular matrix, predominantly collagen type II 
and proteoglycans (Athanasiou, 2009, Hosseininia et al., 2016). The amount of proteoglycans in 
the territorial matrix is higher than the surrounding extracellular matrix. The collagen structure 
is also finer, forming a basket-like network around the chondrocytes (Sophia Fox, 2009). The 
function of the territorial matrix is thought to be to protect the chondrocytes from mechanical 
stresses and it may be partially responsible for the resilience of the articular cartilage structure 
and its resistance to high loads (Sophia Fox, 2009). 
1.1.6.3 Inter-territorial matrix 
The inter-territorial matrix is the largest of the three matrices, contributing to the 
biomechanical properties of the tissue (Sophia Fox, 2009), (Athanasiou, 2009, Hosseininia et al., 
2016). It comprises large collagen type II fibres orientated in different planes depending on the 
zone of the inter-territorial matrix; parallel to the surface in the superficial zone, obliquely in 
the middle zone and perpendicular to the surface in the deep zone (Sophia Fox, 2009), 
(Athanasiou, 2009). The concentration of proteoglycans varies within this matrix; depending on 
the zone (Sophia Fox, 2009), (Athanasiou, 2009).  
1.1.7 Macrostructure of articular cartilage 
Hyaline cartilage has a macro structure in which, morphologically, there are four separate zones 
as mentioned above, in increasing depth: the superficial zone, transitional zone, middle or deep 
zone and calcified cartilage zone (Bhosale, 2008, Pearle, 2005, Athanasiou, 2009, Gaut and 
Sugaya, 2015). 
The composition and structure of the extracellular matrix along with the composition, structure 
and function of the chondrocytes within each zone changes due to the different roles each plays 
within the whole cartilage structure (Bhosale, 2008). The macrostructure of articular cartilage 
is illustrated in Fig 1.4. 
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Fig 1.4: The macrostructure of articular cartilage, with the chondrocyte morphology and localisation (A) and 
collagen orientation (B) of the corresponding zone show (reproduced from Jazrawi et al., 2011 with permission 
from Journal of the American Academy of Orthopaefic Surgeons). 
1.1.7.1 Surface – lamina splendens 
The surface of articular cartilage, ranging from between hundreds of nanometres to several 
microns, is covered by a proteinaceous layer called the lamina splendens (Athanasiou, 2009). 
The lamina splendens is an acellular, predominantly non-fibrous region, the function of which 
is not precisely known but there are several hypotheses which have been suggested ranging 
from an added layer of protection for the cartilage surface through supporting proteins involved 
in lubrication such as lubricin, hyaluronan-aggrecan aggregates, collagen type II and fibronectin 
through to acting as a surface anchor for collagen networks to form microstructures within the 
cartilage structure called arcades of benninghoff (Athanasiou, 2009, Glowacki and Thornhill, 
Andresen Eguiluz et al., 2015).   
1.1.7.2 Superficial zone 
The superficial zone (SFZ) or tangential zone, as it is sometimes called, is the upper most region 
of articular cartilage. This zone is reported to protect the deeper zones from damage caused by 
sheer, tensile and compressive forces and stresses (Sophia Fox, 2009). One theory behind how 
this zone may protect the deeper zones is through the collagen fibril content and alignment. 
Here the fibres have a small diameter and are densely packed and are orientated in a highly 
ordered fashion parallel to the articular surface (Athanasiou, 2009, Pearle, 2005, Sophia Fox, 
2009). 
The collagen in this zone is mainly type II and IX (Sophia Fox, 2009). The appearance, shape and 
function of the chondrocytes within this region also contributes to the protecting function as 
SFZ (10%-20%) 
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the chondrocytes are small in size and are flattened with a parallel orientation to the surface 
(Kheir, 2009, Gaut and Sugaya, 2015). 
The chondrocytes in the superficial zone express proteins which have a lubricating and 
protective function specifically superficial zone protein (SZP), while secreting relatively low 
levels of proteoglycans (Pearle, 2005). The majority of the tensile properties of articular 
cartilage result from this region, where the compressive modulus is the lowest of the zones and 
can deform up to 25 times more than the zone below it – the transitional or middle zone. 
1.1.7.3 Transitional zone 
The transitional or middle zone acts as a “functional and anatomic bridge” (Sophia Fox, 2009) 
between the superficial and deep zones by being the first line of resistance to compressive 
forces. The compressive modulus is higher compared to the superficial zone, partially due to 
the orientation of the collagen fibrils that are also thicker than the superficial zone fibrils. The 
less organized arrangement is exhibited by an “arcade-like structure” (Athanasiou, 2009) 
interspersed with random obliquely orientated fibres (Athanasiou, 2009, Pearle, 2005, Sophia 
Fox, 2009). 
The amount of proteoglycans is at a higher level in the middle zone and the shapes of the 
chondrocytes are different. The chondrocytes are larger; more rounded and arranged either 
singly or in isogenous groups, but the density of the cells is lower than in the superficial zone 
(Athanasiou, 2009, Pearle, 2005, Sophia Fox, 2009, Kheir, 2009). 
1.1.7.4 Deep zone 
The deep zone is the last purely hyaline tissue region. It provides the majority of the 
compressive force resistance, which arises from the orientation of the collagen fibrils which are 
larger in diameter and sit in a perpendicular orientation to the surface with anchors to the 
subchondral bone lying underneath (Athanasiou, 2009, Pearle, 2005, Sophia Fox, 2009). 
The amount of proteoglycans is at a maximum in the deep zone, while having the lowest water 
content and cell density.  The chondrocytes in the deep zone are larger and group into a 
columnar organization, being parallel to the collagen fibres and perpendicular to the joint 
surface (Athanasiou, 2009, Pearle, 2005, Sophia Fox, 2009, Kheir, 2009, Gaut and Sugaya, 2015).  
1.1.7.5 Calcified cartilage zone 
There is a thin line between the deep zone and the calcified zone called the “tidemark” 
(Athanasiou, 2009, Pearle, 2005, Sophia Fox, 2009). The calcified zone is where the tissue 
undergoes a transition into subchondral bone, and aids in maintaining the structural integrity 
of the articular cartilage by securing the collagen fibrils of the deep zone to the subchondral 
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bone underneath (Athanasiou, 2009, Pearle, 2005, Sophia Fox, 2009). It minimises the stiffness 
gradient experienced between stiff, rigid bone and softer, more pliable cartilage (Athanasiou, 
2009, Pearle, 2005, Sophia Fox, 2009). The chondrocytes scarcely populate this region and are 
in a state of hypertrophy (Athanasiou, 2009, Pearle, 2005, Sophia Fox, 2009, Kheir, 2009). 
1.1.8 Lubrication mechanism of hyaline cartilage 
In articulating joints, despite the resistance articular cartilage has inherently due to its structure, 
there is a need for lubrication. The joint comprises of three components: the two corresponding 
ends of the bone involved in the joint and the synovial fluid and membrane. The synovial fluid 
is a non-newtonian fluid that surrounds the joint and is involved in lubricating the joint to 
achieve two main objectives: help dissipate the force experienced when the joint is under 
loading and to help dissipate the heat generated through friction during articulation. The actual 
mechanism through which the synovial fluid and cartilage surface interact to achieve adequate 
lubrication has been studied and developed over many decades (Majd et al., 2014, Daniel, 
2014). 
1.1.8.1 Fluid film lubrication 
Various theories have been proposed over the years on how articular cartilage undergoes 
lubrication during articulation. These theories originated with the fluid film lubrication regime, 
and its subsequent variations, which were proposed initially in 1886 by Reynolds (Reynolds, 
1886). The basic idea of the regime was that the synovial fluid supported the entire joint when 
articulation occurred thus lubricating the joint and preventing contact from occurring (Jin and 
Dowson, 2011). This mechanism regime occurs when two articulating surfaces are partitioned 
entirely by a film of thin fluid which enables the joint to articulate while experiencing very low 
friction. 
As fluids are incompressible, when a pressure is applied the fluid supports the load experienced 
by the surfaces. One key feature for this mechanism to work is that the thickness of the fluid 
film is at least three times greater than the height of the combined surface projections or 
asperities.  
Over the past seven decades, there have been five variations of the fluid film regime proposed: 
hydrodynamic (Ateshian et al., 1997, Dowson, 1967), elasto-hydrodynamic/micro-
elastohydrodynamic (Dowson and Jin, 1986, Daniel, 2014), squeeze film (Ateshian et al., 1997), 
boosted (Walker et al., 1968; Langfield et al., 1969) and weeping/hydrostatic lubrication 
(McCutchen, 1959).   
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1.1.8.2 Boundary lubrication 
The inherent problem with the fluid film lubrication regime theory was highlighted by Sir John 
Charnley in 1960 (Charnley, 1960). He proposed that the speeds and loads experienced within 
the joint were not appropriate to generate a hydrodynamic lubricating film. He in turn proposed 
the boundary lubrication regime (Jin and Dowson, 2011). The basic idea of the boundary film 
regime is that instead of the synovial fluid supporting the whole joint, the fluid interacts with 
molecules produced during articulation because the local pressure exerted on the joint causes 
thermal degradation of the surface. The mono or multilayer of synovial fluid is adsorbed on to 
the surface which prevents direct contact of the surfaces to occur. Boundary lubrication regime 
takes over from fluid film when the combined surface roughness of the surfaces is greater than 
the thickness of the fluid film. Synovial fluid comprises of many different molecules, in particular 
hyaluronic acid (Gomis et al., 2004, Kobayashi et al., 2004, Lohmander et al., 1996, Puhl et al., 
1993), lubricin (Jay et al., 2007, Schumacher et al., 1994), surface phospholipids (Basalo et al., 
2007a, Forsey et al., 2006, Ozturk et al., 2004) and chondroitin sulfate (Basalo et al., 2007a). All 
of these, apart from chondroitin sulfate, have been proposed to be responsible as the lubricant 
responsible for this regime and studied in great detail. Chondroitin sulfate has been studied the 
least (Daniel, 2014).  
1.1.8.3 Mixed lubrication 
Mixed lubrication was proposed to explain how synovial joints are lubricated through a 
combination of both fluid film and boundary lubrication regimes. 
The two different regimes were combined in 1967, when Dowson (Dowson, 1967) noticed a 
combination of the two regimes was probably responsible in equal parts: the film fluid regime 
involved in entraining and squeeze-film actions and the boundary film regime protecting the 
surface during extreme loads or during periods of inactivity (Jin and Dowson, 2011). The fluid 
film regime dominates until it breaks down when extreme or unfavourable loading conditions 
are experienced and then boundary lubrication dominates to help maintain the low friction 
between surfaces.  
This is the most probable mechanism by which synovial joints are lubricated when under normal 
physiological conditions, but the other mechanisms may come into play under non-
physiological or extreme loading conditions (Zhang et al., 2015).  
1.1.8.4 Biphasic model 
The previous lubrication regimes were based at the level of the synovial joint, being influenced 
by the composition and biochemical makeup of the joint surfaces. The biphasic lubrication 
model is based upon the intrinsic properties and structure of the articular cartilage itself. The 
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reason for this mechanism being termed biphasic is that articular cartilage is considered to have 
two distinct phases; a solid phase which constitutes a collagen-proteoglycan network, and a 
fluid phase which is the interstitial fluid (Zhang et al., 2015). 
The biphasic model is a two component version of the mixed lubrication model.  It was 
formulated by Mow et al in 1980 (Mow, 1980) based on the idea of interstitial fluid within 
cartilage being involved in the load bearing properties as proposed in 1959 by McCutchen 
(McCutchen, 1959). The model is based on the collagen-proteoglycan matrix being proposed to 
be intrinsically incompressible and a porous-permeable solid with the interstitial fluid modelled 
as an incompressible fluid (Ateshian et al., 2004).  
The physical properties of the solid phase were assumed to be linearly elastic and permeable 
with a constant value throughout the entire tissue. The permeability was later modified to 
include strain-dependent permeability to improve the model (Lai et al., 1991). The reason 
articular cartilage is well suited to the biphasic regime is it is highly porous with pore sizes 
<10nm (Dowson, 1990). 
The solid collagen-proteoglycan network is highly charged which allows the permeability to be 
very low < 10-15m4Ns-1 (Ateshian et al., 1997). The interstitial fluid, which moves upon exudation 
when under load, has a large drag force when flowing. These forces cause pressurisation of the 
interstitial fluid and allow it to be capable of bearing a load until the load pushes all the fluid 
into the unloaded regions. This then causes the solid collagen-proteoglycan phase to take over, 
which allows a low friction coefficient during motion to be maintained until the interstitial fluid 
can be regenerated to support the load again. 
1.1.8.5 Triphasic model 
The biphasic model was expanded further by Lai et al in 1991 (Lai et al., 1991) to include 
proteoglycans. The negatively charged proteoglycans are modelled as a negative charge density 
which is fixed to a solid matrix and the corresponding counter ions in the interstitial fluid 
modelled as additional fluid phases (Huang et al., 2005, Mow and Huiskes, 2005). The counter 
ions consist of monovalent cations present in the interstitial fluid that balance the negative 
charge on the collagen-proteoglycan network. The addition of this phase allowed greater 
accuracy when modelling and predicting cartilage tissue deformations (Lu, 2004). The different 
phases and the corresponding aspects within cartilage are shown in Fig 1.5. 
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Fig 1.5: The different phases associated with the triphasic model, where for the biphasic model only the Fluid 
and Solid components are modelled. 
From researching the various studies and results of these different components, the consensus 
of this author is that neither one of these components is the sole lubricant that allows boundary 
lubrication to occur. It is also this author’s opinion that the lubrication regime responsible for 
lubricating articular joints is in fact the mixed lubrication regime as shown in Fig 1.6. During 
locomotion and articulation of the joint, there is a steady ingress and egress of synovial fluid 
within the joint which is explained through elastohydrodynamic lubrication – which is the 
extension and compression of components such as GAGs and proteins such as lubricin from the 
exertion of pressure upon the fluid (Daniel, 2014). However once locomotion has ceased and 
the joint becomes stationary the flow of synovial fluid ceases. When motion occurs again there 
is a “start-up” phase where different lubrication regimes are hypothesized to be involved. A 
mixed regime occurs to begin with where a combination of boundary and gel hydration 
lubrication occurs which ultimately leads to a weeping type lubrication regime to occur. It is 
these varying regimes that make the overall lubrication of cartilage so efficient and effective 
during locomotion. 
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Fig 1.6: The various lubrication regimes association with articulation of articular joints (reproduced from 
http://bio.mech.kyushu-u.ac.jp/SPR/research-en.html, accessed 20/07/2014Đ 
1.1.9 Wear of cartilage 
Articular cartilage can wear through two mechanisms: mechanical and biochemical.  In the basic 
definition wear is the removal of material from a surface or object through a repeating 
mechanical action of the surface against another surface or object. 
This applies to articular cartilage due to the fact it is a “mechanical” joint in terms of the 
mechanics involved during articulation, but due to it being a biological tissue it can degrade 
through disease or due to biochemical agents. This may relate to the disruption of the collagen 
network, loss of proteoglycans or changes in the ionic equilibrium in both the tissue and 
synovial fluid. 
Normal articular cartilage can undergo years of articulation with minimal wear due to the 
various features it possesses and mechanisms of lubrication. When abnormal conditions are 
applied to the tissue and/or joint such as trauma, disease or excessive biomechanical loading 
then the tissue cannot respond to the changes and wear occurs which can lead to irreparable 
damage. 
1.1.9.1 Mechanical wear 
There are two types of wear that articular cartilage may be subject to: fatigue wear and 
interfacial wear. 
Fatigue wear is independent of the lubrication regime involved in the joint as it has been 
reported to occur because of cyclic stresses and strains that the application of repetitive loading 
causes during motion. The typical human joint undergoes 1-3 million cycles annually, and these 
17 
 
 
 
repetitive cycles have been shown to cause cyclic stresses and strains to form which can cause 
failure in the bulk material (Cawston and Wilson, 2006, Kienle et al., 2015).  
The stresses and strains cause disruptions in the bone and cartilage structure which starts a 
cascade of reactions that potentially end with the onset of osteoarthritis as described below 
(Cawston and Wilson, 2006). The disruptions in the bone and cartilage result from interfacial 
wear. 
Interfacial wear is when two or more surfaces come into proximity and solid-solid contact 
occurs. There are two types of interfacial wear: adhesive wear and abrasive wear (Cawston and 
Wilson, 2006). Adhesive wear occurs when two opposing surfaces form a junction when contact 
is made. When the junction is stronger than the inherent cohesive strength of each material 
then particles of the weaker material can tear off and adhere to the stronger material. Abrasive 
wear occurs in a similar way but it is when the two surfaces make contact and the softer 
material is damaged by the asperities of the harder material, which may be either the other 
surface or particles formed through other wear mechanisms (Cawston and Wilson, 2006, Kienle 
et al., 2015). 
1.1.9.2 Biochemical wear 
Biochemical wear occurs when the tissue enters a pathological state caused by conditions such 
as rheumatoid arthritis or collagen metabolic disorders. This type of degradation may also be a 
natural effect of chondrocytes aging which may alter the makeup of the ECM in terms of GAG 
molar ratios. These changes have been reported to cause the biomechanical properties of the 
cartilage tissue to deteriorate leading to degradation (Pecchi et al., 2012, Trevino et al., 2016). 
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1.2 Articular cartilage defects 
There are three main types of defect associated with articular cartilage: superficial matrix 
disruption, partial thickness defects and full thickness defects. These can be expanded to five 
classifications to include normal cartilage and defects between partial and full thickness defects 
(Matsiko et al., 2013). The five classifications are shown in Table 1.3. 
Grade Description 
0 Normal, healthy cartilage 
I Cartilage with visible swelling and softening 
II Partial thickness defect < 50% total cartilage thickness with no exposure of subchondral bone 
III Partial thickness defect > 50% total cartilage thickness with no exposure of subchondral bone 
IV Total loss of cartilage with subchondral bone exposed 
Table 1.3: Grades and descriptions of the different classifications of articular cartilage defects as catergorised by 
ICRS. (Adapted from Perera et al., 2012 with permission from the Royal College of Surgeons of England) 
Grade I defects occur when microfractures form within the cartilage structure which can cause 
loss of GAGs in the superficial zone. These microfractures also cause thinning of the articular 
cartilage and in turn thickening of the calcified cartilage layer (Nukavarapu and Dorcemus, 
2013).  These types of defects occur when blunt trauma damages the ECM, but the 
chondrocytes can synthesise new matrix through aggregating into clusters near the site of 
damage (Matsiko et al., 2013). 
Grade II defects occur when the articular cartilage is damaged beyond the superficial layer but 
only up to the middle zone. Grade III is when the articular cartilage damage extends into the 
calcified cartilage layer. Both grades are not self-repairable unlike grade I defects, meaning 
surgery or other treatments are required to prevent further degeneration (Matsiko et al., 2013, 
Nukavarapu and Dorcemus, 2013). 
Grade IV defects occur when the entire cartilage layer is damaged and the subchondral bone is 
either exposed or damaged. This happens in extreme trauma cases or through progressive 
degradation usually through disease such as osteoarthritis (Matsiko et al., 2013, Nukavarapu 
and Dorcemus, 2013).   
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1.3 Osteoarthritic cartilage 
Osteoarthritis is the most common type of arthritis in the modern world.  It is a degenerative 
disease that causes the integrity of articular cartilage to become compromised (Pitsillides and 
Beier, 2011). 
It was considered for a long time to be a “wear and tear” disease which was the only outcome 
from any process that led to increased pressure on a single joint (Berenbaum, 2013). 
Osteoarthritis can affect any articulating joint, and it often results in decreased quality of life 
such as the inability to work. One of the problems with the disease is that it is usually only 
diagnosed in the advanced stages, by which point non-surgical treatments are generally 
ineffective and limited.  
1.3.1 Pathophysiology of osteoarthritis 
As mentioned in previous sections, cartilage lacks significant regenerative capabilities because 
it is avascular and has limited nutrient supply. This limited regenerative ability means that only 
small defects in the cartilage matrix such as loss of ECM components or deterioration of the 
collagen organisation can be repaired. In large defects the limits of this repairing ability are 
reached and the damage becomes permanent (Lorenz and Richter, 2006). Osteoarthritis has 
certain typical features in the form of degeneration or progressive loss of the functional 
structure of articular cartilage. 
The causes of osteoarthritis can be classified as either primary or secondary. Primary 
osteoarthritis is generally related to aging and general “wear and tear” of daily life where there 
is no detectable structural deformities or abnormalities (Aury-Landas et al., 2016). The pathway 
for development of osteoarthritis, both primary and secondary, is shown in Fig 1.7. 
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Fig 1.7: The pathway for wear and potential development of osteoarthritis in articular cartilage (Adapted from 
Burr and Gallant, 2012 with permission from the Nature Publishing Group). 
 Not everyone develops osteoarthritis but the older someone becomes the more likely that 
person is to develop the disease (Dieppe and Lohmander, 2005, Doherty et al., 1983, Sarzi-
Puttini et al., 2005, Aury-Landas et al., 2016). Secondary osteoarthritis is caused by non-
physiological motions either through obesity overloading the joints or an injury to the joint or 
any of the supportive soft tissues associated with the joint (Dieppe and Lohmander, 2005, 
Doherty et al., 1983, Sarzi-Puttini et al., 2005, Aury-Landas et al., 2016) 
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Fig 1.8: Pathophysiological changes in osteoarthritic articular cartilage when mechanical loading is applied. 
As the disease progresses the physical appearance of articular cartilage changes from a 
normally white/silvery colour, hard tissue to a yellow, soft, damaged tissue. The damage of the 
tissue appears as fissures and pits which increase in size through both mechanical wear and 
molecular degradation, as mentioned in section 2 (Martel-Pelletier et al., 2008, Xia et al., 2014). 
The disease manifests as an imbalance between anabolic and catabolic processes within the 
tissue, in which both processes are accelerated and enhanced (Lorenz and Richter, 2006). The 
precise mechanisms of degradation of articular cartilage are still unclear, but many theories of 
complex interactions between genetic, environmental, metabolic and biochemical factors have 
been proposed as illustrated in Fig 1.8. There is enhanced production of matrix-degrading 
enzymes which result in the progressive loss of collagen and proteoglycans/GAGs from the 
ECM. The chondrocytes initially proliferate, synthesize and secrete increased amounts of matrix 
molecules. This increased synthesis is overcome as osteoarthritis progresses and cartilage 
degradation continues (Lorenz and Richter, 2006). 
Within osteoarthritic cartilage, many different cytokines and growth factors are present, some 
of which are involved in chondrogenesis. These molecules are produced by chondrocytes and 
the synovium (Xia et al., 2014). 
Anabolic processes such as matrix synthesis are facilitated by the secretion of growth factors 
such as insulin-like growth factor (IGF)-1, transforming growth factor (TGF) – β, fibroblast 
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growth factors (FGFs) and bone morphogenetic proteins (BMPs). In contrast, catabolic 
processes such as matrix degradation are promoted by proteases, but in particular matrix 
metalloproteinases (MMPs) such as MMP-1, -8 and -13 which have been shown to lead to the 
degradation of GAGs as mentioned above (Lorenz and Richter, 2006, Martel-Pelletier, 1998, 
Martel-Pelletier et al., 2008, Xia et al., 2014). 
1.3.2 Animal models 
Various animal models have been developed over the years in order to study the complex 
nature of osteoarthritis. These models include approaches involving spontaneous, mechanical 
and chemically induced osteoarthritis in a variety of animals including dogs, rabbits, sheep 
(Dumond et al., 2004, Gaffen et al., 1997, Liu et al., 2011, Marijnissen et al., 2002, Young et al., 
2005, Cook et al., 2014, Ahern et al., 2009). 
These models have enabled a time point for the onset of osteoarthritis to be identified and a 
progressive timescale for particular prominent events as osteoarthritis progresses to be 
constructed. 
The limitations of using animal models are the different timescales for the onset and 
progression of osteoarthritis. The different biomechanics and lifetimes of different species is an 
uncontrollable variable, and makes comparison of the results difficult e.g. dogs are quadrupeds 
and the loading on joints during motion is different to humans who are bipeds (Lorenz and 
Richter, 2006).  
1.3.3 Differences between healthy and osteoarthritic cartilage 
There are many biological differences between healthy and osteoarthritic cartilage. In order to 
classify the differences they can be grouped into two categories: histological changes and 
molecular changes. 
1.3.3.1 Histological changes 
The early stage of osteoarthritic cartilage is categorised by a rougher surface than healthy 
cartilage. GAGs remain distributed in a homogenous manner and slight fibrillation can occur 
within the superficial zone (Miosge et al., 2004). This fibrillation can increase as the disease 
progresses to a degree where the cellular structure changes and there is a noticeable decreased 
concentration of proteoglycans (Fernandes, 1998, Lorenz and Richter, 2006, McDevitt et al., 
1977). 
The morphology of the chondrocytes in the superficial zone changes from flat to round and they 
become hypertrophic, eventually disappearing from the tissue completely.  The chondrocytes 
in the middle and deep zones also become mildly hypertrophic (Fernandes, 1998, Lorenz and 
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Richter, 2006).Other observations include clusters of multi-cellular chondrocytes which contain 
enlarged nuclei found within the tangential zone along with necrotic chondrocytes with 
pyknotic nuclei in the radial zone as well as the transitional zone (Bluteau et al., 2001). 
In the advanced stages of osteoarthritis, there is an observed complete breakdown of the 
cartilaginous tissue (Lorenz and Richter, 2006). The breakdown consists of fissures and holes 
which can penetrate the entire thickness of the tissue so that the calcified zone is exposed 
(Pfander, 1999). Around these fissures, chondrocytes congregate in clusters in the early stages 
of advanced osteoarthritis, ultimately disappearing completely (Miosge et al., 2004). 
The internal collagen and ECM organisation becomes completely disorganised and disordered 
and the articular cartilage is replaced by fibrocartilage in the form of scar tissue with a cell 
phenotype similar to fibroblasts (Miosge et al., 2004). In extreme cases, the fissures penetrate 
beyond the calcified zone to expose the subchondral bone below (Hayami et al., 2003). 
1.3.3.2 Molecular changes 
Molecular changes have been analysed using different methods: immunohistochemistry and 
biochemistry. 
Immunohistochemistry 
In early and mild osteoarthritic cartilage there is a change in collagen organisation and 
distribution. Within the deep cartilage zone, the production of collagen type II increases but in 
the superficial zone a shift occurs and collagen type I is produced within osteoarthritic cartilage 
(Miosge et al., 2004, Young et al., 2005, Xia et al., 2014). 
In advanced osteoarthritis, collagen type II is still produced but only in clusters and collagen 
type I is still present but the production of collagen in general slows as osteoarthritis progresses 
(Pfander, 1999, Young et al., 2005). 
The specific changes have been collated and presented in Table 1.4. 
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 Early or Mild Osteoarthritis Advanced Osteoarthritis 
Collagen type I Increase (Miosge et al., 
2004, Teshima 
et al., 2004) 
Increase (Miosge et al., 
2004) 
Collagen type II Decrease 
Increase 
(Young et al., 
2005) 
(Pfander, 1999) 
No change 
Decrease 
(Nerlich et al., 
1993) 
 
(Pfander, 1999) 
Collagen type III Increase (Aigner et al., 
1993) 
-  
Collagen type VI Increase (Hambach, 
1998) 
No change (Hambach, 
1998) 
Collagen type X Increase (Von der Mark 
et al., 1992) 
-  
Fibronectin Increase (Pfander, 1999) Increase (Pfander, 1999) 
MMP1 Increase (Fernandes, 
1998) 
-  
MMP9 Increase (Hayami et al., 
2003) 
-  
MMP13 Increase (Fernandes, 
1998, Hayami et 
al., 2003) 
-  
Table 1.4: Immunohistological observations of osteoarthritic cartilage at varying stages of disease progression. 
(Adapted from Lorenz and Richter, 2006 with permission from Elsevier). 
Biochemical 
As the disease progresses, various biochemical changes are observed, some of which are 
directly related to the immunohistological changes mentioned above. A loss of proteoglycans 
occurs due to an increased rate of degradation while the rate of proteoglycan production 
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changes very little. This is due to the increased production of MMPs which degrade 
proteoglycans. This reduction in proteoglycans causes an increased content of water within the 
tissue due to the formation of an osmotic gradient (Appleyard, 2003, Little et al., 1996). The 
different proteoglycans are affected in different ways, but the most noticeable effect is lower 
levels of chondroitin sulfate (Carney et al., 1992, Carney et al., 1984, Lorenz and Richter, 2006). 
The different biochemical effects and symptoms have been collated and presented in Table 1.5.  
The synthesis of collagen increases up until a certain point where the rate of synthesis decreases 
resulting in an unchanged, balanced content in terms of production and degradation (Little et 
al., 1996).  
 Early or Mild Osteoarthritis Advanced Osteoarthritis 
Water content Increase (Appleyard, 
2003, Little et 
al., 1996) 
Decrease (Mankin and 
Lippiello, 1971) 
Collagen 
content 
No change (Appleyard, 
2003) 
No change (Lippiello et al., 
1977) 
Collagen 
production 
Increase (Floman, 1980) Increase (Squires et al., 
2003) 
Collagen 
degradation 
Increase (Squires et al., 
2003) 
-  
Proteoglycan 
content 
Decrease (Little et al., 
1996) 
Decrease (Squires et al., 
2003) 
Proteoglycan 
production 
Increase/ no 
change 
(Carney et al., 
1992, Carney et 
al., 1984) /(Little 
et al., 1996) 
-  
Proteoglycan 
degradation 
Increase (Carney et al., 
1992, Carney et 
al., 1984) 
-  
Table 1.5: Biochemical observations of osteoarthritic cartilage at varying stages of disease progression. (Adapted 
from Lorenz and Richter, 2006 with permission from Elsevier). 
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1.4 Intervention for early stage cartilage defects 
Osteoarthritis is a debilitating disease. Intervention at the early stages when initial damage 
occurs may prevent disease progression. 
There are currently only limited surgical methods of early intervention, however current 
research within the field of tissue engineering could provide alternative methods of 
intervention. These methods will be addressed and discussed in this section. 
1.4.1 Surgical procedures 
There are four groups of repair procedures for cartilage damage: arthroscopic lavage and 
debridement for very small defects; marrow stimulating techniques; osteochondral autografts 
and allografts and, more recently, cell-implantation based procedures (Muzzarelli et al., 2012, 
Balakrishnan and Banerjee, 2011, Abarrategi et al., 2010, Campbell et al., 2016). The various 
techniques are shown in Fig 1.9. 
 
Fig 1.9: The various surgical techniques currently employed to treat articular cartilage defects (Reproduced from 
Huey et al., 2012 with permission from AAAS). 
Arthroscopic lavage and debridement are termed palliative treatments and are the least 
invasive in that they involve surgically removing loose, damaged cartilage fragments from the 
damaged joint. When the synovial membrane becomes irritated and excessive growth occurs it 
can develop fronds which are inflamed and release cytokines and enzymes which can cause 
further damage to the surrounding joint. It is the inflamed and damaged sections of the synovial 
membrane that are removed during lavage and debridement (Thiede et al., 2012, Matsiko et 
al., 2013, Nukavarapu and Dorcemus, 2013, Campbell et al., 2016).  
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Microfracture is termed a reparative treatment and is employed to treat cartilage defects in 
active patients. This technique involves drilling holes through the articular cartilage defect into 
the bone marrow of the subchondral bone. The holes are between 0.5-1mm diameter and 
approximately 3mm deep and 3-5mm apart (Matsiko et al., 2013, Nukavarapu and Dorcemus, 
2013, Perera et al., 2012). The holes allow influx of the mesenchymal stem cells from the bone 
marrow into the cartilage tissue to promote differentiation into chondrocytes (Matsiko et al., 
2013, Nukavarapu and Dorcemus, 2013, Perera et al., 2012, Campbell et al., 2016). 
Autograft and allograft transplantation is usually reserved for lesions larger than 2cm2 diameter. 
These techniques are used when lavage, debridement and microfracture have failed and the 
patient has high demand on the joint, such as an athlete. Autografts, which are taken from a 
non-load bearing area of the joint, are used for small to medium chondral and osteochondral 
defects which are 2-3cm2 in area. Allografts are taken from another, non-genetically identical 
patient and are used on larger defects > 3cm2 (Matsiko et al., 2013, Nukavarapu and Dorcemus, 
2013, Perera et al., 2012). 
Autologous chondrocyte implantation or ACI was first developed in 1994 by Brittberg et al., 
when it was described in treating full thickness articular cartilage defects of a human knee 
(Perera et al., 2012). This involves a two-stage procedure in which the first stage is an 
arthroscopic biopsy of a healthy area of articular cartilage and the chondrocytes are isolated 
and cultured. The second stage involves debridement of the osteochondral lesion which is then 
covered by a periosteal flap. The lesion is then implanted with the cultured cells (Matsiko et al., 
2013, Nukavarapu and Dorcemus, 2013, Perera et al., 2012, Thiede et al., 2012, Huey et al., 
2012). 
The surgical techniques outlined above are successful in terms of relieving pain and restoring 
some improved joint motion and function (Balakrishnan and Banerjee, 2011), but the cartilage 
formation promoted by these techniques is usually fibrocartilage composed of collagen type I 
instead of type II. Cartilage containing collagen type I is inferior to hyaline cartilage containing 
collagen type II in terms of biochemical and mechanical properties (D. W. Jackson., 2001). 
It is because of this inferior cartilage production that there remains a clinical need to promote 
the formation hyaline cartilage. The field of tissue engineering is providing potential 
alternatives to the current treatments. The ideal treatment would be one in which early 
cartilage defects are repaired by promoting the formation of hyaline cartilage in vivo. Other 
ways of treating cartilage damage, in the short term, would be to reduce the degradation of 
cartilage or to restore the biomechanical properties of the damaged cartilage. 
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1.4.2 Tissue engineering approaches to cartilage repair and regeneration 
Tissue engineering is the field of science that aims to synthetically reproduce human tissue 
through the combined use of cells, cellular components i.e. growth factors, a scaffold material 
and physical stimuli. The field has shown some great leaps forward in producing tissue that has 
pioneered tissue replacements. Various research groups around the world are currently 
investigating different approaches for nearly every tissue type in the human body.  
The complicated structure of articular cartilage, which has many different zones that have 
different orientations of collagen and chondrocytes, gives rise to different biomechanical 
properties. This has led to difficulties in creating living tissue constructs which recapitulate both 
the biological and biomechanical characteristics of articular cartilage. 
A variety of approaches have been undertaken by an enormous number of different groups 
globally to overcome these difficulties, in which different cell types and different scaffold 
materials have been investigated. The literature in this area of research is beyond the scope of 
this review. 
The following sections will attempt to summarise some of the major areas of investigation 
various groups have taken to tissue engineer cartilage. 
1.4.2.1 Cell sources 
Various sources of cells have been investigated for use in cartilage tissue engineering. The 
optimal cell source is still currently unknown (C. Chung., 2008, Makris et al., 2015). The various 
sources are shown in Table 1.6. 
The ideal source of cells would be chondrocytes, as pre-differentiation in vitro would not be 
required, thus potentially decreasing the economic cost of using cellular based treatments. The 
difficulty in using chondrocytes is that when expanding chondrocytes in vitro, dedifferentiation 
can occur. This is an issue which growth factors or the material of the scaffold upon which the 
chondrocytes are seeded, may help to overcome. 
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Cell Source Reference of 
examples 
Reason for choice Issues 
Chondrocytes - Chondrocytes are a natural 
choice as a cell source. 
These have been 
extensively studied in the 
past. Specifically their role 
in producing, maintaining 
and remodelling the ECM 
found in native cartilage (C. 
Chung., 2008). 
The main concern with selecting 
chondrocytes as the cell type is the 
low quantities of these cells 
present within cartilage ~ 1-10% 
depending on the source, thus 
expansion prior to use is required. 
Expansion in monolayer causes 
dedifferentiation  typically 
resulting in decreased rates of 
proteoglycan synthesis and 
collagen type II production along 
with an increased rate of collagen 
type I production (C. Chung., 2008). 
Articular (J. M. Mesa., 2006, 
Y. Li., 2004) 
Auricular (G. J. V. M. van 
Osch., 2004, A. 
Panossian., 2001) 
Costal (A. G. Tay., 2004, T. 
S. Johnson., 2004) 
Fibroblasts (M. M French., 
2004, K. H. Lee., 
2001) 
Fibroblasts are more 
readily obtained in larger 
quantities than 
chondrocytes and can be 
directed to express a 
chondrogenic phenotype 
(C. Chung., 2008). 
The issue with fibroblasts is that 
differentiation in vitro prior to 
implantation is required (C. Chung., 
2008). 
Stem cells 
 Bone-
marrow 
derived 
 
 Adipose-
derived 
 
 
 
 (W. J. Li., 
2005, J. W. 
Chen., 
2005) 
 (J. I. 
Huang., 
2004, G. R. 
Erickson., 
2002) 
 
Stem cells have been 
studied in depth  in recent 
years due to possessing 
“multi-lineage potential” 
(C. Chung., 2008) These 
cells can be extracted from 
a multitude of different 
tissues. They can then be 
expanded without losing 
the potential to 
differentiate through 
several pathways and 
mechanisms (C. Chung., 
2008). 
The issue with using bone-marrow 
derived stem cells is that the 
extracellular matrix they produce 
when undergoing induced 
chondrogenesis is mechanically 
weaker than that produced by 
native chondrocytes. For adipose-
derived stem cells, the expression 
rate of collagen type II and lower 
concentrations of cartilage-specific 
matrix proteins are the main issues 
that limit their potential within 
cartilage tissue engineering. 
 
Table 1.6: The different cell sources that have been investigated to engineer cartilage tissue (Adapted from 
Warren, 2013).
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1.4.3 Scaffold material 
Scaffold materials can be classed into three groups: synthetic, natural or hybrid which combines 
both synthetic and natural materials.  Synthetic materials are generally synthetic polymers that 
can be produced on an industrial scale via chemical polymerization reactions initiated either by 
radiation or catalysis. They can be formulated in many different compositions which affects 
mechanical properties, chemical modification and rates of degradation both in vitro and in vivo 
(Lee and Shin, 2007, Makris et al., 2015). 
Some of these polymers are biocompatible and biodegradable(Kon et al., 2015). These include 
poly (glycolic acid) (PGA), poly (D, L lactic acid) (PLA), poly (caprolactone) (PCL) and poly(lactic 
co-glycolic acid) (PLGA)(Lee and Shin, 2007); (Lee et al., 2009, Muzzarelli et al., 2012). There are 
also biocompatible polymers such as poly (ethylene glycol) (PEG) that is not biodegradable (Lee 
and Shin, 2007, Balakrishnan and Banerjee, 2011, Muzzarelli et al., 2012). 
Natural materials are biomaterials that are naturally occurring in nature and include collagen, 
gelatin and various polysaccharides such as chitosan and hyaluronic acid (Lee and Shin, 2007, 
Kon et al., 2015). Collagen type I and hyaluronic acid make excellent choices for scaffold 
materials because they occur naturally in the structure of native articular hyaline cartilage. 
Chitosan is a polysaccharide derived from chitin, which is found in the shells of crustaceans (Li 
et al., 2016).  
The reasons for use are shown in Tables 1.7 and 1.8 for synthetic and natural polymers 
respectively, along with brief descriptions of results beneficial to cartilage tissue engineering. 
For a complete investigation into the potential materials upon which cells can be cultured 
decellularized tissue also deserves mention. In comparison to natural or synthetic scaffold 
materials, decellularized tissue is tissue that has had the cellular components removed through 
a variety of washes and treatments which aims to remove any immunogenic material to prevent 
an immunological response upon implantation (Gilbert, 2006). Various tissue types have been 
investigated, from connective tissue such as ligaments and tendons to organ tissue or even 
whole organs (Ott et al., 2010, Petersen et al., 2010, Song and Ott, 2011) but to date, there has 
been little success in decellularization of natural cartilage.  
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1.4.3.1 Synthetic material 
Polymer References Reason for use Results 
PGA (J. C. Becker., 
2005, J. K. 
Mouw., 2005) 
PGA scaffolds have been shown to 
have high rates of degradation as 
well as a high porosity. They have 
also been shown to be 
biocompatible. 
The high porosity and rates of degradation allowed 
an initially  high cellular growth, while the function of 
differentiated chondrocytes was maintained (Lee 
and Shin, 2007). The production and secretion of an 
ECM  that was similar to that which is produced by 
healthy normal articular cartilage was also 
maintained (Lee and Shin, 2007). 
PLA (S. E. Kim., 2003, 
S. I. Jeong., 
2005) 
PLA scaffolds have been shown to 
possess similar properties to PGA 
scaffolds in regards to their 
porosity and rate of degradation. 
PLA scaffolds showed a  decreased  propensity for 
cellular growth and matrix synthesis when compared 
to PGA(Lee and Shin, 2007). 
PCL (S. E. Kim., 2003, 
S. I. Jeong., 
2005, J. C. 
Becker., 2005, 
Q. Huang., 
2002) 
PCL can be copolymerized with 
either PGA or PLA, and this 
improves the resulting polymer’s 
elastic properties. 
PCL scaffold, when in combination with growth 
factor TGF-β1 and mesenchymal stem cells, showed 
potential as a scaffold material because hyaline 
cartilage formed following implantation into a 
subject, along with the seeded cells producing 
glycosaminoglycans after a four week period(Q. 
Huang., 2002). 
PEG (B. S Yoon., 
2004, J. 
Elisseeff., 2001, 
A. J. DeFail., 
2006) 
PEG is not a biodegradable 
polymer but is used widely in 
clinical instruments and other 
medical devices as it is 
biocompatible. The lack of 
biodegradation is overcome by 
the safe excretion via metabolic 
process from the body. This is 
because of the low molecular 
weight < 10,000 (Lee and Shin, 
2007). 
PEG, after being cross-linked into hydrogels, has 
been shown to support chondrogenesis. This can be 
improved by the addition of bioactive peptides and 
hydrolysable units, such as lactic acid units, to the 
scaffold. The improvement was seen in terms of 
increased cell proliferation and ECM deposition (C. 
Chung., 2008, J. Elisseeff., 2001). 
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PLGA (J. Elisseeff., 
2001, A. J. 
DeFail., 2006, X. 
B. Yang., 2004, 
H. J. Shin., 2006) 
PLGA is a block copolymer 
produced from lactic acid and 
glycolic acid. It has similar 
properties to that of the individual 
polymers; PGA and PLA. 
PLGA scaffolds have been shown to support cell 
differentiation and successful induced 
chondrogenesis in vivo within a 12 week period post-
implantation (K. Uematsu., 2005). 
Table 1.7: The different synthetic polymers that have been used as scaffold materials for cartilage tissue 
engineering (Adapted from Warren, 2013). 
  
 
 
33 
 
 
1.4.3.2 Natural materials 
Material References Reason for use Results 
Collagen (B. A. 
Wambach., 
2000, T. 
Ushida., 
2002, S. 
Kawamura., 
1998, S. 
Nehrer., 
1997) 
Naturally found in cartilage tissue. 
It has been shown to be an 
integral part of providing strength 
and flexibility to the tissue. 
Collagen type I, when combined with other synthetic 
polymers such as PLLA, has been shown to promote 
articular chondrocytes to proliferate and support 
them whilst secretion of matrix components specific 
to cartilage occurred (Balakrishnan and Banerjee, 
2011). The chondrocytes were also shown to express 
collagen type II molecules when in the presence of 
collagen type I (J. Elisseeff., 2001). 
Hyaluronic 
acid 
(J. Aigner., 
1998, C. 
Chung., 
2009) 
Naturally found in cartilage tissue. 
It has been shown to help 
distribute any “shock” throughout 
the joint. It also helps in 
maintaining the structural and 
functional properties of the 
matrix of cartilage (Muzzarelli et 
al., 2012). It is involved in cell 
proliferation, leading to the 
conclusion it would make a 
potential good biomaterial choice 
for scaffolds (C. Chung., 2008). 
Hyaluronic acid has been shown, when combined 
with other natural materials such as gelatin to form 
a hydrogel.  When the hydrogel was seeded with 
mesenchymal stem cells is showed favourable 
formation of elastic hyaline-like cartilage when 
applied to a defect in the surface of hyaline cartilage. 
The new cartilage showed good integration into the 
surrounding native cartilage (C. Chung., 2009). 
Also when hyaluronic acid was combined with 
another natural material - chitosan and then seeded 
with chondrocytes, hyaline-like cartilage was again 
formed when compared to that of a control where 
fibrocartilage formed in a defect (Muzzarelli et al., 
2012). 
Chondroitin 
Sulfate 
(Q. Li., 2004, 
B. G. 
Amsden., 
2007) 
Naturally found in cartilage tissue. 
It provides a substantial amount 
of the cartilage tissue’s resistance 
to compression. 
Chondroitin sulfate has been combined with many 
other polymers to produce scaffolds or hydrogels. 
When combined with PEG to form a hydrogel and 
seeded with mesenchymal stem cells, an enhanced 
rate of ECM deposition was observed along with an 
increase rate of chondrogenic marker expression 
(Spiller et al., 2011). 
Table 1.8: The different natural polymers and molecules that have been used as scaffold materials for cartilage 
tissue engineering (Adapted from Warren, 2013). 
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Although tissue engineering shows some promise, as yet no group has successfully produced a 
tissue engineered cartilage with the composition and biomechanical function of natural 
articular cartilage. Moreover, tissue engineering approaches involving the use of living cells will 
require extensive development before being used to treat patients and will be regulated as 
advanced therapeutic medicinal products leading to high development costs. 
A more practical approach would be to use a cell-free method as an early stage intervention. A 
novel class of materials called self-assembling peptides (SAPs) are of particular interest for 
tissue engineering applications.  
1.4.4 Potential uses of self-assembling peptides in regenerative medicine 
applications  
SAPs have the potential to be used in a plethora of ingenious ways within the field of tissue 
engineering and regenerative medicine because of the chemical and physical properties they 
inherently possess. The reversible ability of these molecules to form stable, self-supporting gels 
via controllable stimuli such as pH, temperature, ionic strength and concentration/dilution 
makes them potentially useful and quite a versatile tool within a difficult field of science (Aggeli, 
1997).  
As shown in Fig 1.10, the proposed applications of SAPs will vary depending on the chemical 
structure and sequence of the base-level peptide before secondary self-assembly occurs. 
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Fig 1.10: Diagrams and images of SAP’s which have formed into different structures through different methods 
of self-assembly and different applications. Route A shows how ionic self-complementary peptides undergo self-
assembly to form a hydrogel scaffold. Route B shows how surfactant-like peptides can self-assemble to form 
nanotubes and nano-vesicles. Route C shows how peptides can be used to nano-coat a surface using a functional 
group such as a thiol onto a gold surface for nanotechnology applications. Route D shows how controlling the 
environment in which secondary peptide assembly occurs, peptides can be exploited for use as nano-switches 
depending upon external stimuli (reproduced from Zhang, 2003 with permission from the Nature Publishing 
Group). 
These inherent properties of SAPs can be exploited for uses within regenerative medicine and 
tissue engineering ranging from biomaterials to potential carriers for either pharmacological 
agents or proteins for a variety of therapies. A greater insight into each of these uses is 
discussed below. 
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1.5 Self-assembling peptides 
Self-assembling peptides (SAPs) are chains of amino acids that are covalently linked through an 
amide bond which is known as a peptide bond. The chains can undergo association that is 
governed by thermodynamics which allows a spontaneous process known as self-assembly to 
occur. This self-assembling process allows the peptides to form structures that are ordered in a 
hierarchical manner. The assembly is reversible, where the driving force for assembly is the 
formation of favourable interactions either intramolecularly or intermolecularly and the 
establishment of a thermodynamic equilibrium (Carrick, 2007a). These interactions, in the order 
of strongest to weakest, are hydrogen bonding, electrostatic/ columbic interactions, 
hydrophobic/π-π stacking interactions, Van der Waal interactions and solvent mediated 
hydrogen bonding (Zhang, 2003). Covalent bonding can also occur in SAPs. This type of bonding 
is stronger than those mentioned above but because covalent bond formation may interfere 
with the reversible processes required for self-assembly these bonds are usually formed post 
self-assembly during crosslinking steps (Zhang, 2003).  
The hierarchical nature of the structures formed through self-assembly is similar to that 
observed within nature in organisms. The first level of structural assembly is a simple peptide 
chain which straightens from a random coil to an entropically unfavourable β-strand– known 
as 1-D primary self-assembly. The second level of self-assembly is known as secondary and this 
involves the formation of either an α-helical structure or a β-sheet like structure from β-strands 
through non-covalent interactions. Tertiary self-assembly is based on interactions of side chains 
from amino acid residues between secondary structures to form 3-D structures which form tape 
and subsequently ribbons with a twisted structure which is the result of hydrophobic 
interactions between aromatic and uncharged residues to decrease the entropic penalty from 
ordering within the solvent. The fourth and final level, which is known as quaternary self-
assembly, is the formation of fibrillar structures which are bundles of ribbons to further reduce 
the entropic penalty from ordering.(Aggeli, 2001a). These fibrils can further associate to form 
fibers, which are micron-scale structures of entwined fibrils, and these fibers are similar to the 
structure of connective components such as collagen. 
In the case of the tape-like structure assembly to produce ribbons, fibrils and fibers when 
favourable physiological conditions occur, the density of peptides increases alongside the 
dimensions of the structure (Aggeli, 2003b). These tape-based structures also occur naturally 
in diseases that are termed Amyloid diseases which include Alzheimer’s and Huntington’s and 
result from mutations such as amino acid deletion or aberrant protein folding or processing 
(Krysmann, 2008).  
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The potential uses of SAPs in regenerative medicine range from simple biomaterials to potential 
drug carriers.  
1.5.1 Self-assembling peptides as biomaterials 
SAPs are ideal biomaterials because of their relatively simple chemical synthesis within a 
chemistry lab ex vivo or recombinant production in micro-organisms. They are advantageous 
over other natural materials because the morphology that is adopted can be controlled and 
reversed under certain conditions, as well as being modifiable post-synthesis (Holmes, 2002). 
The advantage SAPs have over synthetic materials is that they can be designed to promote a 
minimal host response and limit or eliminate any potential cytotoxicity. There are “general” 
criteria for potential materials for use in regenerative medicine (Holmes, 2002): 1)  the material 
is customisable in terms of structure and function to suit specified range requirements, 2)  the 
material possesses a pre-determinable rate of degradation, 3)  the rate of degradation of the 
material is controllable once determined, 4) the material is chosen with the aim of limiting 
cytotoxicity problems, 5)  the material possesses favourable properties that promote 
interactions between the cells and material itself, 6) or in contrast to the point above, inhibits 
said interactions, 7) the material is chosen with the aim of promoting a minimal or non-existent 
immunological response in vivo upon implantation, 8) the possibility of  scaling up synthesis and 
functionalization of the material on an industrial and thus clinical scale , 9)  the material is 
soluble in aqueous solutions if required to be, 10)  the material is compatible with human 
physiology under physiological conditions in terms of pH ~ 7.4 and temperature ~37°C. 
1.5.1.1 Hydrogel scaffolds 
The term hydrogel refers to a gel that is predominantly water, in which the water is entrapped 
in a matrix of interconnecting projections. SAPs can form gels with a fibrillar structure which fits 
the description of a hydrogel. This entrapment arises from the hydrophilic side chains of the 
peptide forming favourable interactions with water molecules that are trapped between 
“pockets” of hydrophobic regions that repel the water molecules (Liu, 2011).  
As mentioned in below, SAP assemble through one of two specific mechanisms. These 
mechanisms can be exploited within regenerative medicine to allow an injectable material 
which upon injection into a patient will undergo self-assembly, and due to the fact that self-
assembly occurs post injection a greater level of tissue penetration is possible compared to 
attempting to inject an already assembled hydrogel. This ability makes SAPs unique in terms of 
other hydrogel scaffold materials. The SAPs are prepared in a monomeric state, which when 
subjected to physiological conditions or through three different processes by which SAPs can 
be triggered to self-assemble (Chow, 2008):  
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1. External stimuli such as changes in ionic strength, pH or temperature of the immediate 
environment  
2. Chemical processes such as irradiation, enzymatic catalysis or polymerisation through radical or 
photonic can cause crosslinking 
3. Physical processes causes similar crosslinking 
1.6 Self-assembly mechanism 
The classes of SAPs mentioned in the previous section all self-assemble via either one of two 
mechanisms: nucleated growth self-assembly or complementary self-assembly. Nucleated 
growth self-assembly occurs in a single component system and involves monomers that are in 
a random coil state orientating in space so that a favourable conformation for self-assembling 
is achieved (Kyle et al., 2012). 
For example, a monomeric peptide will change from a random coil conformation to a β-strand 
conformation when the peptide conformation transition energy; 𝜀𝑐𝐾𝐵𝑇 is reached. This energy 
requirement is mainly due to the entropy loss which is associated with the peptide straightening 
out from the random coil to the β-strand. 
Once in the β-strand conformation, further self-assembly can only occur once the tape scission 
energy; 𝜀𝛽𝐾𝐵𝑇 is reached. This energy requirement is mainly due to the gain of enthalpy which 
stems from the intermolecular peptide backbone complementary hydrogen bonds and 
interactions between peptide side chains such as hydrophobic, complementary hydrogen 
bonds and columbic interactions. These two energies direct self-assembly of peptides to form 
β-sheet structures or a similar structure in the case of certain classes mentioned above. To form 
a stable β-sheet there are however further factors which need to be taken into consideration. 
Even if 𝜀𝛽𝐾𝐵𝑇 is reached, the concentration of the peptides has to be greater than a specific 
concentration – critical tape concentration of c*. This concentration is the point when the 
peptides can nucleate to form a stable nucleus upon which other peptides can continue to 
grow. 
Even when the energetics for self-assembly are met, if: 
c < c* - small tapes are not stable at these low concentrations so the peptides are all in a 
monomeric state 
c ~ c* - nucleated self-assembly starts 
c > c* - tape growth occurs 
When the concentration dependent mechanism is involved, the monomeric peptide chains 
form structures based on the hierarchical pattern mentioned in a previous section. The 
monomers form tape-like structures at a critical concentration (c*) so that hydrogen bonding 
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and electrostatic interactions order the monomers once the aromatic groups align the peptides 
for 1-D self-assembly. The tape-like structure then forms a ribbon once the concentration 
increases to the required amount. This is the result from the presence of more hydrogen 
donating or receiving groups on the additional monomers. At higher concentrations, the 
ribbons can interact with one another through additional hydrogen bonding and electrostatic 
interactions to form fibrils which then can also go on to form fibres as shown in Fig 1.11 (Aggeli, 
2001b). The monomers are affected by external stimuli such as changes in pH or ionic strength 
of salt ions in solution. During a pH change, for example from basic to acidic, the various side 
chains on the peptide sequence are protonated. This affects the self-assembly by either 
promoting it or disrupting it depending on the peptide sequence. The ionic strength of the salt 
also influences the self-assembly as the mono and divalent positively charged salt ions screen 
the negatively charged side groups of the peptide sequence (Kirkham et al., 2007). 
 
Fig 1.11: The different intermediates of self-assembly for the P11-X class of peptides experience when under a 
concentration dependent regime. 
In the case of the complementarity mechanism for self-assembly, the peptides are a binary pair 
that have been rationally designed in such a way that self-assembly can only occur between the 
peptides when two complimentary peptides are in the presence of one another (Kyle et al., 
2012). Once this requirement is met then the peptides can be triggered by a pH change, thermal 
or mechanical process to start the self-assembling process. The two monomers will only 
associate as a complementary pair and not with identical monomers of each type. The difficulty 
with designing peptide system that self-assembly via this type of mechanism is that the two 
monomeric peptides have to have be triggered by a similar stimulus, e.g. monomeric at a similar 
pH and switch to a polymeric gel at a similar pH.  
In the case of two peptides from the P11-X family designed by the Aggeli group – P11-13 (CH3CO-
Gln-Gln-Glu-Phe-Glu-Trp-Glu-Phe-Glu-Gln-Gln-NH2) and P11-14 (CH3CO-Gln-Gln-Orn-Phe-Orn-
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Trp-Orn-Phe-Orn-Gln-Gln-NH2) there are varying interactions which cause the onset of self-
assembly(Kyle et al., 2012). 
The phenylalanine (Phe) and tryptophan (Trp) residues are hydrophobic so promote 
hydrophobic interactions between the side chains and intermolecular π-π interactions. The  
Ornithine (Orn) and  Glutamic acid (Glu) residues are hydrophilic and promote strong columbic 
and complementary electrostatic interactions where one side of the surface of the β-sheet is 
more hydrophilic than the other because of the Gln, Orn and Glu residues (Kyle et al., 2012). 
1.6.1 External effects on self-assembly 
There are external stimuli that can affect self-assembly in terms of affecting the system 
physically such as change in temperature or physio-chemistry such as change in pH or ionic 
strength of the solution in which the peptides are dissolved. 
1.6.1.1 pH 
By changing the pH of the solution in which the peptides are dissolved, different side chains are 
either protonated or deprotonated. In the case of P11-4, another peptide designed by the Aggeli 
group (Riley et al., 2009, Knapman et al., 2008, Maude et al., 2011, Carrick et al., 2007, Aggeli 
et al., 2001, Maude et al., 2012, Kyle et al., 2009, Kyle et al., 2010, Kirkham et al., 2007, Bell et 
al., 2006, Davies et al., 2006, Davies and Aggeli, 2011), changing the pH caused changes in the 
glutamic acid residue in positions 5,7 and 9 of the sequence (Carrick et al., 2007).  At low pH ~ 
3, P11-4 has fully self-assembled into a β-sheet and has an overall net charge of +1 due to the 
arginine (Arg) residue being protonated. As the pH increases to ~3.4, the electrical charge on 
the Arg residue is neutralised by the glutamic acid and insoluble, self-assembled aggregates 
known as flocculates form. When the pH is increased above 4 the glutamic acid becomes further 
deprotonated and the gel changes to a viscous weakly nematic fluid. The increasing negative 
net charge causes repulsion between the fibrils and fibres such that more of the peptides enter 
a monomeric state. Once the pH is above 8, then the β-sheet completely disintegrates and all 
the peptide chains become monomeric (Carrick et al., 2007). 
These changes in peptide structure and self-assembly by changing pH occur with all SAPs as the 
side chains are susceptible to protonation/deprotonation because of their biological nature. 
1.6.1.2 Ionic strength 
The ionic strength of the solution has also been shown to affect the self-assembling mechanism, 
in that it increases the pH range over which a self-assembled structure can form. It does not 
affect the protonation/ deprotonation of amino acid side chains, implying it affects the self-
assembly by screening the electrostatic repulsion between positive and negatively charged side 
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chains. The charge of the salt also affects the ionic strength as divalent cations such as calcium, 
which have a larger debye radius than univalent cations such as sodium or potassium, means 
screening of the electrostatic interactions over a larger range can occur (Carrick et al., 2007). 
This larger debye radius can also cause unfavourable interactions between calcium ions within 
a fibril which can disrupt self-assembly (Carrick et al., 2007).  
1.6.1.3 Temperature 
Physical changes such as temperature will have multiple effects on both monomeric peptides 
and the self-assembled gels. As the temperature increases, the rate of association/dissociation 
of the side chains changes so that it causes protonation/deprotonation to change when the pH 
is changed. The increased thermal energy also causes the individual molecules to vibrate and 
rotate more so the hydrogen bonds formed between the peptides weaken and the self-
assembled gel disintegrates. 
The physical change from the gel to a fluid is fully reversible upon cooling, as the hydrogen 
bonds are restored and self-assembly reoccurs (Carrick et al., 2007). 
1.7 Different classes of self-assembling peptides 
In current research and literature, there are a variety of different broad ‘classes’ of SAPs. These 
classes differ from each other dependent on the chemistry of the self-assembling mechanism 
and the chemical make-up of the peptide chain. The chemical make-up of the classes can 
include: 
 Different distinct regions within the peptide such as hydrophobic and hydrophilic regions 
 A specific sequence of amino acids  
 Or a different number of specific amino acid  
There are two secondary structures these peptide classes can adopt; β-sheets (as mentioned 
previously) or helices. The different stages of secondary self-assembly are shown in Fig 1.12. 
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Fig 1.12: The different secondary structures adopted by self-assembling peptides (Boyle and Woolfson, 2011). (A) 
represents the random coil state of unassembled SAPs, where upon self-assembling (B) is a β-strand where an 
entropic loss is associated with this state and (C) is an α-helix. These two different secondary structures undergo 
further self-assembly to form (D) which is a β-sheet or (E) and (F) which are multiple interacting α-helices 
(reproduced from Boyle and Woolfson, 2011 with permission from the Royal Society of Chemistry). 
1.7.1 Self-assembling peptides forming helical structures 
1.7.1.1 Helical peptides 
Helical SAPs are different from the previous classes mentioned in this review in that the 
structures are not based around forming a β-sheet secondary structure but instead based 
around forming a helical secondary structure which then assembles into bundles. The hydrogen 
bonding involved in stabilising the α-helix is localised intramolecularly in contrast to that 
witnessed in β-sheet based peptide structures where it is predominately intermolecular 
hydrogen bonding that is responsible for the self-assembly.  
In helical structures the pitch twist is typically smaller compared to β-sheet based structures, 
with 3.6 residues per turn. This results in a smaller fibrillar structure when compared to a similar 
β-sheet forming peptide chain (Boyle, 2012, Boyle and Woolfson, 2011, Boyle and Woolfson, 
2012, Bromley, 2010, Fletcher, 2012, Yoshizumi, 2011).  
In this class the number of amino acids residues in the self-assembling units can vary from as 
few as seven up to as many as twenty eight, but the amino acids within the chains do not vary 
a great deal as they usually contain proline, lysine and glutamic acid. An example of helical 
forming self-assembling peptides is shown in Fig 1.13. 
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Fig 1.13: The repeating units within a helical forming self-assembling peptide (O'Leary, 2011). 
The residues adopt a repeating backbone which have dihedral angles of ϕ-60° and ψ- 45°, 
where this repeating pattern leads to the formation of a tight, right handed helix to form. The 
helix is stabilised through hydrogen bonds from carbonyl and amide groups of the amino acids, 
these groups though are spaces four residues apart along the peptide chain. As mentioned 
above, the average number of residues in each turn is 3.6 which causes the side groups of the 
amino acids that are usually four residues apart into close proximity in space which interact 
through hydrogen bonds of polar groups as well as π-π stacking and hydrophobic interactions 
of aromatic groups. The incorporation of the strained proline residues aids in projecting these 
side groups of nearby residues to be able to interact through aforementioned interactions 
(Boyle and Woolfson, 2011).  
Helical peptides have been used for tissue engineering as scaffolds for cell culture but have 
neither the versatility nor ease of structural modification for use as part of a cell-free early stage 
intervention (Boyle and Woolfson, 2011).  
1.7.2 Self-assembling peptides forming β-sheet like structures 
1.7.2.1 Amphiphiles 
Amphipihilic peptides or peptidic amphiphiles (PAs) are a family of SAPs that are sequences of 
amino acids that form a hydrophilic region and a hydrophobic region. The hydrophilic region of 
the peptide chain is made up of polar, charged amino acids while the hydrophobic region is 
made up of aromatic or uncharged amino acids. This structure causes the peptide chains to 
assemble in the way surfactants do to form micelle-like structures, in which the core is 
composed of the hydrophobic regions that interact mainly through hydrophobic forces and the 
outer surface comprises of hydrophilic regions which interact with the surrounding aqueous 
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solution through hydrogen bonding. A diagram of a typical amphiphilic peptide is shown in Fig 
1.14. 
 
 
 
Fig 1.14: Typical amphiphilic peptide (Sargeant, 2008). 
The structure of PAs can be divided into four distinct regions that require consideration during 
the design stage (CUI, 2010b): 
1. Hydrophobic section – usually an alkyl chain of medium length 
2. Short sequence of amino acids that when the appropriate pH is attained can form intra 
and intermolecular hydrogen bonding 
3. Hydrophilic section – amino acids that are polar and charged that assist by increasing 
the solubility of the peptide and increase the sensitivity of the peptide to changes in pH 
4. A region in which selected ligands can be attached for bioactive signalling 
PAs have been used extensively under the umbrella term of regenerative medicine and these 
applications have included a scaffold material which incorporated Ti-6Al-4V foam that formed 
a nanofiber matrix which altered the bioactivity of the matrix so that it could be a potentially 
active scaffold construct (Sargeant, 2008). PAs, as well as RADA  peptides, have been involved 
in studies on human MSCs (Sargeant, 2012). The final application which is the most pertinent 
to the objective of this review is that of PAs promoting the mineralisation of hydroxyapatite, 
which resembled the extracellular matrix established by proliferating osteoblasts (Hartgerink, 
2001).  
1.7.2.2 Fmoc dipeptides 
Fmoc dipeptides are a class of self-assembling peptides that are formed by the coupling of two 
different amino acid residues, in which one amino acid is protected by a 
fluorenylmethyloxycarbonyl (Fmoc) group on the N terminus. This simple design allows for 
effective block polymeric chains to be produced (Orbach, 2009, Jayawarna, 2009, Das, 2009, 
Jayawarna, 2006, Mart, 2006, Williams, 2008).  
1 
 
3 4 
2 
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These SAPs assemble through hydrogen bonding and electrostatic interactions. The amino acid 
side chains can be either hydrophilic or hydrophobic, in which the strength of assembly depends 
on the number of hydrogen bonds formed between hydrogen bond accepting residues and 
carbonyl groups of the amide bond or hydrogen bond donating residues and amine groups of 
the amide bond of two dipeptides. Other than hydrogen bonding, π-π stacking occurs because 
of the Fmoc group present. The delocalised electrons in the Fmoc groups align one another to 
minimise the unfavourable entropic penalty that interactions with the aqueous solvent causes. 
This alignment of the Fmoc groups is the first stage during self-assembly which forms a template 
upon which hydrogen bonding can form. The stacking forms a tubular column of planar Fmoc 
molecules, around which the hydrophilic side chains branch out to form intra and 
intermolecular hydrogen bonds as illustrated in Fig 1.15. 
 
Fig 1.15: Representation of the two types of interactions involved in the self-assembly of Fmoc dipeptides – 
hydrogen bonding and π-π stacking. 
 A diagram showing how the two amino acids form the Fmoc dipeptide is shown in Fig 1.16.  
 
Fig 1.16: Two different amino acids are covalently bound to form the Fmoc dipeptide (Williams, 2008b). 
Fmoc peptides have been used in many applications in the field of tissue engineering. Some 
studies have involved the Fmoc dipeptides forming hydrogels in which cells were promoted to 
proliferate and differentiate into neurons selectively (Jayawarna, 2006), as seen with studies 
carried out using the PAs and RADA classes of SAPs. Another application,  is the promotion of 
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proliferation and differentiation of chondrocytes, in which different protected amino acids 
were shown to affect chondrocytes when seeded onto a scaffold constructed of these amino 
acids (Jayawarna, 2009).  
1.7.3 Self-assembling peptides forming tape or β-sheet structures 
1.7.3.1 RADA 
The RADA class of self-assembling peptide, which is shown in Fig 1.17, is a peptide with a 
sequence of four repeating amino acids: arginine (R), alanine (A), aspartic acid (D) and alanine 
(A) to form a four amino acid chain with alternating hydrophilic side chain containing residues 
- arginine and aspartic acid, and hydrophobic side chain containing residues - alanine. The 
number of repeats of these four amino acids can range from one group up to four groups 
resulting in a sixteen amino acid containing peptide sequence (Horii, 2007a, K. Chen., 2012, Wu, 
2011, Chau, 2008, Holmes, 2000b, Hamada, 2007, E. Genove., 2005). 
  
Fig 1.17: The repeating structure of a RADA peptide chain (Horii, 2007b). 
RADA SAPs have been studied extensively within the field of tissue engineering as a scaffold 
material for various cell types such as: bone marrow derived mesenchymal stem cells (Genove, 
2005); (Hamada K., 2007), neurites (Holmes, 2000a), and osteoblasts (Horii, 2007b).  
1.7.3.2 MAX peptides 
MAX self-assembling peptides are similar to RADA self-assembling peptides with alternating 
hydrophilic and hydrophobic amino acids in the sequence. The difference is that the choice of 
amino acids is not restricted to only arginine, aspartic acid or alanine residues when being 
designed. The sequence tends to be longer than RADA peptides in that the sequence is 
approximately 20 amino acids long. A diagram of a MAX peptide is shown in Fig 1.18.  
MAX peptides consist of two domains that are linked through a spacer made up of the amino 
acids residues: valine, proline and tyrosine, which form a β-turn (Krysmann, 2008, Nagy, 2011, 
Rajagopal, 2006, Guvendiren, 2012, Nowak, 2002, Rajagopal, 2009, Ozbas, 2007).  
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Fig 1.18: A MAX peptide, where V = Valine and K = Lysine (Rajagopal, 2006b). 
This class of SAPs have been used within tissue engineering research to form scaffolds and 
hydrogel structures upon which cells can proliferate and differentiate. These SAPs have shown 
minimal cytotoxicity, and are cytocompatible with fibroblasts, osteoblast progenitor cells, 
MSCs, hepatocytes and articular chondrocytes (Guvendiren et al., 2012).  
1.7.3.3 P11- X tape based peptides 
P11-X peptides are based on a sequence of eleven amino acids which are either 
hydrophilic/polar or hydrophobic except for three amino acid residues which form an aromatic 
core consisting of phenylalanine and tryptophan residues. A typical structure of a P11-X peptide 
is shown in Fig 1.19. The basic design of this class of SAPs is shown in Fig 1.20. 
 
Fig 1.19: The typical structure of a P11-X peptide, the example above is known as P11-4 (Kirkham et al., 2007). 
The choice of amino acid residues also dictates the pH at which the monomeric form exists as 
they change the overall charge of the peptide chain. These peptides can self-assemble through 
one of two mechanisms: 1) concentration dependency or 2) complementarity (Aggeli, 1997, 
Aggeli, 2001a, Aggeli, 2003a, Aggeli, 2001b, Bell, 2006, Carrick, 2007b, Kirkham et al., 2007, 
Kyle, 2009, Kyle, 2010, Riley, 2009). 
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Fig 1.20: The basic design parameters of the P11-X peptide family. 
This class of SAPs has already been used in cell-free studies by the Aggeli group in the past. One 
application which this class of SAP has been used for is to promote enamel remineralisation in 
the treatment of dental caries. Kirkham et al. used P11-4 to promote hydroxyapatite to 
mineralise in dental caries. The study showed that the crystal structure of P11-4 was perfect for 
hydroxyapatite due to the distance between the glutamic acid residues being the same as the 
crystal lattice structure of hydroxyapatite (Kirkham et al., 2007).   
The most relevant application involved the investigation into the potential application as 
injectable lubricants for osteoarthritic joints. Bell et al. showed that the P11-X series could be 
used in the treatment of osteoarthritis. P11-X peptides, in particular P11-9 which resembled 
hyaluronic acid the closest, were used to investigate whether the application via injection into 
damaged articular cartilage had any measureable restoration of the biomechanical properties 
of the cartilage samples when compared to healthy articular cartilage. The results showed that 
the application of P11-9 restored some of the lubrication properties but was still less efficient 
when compared to hyaluronic acid. It showed that this class of peptides had potential to act as 
a cell-free therapeutic material for the early stage treatment of osteoarthritic cartilage (Bell et 
al., 2005).  
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1.8 Project aims 
The link between the loss of GAGs within articular cartilage and the onset and progression of 
osteoarthritis raises led us to ask: if GAGs can be stably reintroduced into the tissue, would the 
onset and progression of OA be slowed or stopped?  
Previous studies have been carried out to investigate whether simply injection GAGs into 
osteoarthritic joints had any significant effect on restoring the biomechanical properties of the 
tissue, but it was noted that applying physiological loads to the tissue caused expulsion of the 
GAGs. The lack of permanence in the integration of the GAGs into the stable matrix clearly 
prevents them from improving the biomechanical properties of the tissue. If the GAGs can be 
trapped within the tissue somehow, could an improvement of biomechanical properties be 
observed? 
We considered that the use of self-assembling peptides could provide a solution to this 
problem. The formation of a self-supporting stable hydrogel with a cross-linking network of 
fibrils entwined within one another could be a suitable platform for entrapping GAGs within 
cartilage tissue.  
To ensure the full entrapment of GAGs within the SAPs matrix, it was envisaged that the GAGs 
could be bound covalently to the SAP matrix through the synthesis of a GAG functionalised SAP 
with the GAG linked to the peptide through the use of click chemistry. The idea was to mimic 
the structure of aggrecan, with the covalently bound GAGs projected out from the SAP core 
similar to the protein core found within aggrecan, but rather than the use of a linker protein to 
bind the two fragments together, a triazole motif would be used. As illustrated in Fig 1.21, the 
idea for the design of the Pep-GAG conjugate is that upon in situ self-assembly within the 
cartilage tissue to ensure penetration, the self-assembling peptides, both non-functionalised 
and functionalised variants, will assembly into an aggrecan-like brush structure where the CS 
chains project out from the core which would comprise of the self-assembling peptide strands. 
 
Fig 1.21: A representation of the aim to form an aggrecan like brush structure using the Pep-GAG conjugates. 
CS molecule 
Core protein 
Click bond 
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A proof of concept project was carried out in house by a group of researchers led by Kainmuller 
(unpublished). However, although small quantities of the SAP-GAG conjugate were obtained, it 
could not be fully characterised. This made quantification and analysis of the effect of 
introducing the conjugate into both self-assembled gels and biologically derived materials 
difficult to perform on scale and made results inconclusive. The aim of this project were: 
1. To design, develop and optimise the synthesis of a SAP-GAG conjugate  
2. To characterise the effect of incorporating the conjugate within a SAP hydrogel matrix.  
3. Once the most suitable conditions have been identified, to develop and produce an 
osteoarthritic porcine cartilage model to enable the response of the biomechanical 
properties to incorporation to the peptide GAG conjugate to be measured.  
The different stages are described in the following Chapters. 
 Chapter 3 describes the optimisation of the chemical synthesis of self-assembling 
peptides and their functionalisation by covalently linking chondroitin sulfate utilizing 
click chemistry 
 Chapter 4 discusses the effects of mixing the SAP/GAG conjugates and SAPs at varying 
molar ratios (1:64 and 1:32) on the self-assembly, biomechanical and biophysical 
properties of the resulting materials. 
 Chapter 5 investigates the biomechanical properties of the GAG depleted articular 
cartilage treated with SAPs/GAGs. 
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Chapter 2 
Material and methods 
2.1 Materials 
2.1.1 Equipment 
A list of general laboratory equipment used during the study including the suppliers is presented 
in Appendix 1. 
2.1.2 Glassware 
All laboratory glassware was purchased from Fisher Scientific (Loughbourgh, UK) unless 
otherwise stated. Glassware was cleaned by either immersion in a 1 % (v/v) solution of 
Neutracon® for one hour and was then rinsed with tap water and dried or sterilised using dry 
heat (for biological or tissue work) or cleaned with detergent, then rinsed with tap water, then 
acetone and dried or placed in an oven (~60-70 °C) until required (for chemical synthesis). 
2.1.3 Plastic ware 
All non-sterile and sterile disposable plastic ware was purchased from Scientific Laboratory 
Supplies Ltd. (Nottingham, UK) unless otherwise stated. All plastic ware was stored as per 
suppliers' instruction. 
2.1.4 Reagents 
All chemical reagents, Cat No’s and supplier information are listed in Appendix 1. 
2.1.5 Cells  
The cell lines used during this study, along with suppliers, are listed in Table 2.1. 
Cells Type Species Supplier 
BHK Fibroblasts Hamster Health Protection 
Agency 
L929 Fibroblasts Murine Health Protection 
Agency 
Table 2.1: Cells used during the study. 
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2.1.6 General stock solutions 
2.1.6.1 Phosphate buffered saline (PBS) 
One PBS tablet was dissolved in 100 ml distilled water. The pH was adjusted to pH 7.2 -7.4 using 
6M hydrochloric acid (HCl) or 6M sodium hydroxide (NaOH) solution. 
2.1.6.2 Baby hamster kidney (BHK) cell culture medium 
Glasgow’s minimal essential media (GMEM) 82 ml was used with 5 % (v/v) foetal bovine serum 
(FBS) 5 ml, 10 % (v/v) tryptone phosphate broth (TPB) 10 ml, 2 mM L- glutamine 1 ml, 100 U.ml-
1 penicillin and 100 U.ml-1 streptomycin – 2 ml total volume. 
2.1.6.3 L929 cell line culture medium 
Dulbecco’s modified Eagle’s medium (DMEM) 87 ml was used with 10 % (v/v) FBS 10 ml, 2 mM 
L-glutamine 1 ml, 100 U.ml-1 penicillin and 100 U.ml-1 streptomycin – 2 ml total volume 
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2.2 General methods 
2.2.1 Sterilisation 
2.2.1.1 Dry heat sterilisation 
Equipment or glassware to be sterilised was placed in suitable containers or wrapped in tinfoil 
and placed into a hot air oven (190°C for 4 hours). Items were allowed to cool and then 
removed, with care being taken to maintain sterile conditions. 
2.2.1.2 Moist heat/ autoclave sterilisation 
Solutions and equipment such as plastic ware not suitable for dry heat sterilisation were 
sterilised using an autoclave. Items were placed into autoclave bags and labelled with autoclave 
tape. Items were autoclaved (121°C for 20 minutes at 15 psi). Items were allowed to cool and 
were then removed with care being taken to maintain sterility. 
2.2.1.3 Measurement of pH 
The pH meter used was either a Jenway 3020 pH meter, Satorius Docu-pH meter or WPA CD720 
pH meter. The meter was calibrated using purchased standard solutions of pH 4, 7, and 10. The 
pH of solutions was measured at room temperature using temperature compensation. The pH 
of solutions was changed by the drop-wise addition of 6 M HCl or 6 M NaOH whilst being stirred 
unless otherwise stated. 
2.2.1.4 Lyophilisation of samples 
Samples were lyophilised differently depending on whether the samples were chemical or 
biological in nature. Chemical samples were placed in freeze-able glass vials and frozen by 
immersion in liquid nitrogen (N2). The vial caps were then pierced and placed in a freeze dryer 
(Thermo, Heto Powerdry LL1500 or VirTis, Benchtop BTP 8ZL) at -101 °C, 0.15 - 0.1 mbar until 
completely lyophilised.  
For biological samples such as cartilage tissue, the cartilage tissue was cut away from the 
subchondral bone and macerated. Samples were then placed in suitable containers and 
weighed three times with mean wet weight calculated. Samples were placed in a freeze dryer 
(Thermo, Savant ModulyoD) at -50 °C, 0.15 - 0.2 mbar, and the weight measured every 24 hr 
until constant (48 - 72 hr). 
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2.3 Chemical methods 
2.3.1 Synthetic methods 
 
Compound 3 
 
 
4-ethynybenzylalcohol (500 mg, 3.78 mmol, 1 eq), N-hydroxyphthalimide (925 mg, 5.67 mmol, 
1.5 eq) and PPh3 (1.5 g, 5.67 mmol, 1.5 eq) were suspended in dry THF (10 ml) under N2, cooled 
to 0 °C, and DIAD (ρ=1.027, 1.1 ml, 5.67 mmol, 1.5 eq) was added dropwise. After the addition 
was complete the reaction mixture was warmed up to rt and the clear/slightly yellow solution 
was stirred under N2 overnight, during which some product precipitated from the mixture, It 
was isolated by filtration and the filtrate was concentrated to dryness under reduced pressure. 
The residue was purified by recrystallization from hot MeOH/EtOAc to yield compound 3 (814 
mg, 78%) as slightly yellow crystals. 
δH (500MHz, CDCl3) 7.85-7.80 (2H, m, Ar Phthalimide), 7.75-7.70 (2H, m, Ar Phthalimide), 7.50 (4H, s, 
ArBenzyl), 5.22 (2H, s, CH2), 3.12 (1H, s, Alkyne H).  δC (75MHz, CDCl3) 163.4, 134.5, 134.3, 132.3, 
129.6, 128.9, 123.5, 123.1, 83.2, 79.2, 78.0. m/z (ESI=) 300.1 ([M+Na]+ 100%); found MNa+ 
300.0734, C17H11NO3Na requires 300.0631. 
 
Compound 4 
 
 
JW1-5 (1.6g, mmol, 1eq) was suspended in DCM (20ml), hydrazine monohydrate (ρ=1.032, 
560µl, 5.67mmol, 2eq) was added and the reaction mixture heated under reflux overnight. After 
filtration, 1.0M HCl in Et2O was added to the filtrate until pH<2. The colourless precipitate was 
isolated by filtration, washed with DCM and dried to yield compound 4 (941mg, 84%) as a 
colourless powder. 
δH (500MHz, DMSO) 11.1 (3H, s, NH3), 7.54 (2H, d, J 8.2, Ar), 7.45 (2H, d, J 8.2, Ar), 5.08 (2H, s, 
CH2), 4.27 (1H, s, Alkyne H). δC (75MHz, DMSO) 134.4, 132.0, 129.5, 122.4 82.9, 81.5, 75.1. m/z 
(EI+) found M+ 147.0682, C9H9NO requires M 147.0684. 
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Compound 5 
 
Chondroitin 6-sulphate (50mg, ~2.8µmol, 1eq) and compound 4 (25.5mg, 0.14mmol, 50eq) in 
DMSO/AcOH 85:15 (5ml) (pH 3-3.3) was stirred at 40°C for 1.5-2hr then NaBH3CN (87.3mg, 
1.4mmol, 500eq) in H2O (5ml) was then added to the mixture. The solution was stirred 
overnight (pH 3.5-.3.7). During this process, gas formation (HCN) occurred. The gas was bubbled 
through aqueous NaOH (pH 11-11.5) and later destroyed together with any cyanide containing 
waste by addition of bleach. After 1, 2 and 3d more NaBH3CN (3x 87.3mg, Σ1500eq) was added 
and after 6d the crude mixture was purified by dialysis over 2 days. The solution was 
concentrated after each change using TLC (KMnO4 and H2SO4 in MeOH). The resulting mixture 
was freeze dried to yield compound 5 (48mg) as a colourless solid.  
νmax/cm-1 (DMSO) 3450 (br, O-H). 2950-3050 (m, C-H), 1830 (m, C=O, acid), 1755 (s, C=O, amide 
I), 1630 (m, N-H, amide II) 
νmax/cm-1 (Solid) 2910-2930 (m, C-H), 1738 (m, C=O, acid), 1652 (s, C=O, amide I), 1553 (m, N-H, 
amide II). 
 
Compound 6 –Protocol 1 
 
Chondroitin 6-sulphate (50mg, ~2.8µmol, 1eq) and compound 4 (25.5mg, 0.14mmol, 50eq) in 
10 mM aqueous Aniline solution (2 ml), 100 mM NaOAc buffer(2 ml) (pH 4) and 1mM aqueous 
Na Ascorbate (1 ml) was stirred at 40°C overnight. The crude mixture was purified by dialysis 
over 2 days. The solution was monitored after each dialysis change using TLC (KMnO4 and H2SO4 
in MeOH). The resulting mixture was freeze dried to yield compound 6 (45mg) as a colourless 
solid.  
δH (500MHz, DMSO) 9.1 (1H, s, HC=N), 7-7.3 (4H, m, aromatic), 4.2-5 (multiple, m, CS chains) 
νmax/cm-1 (DMSO) 3450 (br, O-H). 2950-3050 (m, C-H), 1830 (m, C=O, acid), 1755 (s, C=O, amide 
I), 1630 (m, N-H, amide II). 
νmax/cm-1 (Solid) 2910-2930 (m, C-H), 1738 (m, C=O, acid), 1652 (s, C=O, amide I), 1553 (m, N-H, 
amide II). 
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Compound 6 –Protocol 2 
 
Chondroitin 6-sulphate (50mg, ~2.8µmol, 1eq) and compound 4 (25.5mg, 0.14mmol, 50eq) in 
10 mM aqueous p-phenylenediamine solution (2 ml), 100 mM NaOAc buffer(2 ml) (pH 4) and 
1mM aqueous Na Ascorbate (1 ml) was stirred at 40°C for 1 hr. The crude mixture was purified 
by dialysis over 2 days. The solution was monitored after each dialysis change using TLC (KMnO4 
and H2SO4 in MeOH). The resulting mixture was freeze dried to yield compound 6 (45mg) as a 
colourless solid.  
δH (500MHz, DMSO) 9.1 (1H, s, HC=N), 7-7.3 (4H, m, aromatic), 4.2-5 (multiple, m, CS chains) 
νmax/cm-1 (DMSO) 3450 (br, O-H). 2950-3050 (m, C-H), 1830 (m, C=O, acid), 1755 (s, C=O, amide 
I), 1630 (m, N-H, amide II). 
νmax/cm-1 (Solid) 2910-2930 (m, C-H), 1738 (m, C=O, acid), 1652 (s, C=O, amide I), 1553 (m, N-H, 
amide II). 
 
Base peptide 1 (P11-4) Protocol 1 
Rink Amide PEGA (loading 0.35 mmol/g) or Rink Amide Novagel (loading 0.63 mmol/g) were 
swollen in DMF for 1 hr and then either washed with DMF (5×). Fmoc-Gln(Trt)-OH  (5.0 eq) and 
HCTU (5.0 eq) were dissolved in DMF and DIPEA (10.0 eq) was added to the solution. The 
mixture was inverted to mix and then added to the resin and agitated for 1 hr. Consecutive 
couplings (Q (Fmoc-Gln(Trt)-OH),E (Fmoc-Glu(OtBu)-OH),F (Fmoc-Phe-OH),E (Fmoc-Glu(OtBu)-
OH),W (Fmoc-Trp(Boc)-OH),E (Fmoc-Glu(OtBu)-OH),F (Fmoc-Phe-OH),R (Fmoc-Arg(Pbf)-OH),Q 
(Fmoc-Gln(Trt)-OH),Q (Fmoc-Gln(Trt)-OH)) were carried out using an automated peptide 
synthesizer (Liberty CEM 12 908505). The resin was filtered then sequential washes of DMF 
(5x2min), 20% Piperidine in DMF (5min), DMF (2min), 20% Piperidine in DMF (5min), DMF 
 
 
57 
 
 
(2min), 20% Piperidine in DMF (5min) and DMF (5x2min) to carry out Fmoc deprotection. The 
next amino acid (5.0 eq) and HCTU (5.0 eq) were dissolved in DMF, addition of DIPEA (10.0 eq) 
to the solution and the mixture was added to the resin and agitated for 20 min under microwave 
assistance except for the Arginine residue where a normal coupling of 1hr without microwave 
assistance was carried out.. Once the final amino acid had been coupled, the resin was washed 
with DMF (5x2ml) then stored in DMF until required for further functionalisation. 
 
Base peptide 1 (P11-4) Protocol 2 
NovaSyn TG Sieber (loading 0.1-0.25 mmol/g) were swollen in DMF for 1 hr and then activated 
by addition of 20% Piperidine in DMF (3x2 min) and then washed with DMF (5x 2min). Fmoc-
Gln(Trt)-OH  (5.0 eq) and Oxyma Pure (5.0 eq) were dissolved in DMF and DIC (5.0 eq) was 
added to the solution. The mixture was inverted to mix and then added to the resin and agitated 
for 1 hr. Consecutive couplings (Q (Fmoc-Gln(Trt)-OH),E (Fmoc-Glu(OtBu)-OH),F (Fmoc-Phe-
OH),E (Fmoc-Glu(OtBu)-OH),W (Fmoc-Trp(Boc)-OH),E (Fmoc-Glu(OtBu)-OH),F (Fmoc-Phe-OH),R 
(Fmoc-Arg(Pbf)-OH),Q (Fmoc-Gln(Trt)-OH),Q (Fmoc-Gln(Trt)-OH))  were carried out using an 
automated peptide synthesizer (Liberty CEM 12 908505). The resin was filtered then sequential 
washes of DMF (5x 2min), 20 % Piperidine in DMF (5 min), DMF (2 min), 20% Piperidine in DMF 
(5 min), DMF (2 min), 20 % Piperidine in DMF (5 min) and DMF (5x2 min) to carry out Fmoc 
deprotection. The next amino acid (5.0 eq) and Oxyma Pure (5.0 eq) were dissolved in DMF, 
addition of DIC (5.0 eq) to the solution and the mixture was added to the resin and agitated for 
20 min under microwave assistance except for the Arginine residue where a normal coupling of 
1hr without microwave assistance was carried out. Once the final amino acid had been coupled, 
the resin was washed with DMF (5x2 ml) then stored in DMF until required for further 
functionalisation. 
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Base peptide 2 (P11-8) 
 
NovaSyn TG Sieber (loading 0.1-0.25 mmol/g) were swollen in DMF for 1 hr and then activated 
by addition of 20% Piperidine in DMF (3x2 min) and then washed with DMF (5x 2min). Fmoc-
Gln(Trt)-OH  (5.0 eq) and Oxyma Pure (5.0 eq) were dissolved in DMF and DIC (5.0 eq) was 
added to the solution. The mixture was inverted to mix and then added to the resin and agitated 
for 1 hr. Consecutive couplings (Q (Fmoc-Gln(Trt)-OH),E (Fmoc-Glu(OtBu)-OH),F (Fmoc-Phe-
OH), O (Fmoc-Orn(Boc)-OH),W (Fmoc-Trp(Boc)-OH),O (Fmoc-Orn(Boc)-OH),F (Fmoc-Phe-OH),R 
(Fmoc-Arg(Pbf)-OH),Q (Fmoc-Gln(Trt)-OH),Q (Fmoc-Gln(Trt)-OH))  were carried out by an 
automated peptide synthesizer (Liberty CEM 12 908505). The resin was filtered then sequential 
washes of DMF (5x2 min), 20% Piperidine in DMF (5 min), DMF (2 min), 20% Piperidine in DMF 
(5 min), DMF (2 min), 20% Piperidine in DMF (5 min) and DMF (5x2 min) to carry out Fmoc 
deprotection. The next amino acid (5.0 eq) and Oxyma Pure (5.0 eq) were dissolved in DMF, 
addition of DIC (5.0 eq) to the solution and the mixture was added to the resin and agitated for 
20 min under microwave assistance except for the Arginine residue where a normal coupling of 
1 hr without microwave assistance was carried out. Once the final amino acid had been coupled, 
the resin was washed with DMF (5x2 ml) then stored in DMF until required for further 
functionalisation.  
 
Peptide 1 
 
P11-4 on Rink Amide Novagel resin (0.1 mmol) was coupled with Fmoc-Lys(Mca)-OH (175.6 mg, 
0.3 mmol, 3 eq) using HCTU (121 mg, 0.29 mmol, 2.9 eq) and DIPEA (ρ=0.74, 105 µl, 0.6 mmol, 
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6 eq) in DMF (3 ml) overnight. Next, Fmoc-PEG-COOH (119 mg, 0.21 mmol, 2.1 eq) was 
introduced using HCTU (83.2 mg, 0.2 mmol, 2 eq) and DIPEA (ρ=0.74, 73.5 µl, 0.42 mmol, 
4.2 eq) in DMF (3 ml) overnight. For the attachment of 6-bromohexanoic acid, the acid (195 mg, 
1 mmol, 10 eq) and DIC (ρ=0.81, 78.1 µl, 0.5 mmol, 5 eq) were dissolved in dry DCM (5 ml) at 
0 °C under N2. After 30 min, the solvent was removed under reduced pressure and the 
colourless needles were redissolved in warm DMF (4 ml) and added to the solid phase. The 
mixture was agitated overnight, filtered and the resin was washed with DMF (5x2 min) and 
DMSO (5x2 min). For introduction of the azide, NaN3 (52 mg, 0.8 mmol, 8 eq) was dissolved in 
DMSO (5 ml) and reacted with the resin overnight. After filtration and washing of the solid 
phase with DMSO (5x2 min), DMSO/H2O 1:1 (5x2 min), DMF (5x2 min) and DCM (5x2 min) the 
peptide was cleaved using TFA/TIPS/DCM 95:2.5:2.5 (1 ml). The mixture was agitated for 6 hr, 
filtered and the filtrate concentrated under reduced pressure. The crude peptide was 
precipitated by addition of cold Et2O, centrifuged and the pellet suspended in 1% NH3 solution 
and lyophilised. Complete removal of the Trp-COOH protecting group was achieved by 
repetitive re-suspension of the peptide in 1% AcOH and lyophilisation. The peptide was purified 
by a reverse phased UV-directed Biotage system with 0.1% NH3 in H2O as solvent A and 0.1% 
NH3 in CH3CN as solvent B with a gradient 10% -> 90% solvent B over 20 min. Rt (HPLC-MS 
column 1 positive) 1.752 min, m/z (ESI+) [M+2H]2+-1092.2048 100%, C100H136N26O30 requires 
[M+2H]2+  1092.2056. 
 
Peptide 2 
 
P11-4 on Rink Amide Novagel resin (0.1 mmol) was coupled with Fmoc-PEG-COOH (119mg, 
0.21 mmol, 2.1 eq) was introduced using HCTU (83.2 mg, 0.2 mmol, 2eq) and DIPEA (ρ=0.74, 
73.5 µl, 0.42 mmol, 4.2 eq) in DMF (3ml) Next, Fmoc-Lys(Mca)-OH (175.6 mg, 0.3 mmol, 3 eq) 
using HCTU (121 mg, 0.29 mmol, 2.9 eq) and DIPEA (ρ=0.74, 105 µl, 0.6 mmol, 6 eq) in DMF 
(3 ml) was coupled overnight. For the attachment of 6-bromohexanoic acid, the acid (195 mg, 
1 mmol, 10 eq) and DIC (ρ=0.81, 78.1 µl, 0.5 mmol, 5 eq) were dissolved in dry DCM (5 ml) at 
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0 °C under N2. After 30 min, the solvent was removed under reduced pressure and the 
colourless needles were redissolved in warm DMF (4 ml) and added to the solid phase. The 
mixture was agitated overnight, filtered and the resin was washed with DMF (5x2 min) and 
DMSO (5x2 min). For introduction of the azide, NaN3 (52 mg, 0.8 mmol, 8 eq) was dissolved in 
DMSO (5 ml) and reacted with the resin overnight. After filtration and washing of the solid 
phase with DMSO (5x2 min), DMSO/H2O 1:1 (5x2 min), DMF (5x2 min) and DCM (5x2 min) the 
peptide was cleaved using TFA/TIPS/DCM 95:2.5:2.5 (1 ml). The mixture was agitated for 6 hr, 
filtered and the filtrate concentrated under reduced pressure. The crude peptide was 
precipitated by addition of cold Et2O, centrifuged and the pellet suspended in 1% NH3 solution 
and lyophilised. Complete removal of the Trp-COOH protecting group was achieved by 
repetitive resuspension of the peptide in 1% AcOH and lyophilisation. The peptide was purified 
by a reverse phased UV-directed Biotage system with 0.1% NH3 in H2O as solvent A and 0.1% 
NH3 in CH3CN as solvent B with a gradient 10% -> 90% solvent B over 20 min. Rt (HPLC-MS 
column 1 positive) 1.710 min, m/z (ESI+) [M+2H]2+-1092.2057 100%, C100H136N26O30 requires 
[M+2H]2+  1092.2056. 
 
Peptide 3 
P11-4 on NovaSyn TG Sieber resin (0.1 mmol) was coupled with Fmoc-PEG-COOH (119 mg, 
0.21 mmol, 2.1 eq) was introduced using Oxyma Pure (59.6 mg, 0.42 mmol, 4.2 eq) and DIC 
(ρ=0.815, 102.9 µl, 0.42 mmol, 4.2 eq) in DMF (3 ml). For the attachment of 6-bromohexanoic 
acid, the acid (195 mg, 1 mmol, 10 eq) and DIC (ρ=0.81, 78.1 µl, 0.5 mmol, 5 eq) were dissolved 
in dry DCM (5 ml) at 0 °C under N2. After 30min, the solvent was removed under reduced 
pressure and the colourless needles were redissolved in warm DMF (4 ml) and added to the 
solid phase. The mixture was agitated overnight, filtered and the resin was washed with DMF 
(5x2 min) and DMSO (5x2 min). For introduction of the azide, NaN3 (52 mg, 0.8 mmol, 8 eq) was 
dissolved in DMSO (5 ml) and reacted with the resin overnight. After filtration and washing of 
the solid phase with DMSO (5x2 min), DMSO/H2O 1:1 (5x2 min), DMF (5x2 min) and DCM 
(5x2 min) the peptide was cleaved using TFA/TIPS/DCM 95:2.5:2.5 (1 ml). The mixture was 
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agitated for 6 hr, filtered and the filtrate concentrated under reduced pressure. The crude 
peptide was precipitated by addition of cold Et2O, centrifuged and the pellet suspended in 1% 
NH3 solution and lyophilised. Complete removal of the Trp-COOH protecting group was 
achieved by repetitive resuspension of the peptide in 1% AcOH and lyophilisation. The peptide 
was purified by a reverse phased UV-directed Biotage system with 0.1% NH3 in H2O as solvent 
A and 0.1% NH3 in CH3CN as solvent B with a gradient 10% -> 90% solvent B over 20 min. Rt 
(HPLC-MS column 1 positive) 2.335 min, m/z (ESI+) [M+2H]2+- 919.9373 100%, C82H116N24O25 
requires [M+2H]2+  919.9384. 
 
Peptide 4 
 
P11-8 on NovaSyn TG Sieber resin (0.1 mmol) was coupled with Fmoc-PEG-COOH (119 mg, 
0.21 mmol, 2.1 eq) was introduced using Oxyma Pure (59.6 mg, 0.42 mmol, 4.2 eq) and DIC 
(ρ=0.815, 102.9 µl, 0.42 mmol, 4.2 eq) in DMF (3 ml). For the attachment of 6-bromohexanoic 
acid, the acid (195 mg, 1 mmol, 10 eq) and DIC (ρ=0.81, 78.1 µl, 0.5 mmol, 5 eq) were dissolved 
in dry DCM (5 ml) at 0 °C under N2. After 30 min, the solvent was removed under reduced 
pressure and the colourless needles were redissolved in warm DMF (4 ml) and added to the 
solid phase. The mixture was agitated overnight, filtered and the resin was washed with DMF 
(5x2 min) and DMSO (5x2 min). For introduction of the azide, NaN3 (52 mg, 0.8 mmol, 8 eq) was 
dissolved in DMSO (5 ml) and reacted with the resin overnight. After filtration and washing of 
the solid phase with DMSO (5x2 min), DMSO/H2O 1:1 (5x2 min), DMF (5x2 min) and DCM 
(5x2 min) the peptide was cleaved using TFA/TIPS/DCM 95:2.5:2.5 (1 ml). The mixture was 
agitated for 6 hr, filtered and the filtrate concentrated under reduced pressure. The crude 
peptide was precipitated by addition of cold Et2O, centrifuged and the pellet suspended in 1% 
NH3 solution and lyophilised. Complete removal of the Trp-COOH protecting group was 
achieved by repetitive resuspension of the peptide in 1% AcOH and lyophilisation. The peptide 
was purified by a reverse phased UV-directed Biotage system with 0.1% TFA in H2O as solvent 
A and 0.1% TFA in CH3CN as solvent B with a gradient 10% -> 90% solvent B over 20 min. Rt 
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(HPLC-MS column 1 positive) 1.1824 min, m/z (ESI+)  [M+2H]2+- 1077.0440 100%, C102H146N28O26 
requires [M+2H]2+  1077.0431. 
 
Conjugate 1 Protocol 1 
 
In this order, 0.15 mM ethynyl benzyl alcohol (100 μl, 1 eq) in DMSO (Compound 1), 0.3 mM 
peptide 3 (100 μl, 2 eq) in DMSO, 1 mM CuSO4.5H2O (100 μl, 6 eq) in H2O and 10 mM Na-
Ascorbate in H2O (100 μl, 60 eq) were added together after being degassed with N2 to H2O (600 
μl). The reaction mixture was left for 90 hr. Upon completion, the mixture was purified by six 
rounds of dialysis (1 hr) (MWCO 14 kDs), additional H2O was added and lyophilised. White 
powder was obtained – conjugate 1 in ~20 % conversion based on LC-MS analysis. 
 
Conjugate 1 Protocol 2 
 
In this order, 1 mM peptide 3 (100 μl, 1 eq) in DMSO, 1 mM TCEP in H2O (100 μl, 1 eq) in H2O, 
1 mM CuSO4.5H2O in H2O (100 μl, 1 eq), 1mM TBTA in DMSO (100 μl, 1 eq) and 5 mM ethynyl 
benzyl alcohol (100 μl, 5 eq) in DMSO (Compound 1) were added together after being degassed 
with N2 to 100 mM sodium phosphate buffer (500 μl). The reaction mixture was left for 90 hr. 
Upon completion, the mixture was purified by six rounds of dialysis (1 hr) (MWCO 14 kDa), 
additional H2O was added and lyophilised. White powder was obtained – conjugate 1 in ~80 % 
conversion based on LC-MS analysis.  
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Conjugate 1 Protocol 3 
 
In this order, 1 mM peptide 3 (100 μl, 1 eq) in DMSO, 1 mM ethynyl benzyl alcohol (100 μl, 1 eq) 
in DMSO (Compound 1), 1 mM Na-Ascorbate (100 μl, 1 eq), 1mM TBTA in DMSO (100 μl, 1 eq) 
and 1 mM CuSO4.5H2O in H2O (100 μl, 1 eq) were added together after being degassed with N2 
to 100 mM sodium phosphate buffer (500 μl). The reaction mixture was left for 90 hr. Upon 
completion, the mixture was purified by six rounds of dialysis (1 hr) (MWCO 14 kDa), additional 
H2O was added and lyophilised. White powder was obtained – conjugate 1 in ~90 % conversion 
based on LC-MS analysis.  
 
Conjugate 2  
 
In this order, 1 mM peptide 3 (100 μl, 1 eq) in DMSO, 1 mM Compound 4 (100 μl, 1 eq) in 
DMSO, 1 mM Na-Ascorbate (100 μl, 1 eq), 1mM TBTA in DMSO (100 μl, 1 eq) and 1 mM 
CuSO4.5H2O in H2O (100 μl, 1 eq) were added together after being degassed with N2 to 100 mM 
sodium phosphate buffer (500 μl). The reaction mixture was left for 90 hr. Upon completion, 
the mixture was purified by six rounds of dialysis (1 hr) (MWCO 14 kDa), additional H2O was 
added and lyophilised. White powder was obtained – conjugate 2 in ~70 % conversion based 
on LC-MS analysis.  
 
 
 
 
 
 
 
 
 
64 
 
 
Conjugate 3 
 
In this order, 1 mM peptide 3 (100 μl, 1 eq) in DMSO, 1 mM Compound 5 (100 μl, 1 eq) in 
DMSO, 1 mM Na-Ascorbate (100 μl, 1 eq), 1mM TBTA in DMSO (100 μl, 1 eq) and 1 mM 
CuSO4.5H2O in H2O (100 μl, 1 eq) were added together after being degassed with N2 to 100 mM 
sodium phosphate buffer (500 μl). The reaction mixture was left for 90 hr. Upon completion, 
the mixture was purified by six rounds of dialysis (1 hr) (MWCO 14 kDa), additional H2O was 
added and lyophilised. White powder was obtained – conjugate 3 in ~80 % conversion based 
on LC-MS analysis. 
 
Conjugate 4 
 
In this order, 1 mM peptide 4 (100 μl, 1 eq) in DMSO, 1 mM Compound 5 (100 μl, 1 eq) in 
DMSO, 1 mM Na-Ascorbate (100 μl, 1 eq), 1mM TBTA in DMSO (100 μl, 1 eq) and 1 mM 
CuSO4.5H2O in H2O (100 μl, 1 eq) were added together after being degassed with N2 to 100 mM 
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sodium phosphate buffer (500 μl). The reaction mixture was left for 90 hr. Upon completion, 
the mixture was purified by six rounds of dialysis (1 hr) (MWCO 14 kDa), additional H2O was 
added and lyophilised. White powder was obtained – conjugate 4 in ~70 % conversion based 
on LC-MS analysis. 
2.3.2 Gel preparation 
Lyophilised peptide, and either conjugate 3 or 4 or CS only at varying quantities (~5 mg for 1:64 
ratio or ~10 mg for 1:32 ratio) were weighed out into glass vials and reconstituted in 
monomerising solution – either 1 M sodium acetate buffer at pH 4 or 1 M sodium phosphate 
buffer at pH 10 (1 ml), vortexed for 30 sec and sonicated for 5 min. The sample was then frozen 
in liquid N2 and then lyophilised. Once fully lyophilised the sample was reconstituted in pH 
adjusted (pH 7.4) buffer (1 ml), vortexed for 30 sec and sonicated for 5 min and stored in a cool, 
dark place until required for testing.  
2.3.3 Liquid chromatography-mass spectrometry (LC-MS) analysis 
If the sample was dry, then 5-10 mg was dissolved in either methanol or water (1 ml) if possible, 
or DMSO (1 ml) as an alternative. If the sample was in solution, then 10 μL was taken and made 
up to 1 ml with the solvents mentioned above, depending on the sample. LC-MS analysis (Bruker 
HCT-Ultra) was then carried out with 10 μL of sample injected using one of two techniques: 
small molecular weight sample C18 column – positive procedure with acidic solvents 20-80% 
MeOH in H20, and for large molecular weight sample peptide C18 column– high mass positive 
peptide column with acidic solvents 20-80% MeOH in H2O. Once the sample had been processed 
by the mass spectrometer then the data was analysed on Bruker Data analysis 4.0 software.  
2.3.4 Mass spectrometry analysis 
The sample (5 mg) was dissolved in methanol or water (1 ml).  The solution was then injected 
into the mass spectrometer (Bruker MaXis Impact spectrometer) (10 μL) (without LC 
separation) and run through a high mass electrospray ionisation procedure. The data was 
analysed on Data analysis 4.1 SRI software. 
2.3.5 Fourier transformed infra-red (FTIR) analysis 
The sample (~2-3 mg) was placed on the diamond cell of the spectrometer (Perkin Elmer 
Spectrum 100S) and an infrared spectrum was produced. The spectrum was analysed using 
Omnic software to assign the relative peaks and the associated functional groups. 
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2.3.6 Nuclear magnetic resonance (NMR) analysis 
The sample (~10 mg) was dissolved in either deuterated water, deuterated chloroform or 
deuterated DMSO. The solution was then placed in a 5mm NMR tube and analysed. A variety 
of methods were then carried out on each sample. The 400 MHz apparatus (Bruker Avance 400) 
was used to run low resolution proton NMR, large scan number proton NMR and 2-D NMR 
experiments while the 500 MHz apparatus (Bruker Avance 500) was used to run high resolution 
proton NMR and carbon NMR experiments. The spectra produced was analysed on Mestrenova 
software to assign the relative peaks and corresponding species environment, depending on 
the experiment run. 
2.3.7 Transmission electron microscopy 
                  Transmission electron microscopy was carried out using a JEOL 1400 electron microscope. 
Electron microscope (EM) grids (copper hexagonal 400 mesh) pre-coated with a carbon film 
from mica sheets prepared in house. The peptide solutions remained in contact with the grids 
for one minute, the excess was then removed. The grids were negatively stained by absorption 
of 2 % (w/w) aqueous uranyl acetate solution for 20 seconds. The excess was removed and left 
to air dry. Images were obtained, with the TEM operating at 80 kV accelerating voltage, 
immediately after sample preparation to avoid artefacts and destruction of the sample. 
2.3.8 Rheological analysis 
All the rheological measurements were performed on a Malvern Kinexus Pro rheometer with a 
plate-plate of geometry (diameter: 25 mm, gap: 0.033 mm). All the tests were performed at 
37 oC, utilizing a solvent trap with the atmosphere being kept saturated to minimize 
evaporation of the peptide samples. 
Amplitude sweeps were performed at 0.01-100 % shear strain in a controlled mode. Two 
amplitude sweeps were carried out for each sample (250 μL) (1 Hz and 20 Hz) and a strain level 
was chosen at which the elastic/storage modulus (G’) and viscous/loss modulus (G’’) were 
independent of strain amplitude at the two different frequency levels. 
The dynamic moduli of the hydrogels were measured as a function of frequency with the 
sweeps carried out between 1 and 20 Hz. Peptide samples (250 μL) were allowed to equilibrate 
for 15 minutes once loaded on to the plate prior to the start of testing.  
rSpace for Kinexus 1.10 (Malvern Instruments) was used to control the rheometer and to export 
the raw data into Origin 9.1 (OriginLab Corporation, USA) which was used to process and plot 
the results. 
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2.3.9 Flame atomic absorption spectroscopy  
In order to calculate the concentration of residual copper following click reactions, the solutions 
absorbance were measured using a Perkin Elmer Aanalyst 200 flame atomic absorption 
spectrophotometer. A calibration curve was required so CuSO4 standards were made up in 
distilled water in 100 ml volumetric flasks at the following concentrations 0.001, 0.005, 0.01, 
0.05, 0.1, 0.5, 1, 2 and 5 mM. The standards were measured three times to obtain an average 
and then a calibration curve was plotted using Microsoft Excel of absorbance versus known 
concentration. The unknown samples were then measured in triplicate also and the average 
absorbance was used for each unknown to calculate the residual concentration. 
2.4 Biochemical methods 
2.4.1 Papain Digestion 
For sulphated proteoglycan quantification, macerated, freeze-dried tissues were digested using 
papain. 
Reagents listed in Table 2.2. 
Reagents Substituents 
Digestion buffer (pH 6.0) 0.788 g L-cystine hydrochloride 
1.8612 g EDTA 
1 L PBS 
Digestion solution 1250 U papain 
25 ml digestion buffer 
Table 2.2: List of reagents for papain digestion of cartilage samples 
Papain digestion solution (5 ml) was added to 10 - 20 mg (dry weight) lyophilised cartilage in a 
bijou and incubated in a water bath at 60 °C for 36 - 48 hr, until fully digested. 
2.4.2 DMMB photometric assay 
Reagents listed in Table 2.3. 
Reagents Substitutents 
Phosphate buffer (pH 6.8) 137 ml sodium di-hydrogen 
orthophosphate (0.1 M) 
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63 ml di-sodium hydrogen orthophosphate 
(0.1 M) 
DMMB dye (pH 3.0) 16 mg DMMB 
5 ml ethanol 
2 ml formic acid 
2 g sodium formate 
Table 2.3: List of regents for DMMB photometric assay 
Made up to 1 L with distilled water 
Method: 
Tissues were lyophilised (Section 2.2.1.4) and papain digested (Section 2.4.1). Standard 
calibration solutions of chondroitin sulfate were made up in phosphate buffer at 0, 3.125, 6.25, 
12.5, 25, 50, 100, 150 and 200 μg.ml-1. Test samples were diluted 1:100, in phosphate buffer. 
Each standard and sample (40 μl) were added to a clear, 96 well flat bottomed plate in triplicate, 
to which 250 μl DMB dye was added. Plates were gently agitated for 2 min on a plate shaker at 
50 rpm before the optical density of each well was measured at 525 nm using a micro plate 
spectrophotometer. A standard curve was plotted of the absorbance of the chondroitin sulfate 
standards vs concentration. Dilution factors were then accounted for, and the concentration of 
GAG was determined for tissue dry weight. 
2.4.3 Stains-all photometric assay 
Reagents listed in Table 2.4. 
Stock Stains-all solution 0.1 % (w/v) in formamide 
Reagent Substitutents 
Stains-all dye working solution (pH 8.8) 0.005 % (w/v) Stains-all stock solution 
10 % (v/v) formamide 
25 % (v/v) isopropanol 
15 mM Trizma-HCl, pH 8.8 
65 % H2O 
 
Table 2.4: List of reagents for Stains-all assay 
Made up to 100 ml with distilled water 
Method: 
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Standard calibration solutions of SDS were made up in distilled water at 0, 1.95, 3.91, 7.82, 
15.63, 31.25, 62.5, 125, 250, 500, 1000 and 2000 μg.ml-1. Test samples were diluted 1:100, in 
phosphate buffer. Each standard and sample (40 μl) were added to a clear, 96 well flat 
bottomed plate in triplicate, to which 50 μl Stains-all dye was added. Plates were gently agitated 
for 2 min on a plate shaker at 50 rpm before the absorbance of each well was measured at 447 
nm using a micro plate spectrophotometer. A standard curve was plotted of the absorbance of 
the SDS standards vs concentration. Dilution factors were then accounted for, and the 
concentration of SDS was determined. 
2.4.3 Extract cytotoxicty  
Each copper salt (CuSO4 and CuCl2) was weighed and was added to BHK and L929 media to 
create test solutions that would give varying concentration (0.001 - 5 mM) during the 
cytotoxicity testing. 
Two cell lines, L929 and BHK cells, were sub-cultured and re-suspended in cell culture medium; 
DMEM based medium for L929 cells (Section 2.1.7.3) and GMEM based medium for BHK cells 
(Section 2.1.7.2). Cells were seeded at an appropriate cell density to achieve 80 % confluence 
in a 96 well plate. The cell suspension (200 μl) was added to the wells of a 96 well plate and 
incubated for 48 hours at 37°C in 5 % (v/v) CO2 in air. The cell culture medium was aspirated 
from the cells and replaced with 100 μl of fresh L929 and BHK cell culture medium. 100μl of test 
solution or control (positive, standard cell culture medium with 40 % DMSO; negative, standard 
cell culture medium) was added and incubated at 37°C in 5 % (v/v) CO2 in air for 72 hours. Six 
samples of each peptide were tested. The level of ATP was then measured using the ATPLite- 
M® assay described in Section 2.4.4. The results were collected and plotted as the mean value 
with 95 % confidence limits (Section 2.7.1). Data was analysed for significant difference by one-
way ANOVA. 
2.4.4 ATP-lite photometric assay 
ATPLite-M® assay reagents, lyophilised substrate solution, substrate buffer and mammalian cell 
lysis solution, were allowed to equilibrate to room temperature. The vial of lyophilised 
substrate solution was reconstituted by the addition of 5 ml of substrate buffer. 
The medium was aspirated from each well of the 96 well plate and replaced with 100 μl of fresh 
cell culture medium. To each well 50 μl of mammalian cell lysis solution was added and agitated 
at 500 rpm for five minutes. To each well 50 μl of substrate solution was added; the wells were 
covered in tin foil to prevent photo-bleaching and agitated at 500 rpm for five minutes. The 
luminescence was determined using a Chameleon Plate Reader. The data was exported into 
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Microsoft® Excel 2013, then the results are normalised against the readings for the blank wells. 
. 
2.5 Biological methods 
2.5.1 Tissue culture 
Cells were cultured in cell culture medium (Section 2.1.6). All cell culture work was performed 
aseptically in a class II safety cabinet. Cultures were incubated at 37 °C in 5 % CO2 (v/v) in air. 
Before use, all culture media and additives were equilibrated to 37 °C. 
2.5.1.1 Resurrection and maintenance of cells 
Following removal from liquid N2 storage, cells were thawed in a 37 °C water bath. Thawed cell 
stock (2 ml) was added to a T75 cell culture flask containing 13 ml of the appropriate, pre-
warmed cell culture medium. Flasks were incubated for at least 18 hr at 37 °C in 5 % CO2 (v/v) 
in air to allow cells to attach to the culture plastic. Culture medium was changed every 48-72 hr 
until cells were confluent and could be passaged. 
2.5.1.2 Cell passaging 
Cell culture medium was aspirated and the monolayer gently washed two times with 10 ml PBS 
without calcium or magnesium. Trypsin/EDTA (1.5 ml) was added to the flask and incubated for 
5 min at 37 °C in 5 % CO2 (v/v) in air. Flasks were gently tapped to detach cells and 10 ml culture 
medium was added to suspend cells and inhibit trypsin activity. The cell suspension was then 
centrifuged for 10 min at 150 G. The supernatant was carefully aspirated from the cell pellet, 
which was then re-suspended in 5 ml culture medium. Following a count of viable cells (Section 
2.5.1.3), the appropriate cell density was seeded into a fresh flask with culture medium and the 
medium replaced every 2-3 days until confluent and ready for further passage. 
2.5.1.3 Cell viability 
In order to test the viability of cells, trypan blue was added to cell suspensions before counting. 
Trypan blue is able to enter dead cells due to a loss of membrane potential, so live cells 
microscopically appeared transparent while dead cells appeared blue and could therefore be 
excluded from cell counts. 
To perform a cell count, 20 μl cell suspension was added to 20 μl trypan blue and added to an 
Improved Neubauer counting chamber. Viable cells were counted in n number of grids which 
resulted in a cell count. The total number of cells per ml suspension was calculated as follows: 
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Number of viable cells 
Number of cells / ml = ----------------------------------------- x 104 x Dilution factor 
4 
Where n = number of grids used in count  
And Dilution factor = correction required due to dilution of cell suspension in trypan blue (in 
this case Dilution factor = 2) 
2.5.2 Dissection of cartilage tissue 
Porcine legs were supplied by local abattoirs, usually within 24 hr of slaughter. Pigs were aged 
~ 6 months. Joints were used fresh, or stored at 4 °C overnight for dissection the following day. 
Excess flesh was removed from the skeletal structures to allow easier access and 
manoeuvrability. Joints were exposed by cutting the surrounding tissue and extracapsular 
ligaments, then the joint capsule was excised. All ligaments were severed and the menisci 
removed from the knee so that all joint surfaces were exposed. Excess tissue was removed to 
ensure as clean a surface as possible was achieved prior to any further processing. The femoral 
condyles were then removed using an oscillating saw. Any exposed cartilage surfaces were kept 
hydrated throughout by covering in PBS soaked tissue. Harvested tissue was then kept at 4 °C 
overnight in PBS soaked tissue or carried forward through the 0.1 % SDS washes for GAG 
depletion.  
2.5.3 GAG depletion method 
Reagents listed in Table 2.5. 
Reagents Constituents  
0.1 % SDS 2 g SDS  
2 l distilled water 
PBS See Section 2.1.7.1 
Table 2.5: List of reagents for GAG depletion of cartilage tissue 
Femoral porcine condyles were placed in 250 ml plastic containers. Sequential washes in the 
order or and for duration described - 2 × 0.1 % SDS (200 ml) wash overnight, 3 × PBS (200 ml) 
washes and 1 × PBS (200 ml) wash overnight. Upon completion of the cycle, the tissue was 
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covered in PBS soaked tissue and either treated with peptide hydrogel samples (Section 2.5.6) 
or stored overnight at 4 °C until treatment or tested the following day. 
2.5.4 Cartilage layer retrieval  
Osteochondral pins 9 mm in diameter and ~12 mm deep were extracted from cartilage surfaces 
of the medial and lateral condyles. The pins were initially marked out then a power drill with a 
specialist corer drill bit was used to cut into the subchondral bone. A handheld corer was then 
used to loosen the pin and extract it from the joint. The cartilage layer was removed using a 
scalpel from the pin and placed in a plastic cassette for fixation processed or frozen in optimal 
cutting temperature (OCT) fluid for cryo-sectioning.  
2.5.5 Cryo-sectioning 
Cartilage samples were kept frozen until required. The cryostat (Leica CM3050 S) was pre-
cooled to -28 °C. The embedded cartilage samples were then frozen using OCT fluid on to a 
metal stub and then placed in to a stainless steel holder. The excess frozen OCT fluid was 
removed and then 100 μm sections were taken and placed on to Superfrost Plus slides then 
immersed in 70 % (v/v) ethanol for 30 sec to fix the tissue. Once fixed the sections covered in 
tin foil and were stored at -15 °C until visualised using microscopy. 
2.5.6 Histological methods 
2.5.6.1 Fixation 
Cartilage layer samples were placed in a 250 ml plastic container with 200 ml 1M zinc acetate 
for 24 hr to achieve complete fixation. 
2.5.6.2 Paraffin wax embedding 
Cartilage samples were placed in plastic cassettes (Histocette®) and cycled in the Leica TP 120 
automated tissue processor. Cassettes containing the cartilage tissue were processed by 
immersion in 70 % (v/v) ethanol for 1 hr followed by 1 hr in 90 % (v/v) ethanol. Cassettes 
containing the cartilage tissue were then immersed in absolute ethanol for 2 hr 20 min, 3 hr 20 
min then 4 hr 20 min sequentially. Immersion in xylene followed for cycles of 1 hr, 1 hr 30 min 
and 2 hr sequentially. Cassettes containing the cartilage tissue were then embedded with 
molten paraffin wax for 1 hr 30 min then 2 hr. Tissue cassettes were taken from the automated 
processor, tissues removed and orientated cut-surface-down in moulds. Samples were covered 
in molten wax, left to set overnight at room temperature, after which, excess wax was trimmed 
away. 
 
 
73 
 
 
2.5.6.3 Sectioning and slide preparation 
Wax embedded tissues were sectioned on a microtome (Leica RM2125RTF) to a thickness of 10 
μm. Using forceps and a brush, sections were carefully placed in a water bath at 40 °C. The wax 
sections were then transferred onto Superfrost Plus slides and placed directly onto a hotplate 
at 45 °C to bake on and dry overnight. 
2.5.6.4 Dewaxing and rehydration 
Sections were dewaxed in xylene for 10 min, then in fresh xylene for another 10 min. Sections 
were then dehydrated in 3 successive immersions in 100% (v/v) ethanol for 3 min, 2 min then 
2 min followed by immersion in 70% (v/v) ethanol for 2 min. Slides were then placed under 
running tap water for 3 min to rehydrate the sections. 
2.5.6.5 Dehydration and mounting 
Stained sections were dehydrated by immersion in 70% (v/v) ethanol for 5 sec, followed by 
successive washes in 100% ethanol for 1 min, 2 min and 3 min. Sections were then immersed 
twice in xylene for 10 min each time. Cover slips were mounted to slides using a drop of DPX 
mountant, avoiding bubbles. Slides were left to dry in a fume hood overnight before visualizing 
using microscopy. 
2.5.6.6 Safranin O/fast green staining 
Reagents listed in Table 2.6. 
Reagent Substitutents 
0.1 % (w/v) Safranin O 0.1 g Safranin O 
100 ml distilled water 
0.02 % (w/v) Fast green 0.02 g fast green 
100 ml distilled water 
Table 2.6: List of reagents for Safranin O/fast green staining 
Safranin O stains proteoglycans while fast green stains collagen, nuclei are stained with 
Weigert’s haematoxylin. Following dewaxing and rehydration, sections were immersed in 
Weigert’s haematoxylin for 3 min then running tap water for 10 min. Sections were 
differentiated in 1 % (v/v) acid alcohol for 1 min then rinsed for 3 min in running tap water. 
Sections were immersed in fast green for 5 min before being rinsed in acetic acid for 10-15 sec.  
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2.5.7 Immunohistochemical staining 
2.5.7.1 Reagents 
Reagents listed in Table 2.7. 
Reagent Substituents 
Hydrogen peroxide solution (3 % 
v/v) 
20 ml hydrogen peroxide (30 % v/v) 180 ml PBS 
Tris buffer (2 M, pH 7.6) 242.26 g Trizma base 758 ml distilled water 
Sodium chloride solution (3M) 175.32 g sodium chloride 1 L distilled water 
Tris buffered saline (TBS) 
 
25 ml Tris buffer (2 M) 
50 ml sodium chloride solution (3 M) 
925 ml distilled water 
TBS containing 0.05 % (w/v) Tween 
20 (TBS-T) 
500 μl Tween 20 1 L TBS 
 
Bovine serum albumin (BSA; 5 % 
w/v) 
2.5 g BSA 500 ml PBS 
6 ml Sodium azide (1 % w/v) 
Antibody diluent 
 
300 μl BSA (5 % w/v) 
54 ml TBS 
1 L distilled water 
Table 2.7: List of reagents for immunohistochemical labelling for CS 
2.5.7.2 Sample preparation 
Fresh and GAG depleted cartilage tissue (n=3) were fixed in 0.1M zinc acetate, wax embedded, 
sectioned and transferred onto slides as described in Sections 2.5.4.1 – 2.5.4.2, sections were 
then dewaxed and rehydrated as described in Section 2.5.6.4. 
2.5.7.3 Antigen retrieval 
As tissues had been zinc acetate fixed, antigen retrieval was performed to re-expose tissue 
epitopes for antigen binding. Following dewaxing and rehydration, each section was circled 
using a hydrophobic marker and proteinase K solution applied drop wise until sections were 
fully covered. Sections were incubated at room temperature for 20 min. 
2.5.7.4 Labelling of tissue sections using monoclonal antibodies 
Following sample preparation (Section 2.5.7.2) sections were immersed in hydrogen peroxide 
(3 %, v/v) in PBS for 10 min at room temperature to block endogenous peroxidase activity, and 
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then washed for 3 min in running tap water. Sections were briefly washed with TBS on a plate 
rocker. Following antigen retrieval (Section 2.5.7.3) dual endogenous enzyme block (25 μl) from 
the Ultra vision kit was added to block non-specific background staining, and sections were 
incubated for 10 minutes, followed by two ten min washes in TBS on a plate rocker. The primary 
antibody specific for chondroitin sulfate – CS-56 (Rabbit) was then applied at working 
concentration and incubated at room temperature for 1 hr. Sections were then washed twice 
for 10 min in TBS-T, then twice for 10 min in TBS on a plate rocker. Labelled polymer-HRP (20 
μl) from the Ultra vision kit was then added to each section and incubated for 30 min in the 
dark at room temperature. Sections were again washed twice for 10 min in TBS-T, then twice 
for 10 min in TBS on a plate rocker. Excess buffer was tapped off before substrate chromogen 
(20 μl liquid 3,3-diaminobenzidine (DAB) chromagen plus 1 ml substrate buffer) was added to 
each section and incubated at room temperature for 10 min. Sections were rinsed four times in 
distilled water before being immersed in haematoxylin (Mayer’s) for 10 sec. Sections were 
washed for 3 min in running tap water before being dehydrated and mounted in DPX mountant, 
as described in Section 2.5.6.5. To verify specific antibody binding, an isotype control was 
performed on native and GAG depleted tissue sections using IgG (Rabbit) in place of the primary 
antibody at the same concentration as the primary antibody had been used. An antibody-free 
negative control was also included, in which sections were incubated in antibody diluent alone 
in place of the primary and secondary antibody. Once dry, sections were viewed using normal 
light microscopy. 
2.5.8 Optical microscopy 
Bright-field microscopy was carried out using an Olympus BX40 microscope. Fluorescence 
microscopy was carried out with the fluorescent vertical illuminator (BX51-RFA) and 
appropriate filters using the same microscope. Images were captured using an attached 
Olympus digital camera controlled through Cell^B software (image capture and digitalisation).  
2.5.9 Peptide injection 
Reconstituted peptide solution as described in Section 2.3.2, was drawn up into a 1 ml syringe 
through a 30 G needle. The areas of injection on the GAG depleted condyles were circled using 
a hydrophobic pen. 20 injections were then carried out injecting approximately 50 μl into each 
site and the sample placed in a suitable container, covered in tin foil to avoid photo bleaching 
and left overnight in the dark at 4 °C to equilibrate and self-assemble in situ. 
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2.5.10 Confocal microscopy  
The samples were imaged in a thawed state and were placed on a glass histology slide 
(Superfrost plus). The samples were imaged using a Zeiss LSM 510 META inverted confocal 
microscope using a FITC filter. Fluorescence recovery after photo bleaching experiments were 
carried out by selecting two regions on a live image of the section. The positive control was 
imaged every 1 ms until 5 ms then photo bleached using 100 % power of the 488 nm laser. The 
regions were then imaged every 1 ms for 100 ms. Images were collected using the associated 
image software (Carl Zeiss ZEN) and were analysed using LSM image browser. 
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2.6 Biomechanical methods 
2.6.1 PMMA cementing 
In order to carry out both creep and needle indentation the porcine condyles needed to be 
cemented. The cementing was carried out in stainless steel cylinders, where 2 stages were 
prepared. A ratio of 2:1 Cold Cure ™ rapid repair powder: Cold Cure ™ repair liquid was 
prepared in straight sided glass beakers. The first stage was poured, allowed to cure for 30 min 
and then the condyles were placed on the cured cement and the second stage was poured 
around the condyles to ensure majority of the condyles were covered with the area of interest 
left exposed. The cement was left to fully cure for 30 min and then removed from the cylinders 
and covered in PBS soaked tissue ready for testing, or left in 4 °C overnight for testing the 
following day. 
2.6.2 Creep indentation 
In order to assess the time dependent biomechanical behaviour of articular cartilage, femoral 
condyles underwent creep indentation. Condyles were secured in a stainless steel cylindrical 
sample holder and submerged in PBS to maintain cartilage hydration. An impermeable, 
stainless steel, cylindrical indenter (2.5 mm diameter) was used with an added 20.5 g weight 
added to indent the cartilage with a load of 2.54 N over 1 h. The indenter was positioned ~ 1 
mm above the cartilage surface and the lowering of the indenter shaft was controlled via a 
silicone oil filled dashpot, to reduce the speed of impact, the full load was applied within 0.2 
sec. The displacement of the indenter was measured using a linear variable differential 
transducer (LVDT; RDP D5-200H, Electrosence, PA, USA) and the resistance force measured 
using a piezo-electric force transformer (Part No. 060-1896-02, Electrosence, PA, USA). LabView 
8 software (National Instruments, TX, USA) was used to collect and store data produced by the 
force transducer and LVDT. 
2.6.2.1 Calibration 
Calibration was required to convert the voltage outputs of the LVDT and force transducer into 
millimetres and Newtons respectively. Standard steel slip gauges were used to calibrate the 
LVDT, the voltage was recorded for each height increase following the addition of slip gauges. 
Voltage was plotted against slip gauge height and the linear trend line calculated, the equation 
of which was used as a calibration factor (Fig 2.1). 
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Fig 2.1: Voltage against slip disc height calibration plot. 
To calibrate the force transducer, the voltage was recorded over incremental increases of 
known mass. This again, was plotted as a graph and the equation of the trend line used to 
convert voltage to Newtons (Fig 2.2). 
 
Fig 2.2: Voltage against slip disc weight calibration plot. 
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2.6.3 Needle indentation for cartilage thickness measurement 
The thickness of cartilage was measured in order to normalise deformation data for each 
cartilage thickness of the condyles so that the percentage deformation could be presented and 
the material properties could be derived. Cartilage thickness was assessed using needle 
indentation. An Instron material testing machine (Instron 3365, Bucks, UK) was used for this 
purpose. A needle attached to the instron arm was manually positioned ~1 mm above the 
cartilage surface. During testing the arm was controlled via a PC graphic user interface and 
lowered at a rate of 4.5 mm.min-1. The resistance to motion was measured using a 500 N load 
cell. 
Cartilage thickness was defined as the distance between the increase in resistance from initial 
needle contact with the surface and the steep increase in resistance from needle contacting the 
much stiffer bone. Each condyle was indented 6 times and the mean thickness calculated. 
2.7 Statistical analysis 
2.7.1 Confidence limits 
Numerical data was analysed using Microsoft Excel (version 2013, Microsoft) and presented as 
the mean (n ≥ 3) ± 95 % confidence level (CL). The 95% confidence intervals (a = 0.05) were 
calculated using the descriptive statistics part of the data analysis package in Microsoft Excel 
2.7.2 Statistical analysis 
The student’s t-test was used to compare groups of two means or a one way analysis of variance 
(ANOVA) was used when comparing the means of more than two groups. Individual differences 
between group means were identified by calculating the minimum significant difference (MSD) 
at p = 0.05 using the T-method, or T’-method when comparing groups of unequal sample size 
(Sokal & Rohlf, 1995). 
2.7.3 Arcsin transformation 
Where data is presented as a percentage or proportion, values were transformed to arcsin to 
allow accurate calculation of 95 % CL and statistical analysis. Following analysis, values were 
transformed back for presentation. 
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Chapter 3  
Synthesis and characterisation of a 
synthetic peptide-GAG conjugate 
As discussed in Chapter 1, the aim of my approach was to prepare a GAG functionalised version 
of P11-4.  The target route employed a late stage functionalisation of a peptide and derivatised 
GAG using copper catalysed click chemistry.   
This approach was originally tested at Leeds by a postdoctoral researcher (Dr Eva Kainmueller) 
but only on a very small scale which made characterisation inconclusive and so significant 
optimisation was required in this chapter. The key reactions involved in the peptide synthesis, 
GAG functionalisation and biorthogonal connection of the two units will firstly be reviewed 
followed by discussion of the synthesis of the target functionalised peptide. 
3.1 Introduction 
3.1.1 Peptide chemistry 
Peptide synthesis involves creating a covalent amide bond between the amine group of one 
amino acid molecule and the carboxylic acid group of another amino acid molecule. This 
chemistry has changed significantly over the past 100 years, from the first recorded dipeptide 
synthesis by Fischer in 1901 via hydrolysis of a glycine diketopiperazine (Fischer and Fourneau, 
1901) through to the formation and use of pseudoprolines by two different groups in 1996 (Liu 
et al., 1996, Wöhr et al., 1996). The major development in the synthesis of longer peptides was 
the discovery of solid phase peptide synthesis (SPPS) by Merrifield in 1963.  This technique 
involves attachment of the peptide chain to an insoluble polymeric resin on which the chain 
grows through iterative amino acid additions (Merrifield, 1963), (Carpino et al., 2003, 
Chandrudu et al., 2013, Nishiuchi et al., 1998). SPPS enables the easy removal of coupling 
reagents, simpler peptide isolation/purification procedures and consequently the ability to use 
excess reagents to drive reactions to completion. 
 There are currently two different principal strategies for SPPS which differ in the protecting 
groups used on the α-NH2 and reactive groups on the amino acid side chains. The most 
commonly employed method use N-α-fluorenylmethyloxycarbonyl (Fmoc)-protected amino 
acids which can be deprotected using a mild base – piperidine.  A range of side chain protecting 
 
 
81 
 
 
groups are used in Fmoc based synthesis which can be cleaved in TFA.  A second approach uses  
N-α t-butyloxycarbonyl (Boc)-protected amino acids however as this protecting group uses TFA 
for removal, more resilient side chain protection is required which requires deprotection with 
anhydrous hydrogen fluoride (HF) (Anderson and McGregor, 1957, Carpino, 1957, Carpino and 
Han, 1970). Avoiding the use of hazardous HF has been one of the main reasons that the Fmoc-
based route has gained dominance over the Boc-based methods.  Fmoc-based synthesis  has 
been automated using relatively inexpensive equipment as early as  1968 (Chandrudu et al., 
2013) and many automated synthesisers are now commercially available.  
The relatively simple SPPS method requires four steps – loading, deprotection, coupling and 
cleavage, as illustrated in Fig 3.1, where the deprotection and coupling steps are repeated for 
each subsequent amino acid residue following the attachment of the first amino acid.  
 
Fig 3.1: A representation of Fmoc-SPPS of a peptide amide where the loading stage uses a resin which has a 
terminal amino group, with a single synthetic cycle shown. 
Whilst the fundamental steps of Fmoc SPPS are simple, different protection and coupling 
strategies have been developed to optimise the SPPS process. Firstly, both the terminal Nα and 
the side chain functional group require protection in an orthogonal manner so that chain 
elongation can be performed  without removing the side chain protection (Viola et al., 2003). 
These lateral protecting groups prevent unwanted side reactions occurring during the coupling 
reactions. The common side chain protecting groups employed in Fmoc SPPS are illustrated in 
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Fig 3.2, which include trityl (Trt), pentamethyl-2, 3-dihydrobenzofuran-5-sulfonyl (Pbf), t-butyl 
(OtBu), and Boc motifs.  
 
Fig 3.2: Various terminal N and side chain protecting groups. 
Another consideration when using SPPS is the coupling method which is used to connect the 
resin-attached terminal amine to the next amino acid building block. The ideal coupling method 
should also prevent the potential of racemisation during the coupling (Kokubo et al., 2003). The 
most commonly used coupling methods are based on using activated esters, frequently of 1-
hydroxybenzotriazole (HOBt) or a closely related alternative.  These are generated in situ using 
an activating agent such as a carbodiimide (eg DIC) or a uronium reagent such as HATU, or the 
less allergenic HCTU in the presence of tertiary amine base (Tibbitt and Anseth, 2009).  
Carbodiimide mediated activation involves in situ formation of an O-acylisourea intermediate 
which reacts with HOBt to form the hydroxybenzotriazole ester.  The rapid reaction of the HOBt 
with the intermediate prevents intramolecular cyclisation to form an oxazolone where 
racemisation can occur (Hutmacher, 2001). The HATU method uses a weak base such as N,N-
Diisopropylethylamine (DIPEA) to deprotonate the carboxyl group in order to accelerate the 
coupling reaction but a similar activated ester still results. More recently the observation that 
HOBt can be explosive under certain conditions has led to alternatives being developed.  The 
most popular is OxymaPure® (Behrendt et al., 2016) which is typically employed with DIC in 
coupling reactions. The mechanisms of these two methods are shown in Fig 3.3. 
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Fig 3.3: i) HATU method mechanism using HCTU, where the base is DIPEA ii) HOBt method mechanism using 
HOBt and DIC iii) HOBt method mechanism using Oxyma Pure® and DIC. 
The final consideration in designing SPPS is the choice of resin and linker where are range of 
different base resins have been developed with different loading and swelling properties which 
can affect the yields of peptides, particularly with difficult sequences.  A range of linkers can 
also be used to attach the first amino acid to the resin that produce different C-terminal 
functions on the peptide (Elashal et al., 2016) and which cleave from the resin under different 
conditions. 
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3.1.2 Carbohydrates 
Carbohydrates, and especially polysaccharides, have been extensively investigated in the field 
of biomaterials/regenerative medicine. These naturally occurring polymeric chains comprise 
various saccharide building blocks connected in linear and sometimes branched arrays. The 
main focus of attention for biomaterials research ranges from polysaccharides that are found 
within nature but not the human body – such as chitosan (Bertoldo et al., 2011, Ifuku et al., 
2011, Lallana et al., 2009), through to those found in great abundance within the human body 
– such as hyaluronic acid or chondroitin sulfate (Hu et al., 2011, Upadhyay et al., 2009, 
Yamaguchi et al., 2010, Yamaguchi et al., 2006) The structures of these polysaccharides is shown 
in Fig 3.4.  
Fig 3.4: Different natural polysaccharides, where chitosan consists of a single repeating uncharged saccharide 
unit (β-(1-4)- linked D-glucosamine with random glucosamine residues being acetylated), whilst hyaluronic acid  
(alternating β-(1-3) and β-(1-4)-linked D- glucuronic acid and D-N-acetylglucosamine)  and chondroitin sulfate ( 
D-glucuronic acid and  D-N-acetylgalactosamine with random sulfation of hydroxyl groups) consist of a repeating 
anionic disaccharide unit. 
Hyaluronic acid and chondroitin sulfate are known as glycosaminoglycans, and are found within 
many different tissues within the human body but the main tissue where these two GAGs work 
in synergy is articular cartilage. These GAGs, along with other similar GAGs such as dermatan 
sulfate and heparin sulfate, associate with one another through linker proteins along a central 
backbone to form a family of macromolecules called proteoglycans. The most abundant 
proteoglycan found within the human body is aggrecan, which consists of a hyaluronic acid 
backbone to which linker proteins connect at random sites. A core protein – ACAN is connected 
to the linker protein which is highly modified with chondroitin sulfate and dermatan sulfate 
which project outwards to produce a “brush-like” structure, as illustrated in Fig 3.5.  
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Fig 3.5: A representation of aggrecan, with the GAG chains arranged in a brush-like structure around a protein 
backbone. A more detailed description can be found in Chapter 1. 
These polysaccharides can consist of up to 1000 repeating units of the structures shown in Fig 
3.5 which, when combined with the random modifications through enzymatic processes – such 
as acetylation in the case of chitosan and hyaluronic acid or sulfation for chondroitin sulfate 
make direct chemical synthesis of these species impractical.  Consequently the GAGs that will 
be incorporated into materials in this project will need to be derived from natural sources and 
then selectively derivatised to enable attachment to peptides. Selective derivatisation of GAGs 
is however challenging resulting from the multiple reactivity of the monomeric building blocks 
and the length and polydispersity of the polysaccharides which makes controlling stoichiometry 
and subsequent analysis highly challenging. Various strategies have been employed to modify 
these high molecular weight structures such as azidation, esterification, amidation and 
reductive amination (Elchinger et al., 2011). With the exception of reductive amination, these 
strategies mainly involve modifying the hydroxyl or amino groups on saccharide units. 
Reductive amination can be carried out selectively on the reducing end of a saccharide due to 
the equilibrium between the cyclic hemiacetal and the open chain aldehyde forms at this 
position as shown in Fig 3.6. Reductive amination hence selectively functionalises a single 
position in the saccharide and was the reaction employed in this project. 
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Fig 3.6: The equilibrium state of the reducing end of a saccharide and reductive amination via the formation of 
an imine. 
3.1.3 Click chemistry 
Once the peptide sequence has been successfully assembled, the terminal nitrogen can either 
be derivatised with additional functionality.  The P11-X series of peptides are acetylated to 
prevent the N-termini bearing a positive charge which can be detrimental to self-assembly, with 
the structure of a typical P11-X peptide and the acetylated group shown in Fig 3.7.  Alternatively 
the termini can be modified to enable further functionalisation of the peptide to occur after 
synthesis and cleavage from the resin. One of the most versatile modifications currently 
employed, is to arm the peptide chain with functional groups that enable a range of 
biorthogonal reactions, generically categorised by the term ‘click’ chemistry, to be utilised to 
append further groups onto the peptide. This type of post-synthesis functionalisation has 
become common place in the world of chemical biology, chemical engineering, biomaterials 
and regenerative medicine.  
Fig 3.7: An example of a P11-X peptide and the acetylated terminus highlighted. 
There are various types of click chemistry currently employed, where the biocompatibility and 
rate of reaction of the biorthogonal step can differ greatly.  One of the most common click 
chemistries is the azide-alkyne 1, 3 dipolar cycloaddition, first documented by Huisgen in 1963, 
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where an azide and an internal or terminal alkyne react to form a 1, 2, 3-triazole(Huisgen, 1963). 
However, it was not until 2001, when the Sharpless group utilised this reaction in the context 
of a biological system that the importance of this and other click-type reactions was 
rediscovered. Since this point groups around the world have developed many different  
biorthogonal reaction systems (Kolb et al., 2001). These different reactions have varying rate 
constants (k) ranging from slow ketone condensation reactions with k ~ 10-4 – 10-3 M-1 s-1 
(Rideout, 1986, Mahal et al., 1997, Brustad et al., 2008, Chen et al., 2005, Lang and Chin, 2014) 
through to exceptionally rapid tetrazine-trans cyclooctene (TCO) and enzymatic reactions with 
k ~ 105 M-1 s-1 (Lang et al., 2012a, Lang et al., 2012b, Seitchik et al., 2012). There are at least 
eleven different bioorthogonal reaction systems that have been developed including a family 
of systems involving tetrazines (Lang et al., 2012a, Lang et al., 2012b, Seitchik et al., 2012) while 
another family include strain-promoted alkyne-azide/alkyne-nitrone cycloadditions where the 
alkyne is usually incorporated into a strain cyclooctyne ring system (Plass et al., 2011, Ning et 
al., 2010). The most commonly used system though, is based on utilising copper (I) complexes 
to catalyse the cycloaddition reaction between an alkyne and an azide – this system is called 
Cu (I)-catalysed alkyne-azide cycloaddition (CuAAC), where the k ~ 102 M-1 s-1   Typically this 
reaction is tolerant of a range of pH values and functions in aqueous buffers at a range of 
concentrations. Example of different biorthogonal click reactions are illustrated in Fig 3.8, with 
the typical k values shown. 
 
Fig 3.8: Various types of “click” reactions, with the corresponding rate constants shown. 
The versatility of this chemistry has opened up the potential for far greater control over 
constructing complex, multi-domain structures, which, in the field of chemical biology, has 
allowed labelling of proteins with various diagnostic tools such as fluorophores.  
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As described in Chapter 1, the general synthetic route will be as shown in Fig 3.9. 
 
Fig 3.9: The general synthetic strategy for the total synthesis of a peptide-CS conjugate based on synthesizing 
two fragments: an azide functionalised peptide fragment and a functionalised CS fragment. 
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3.2 Results  
3.2.1 Synthesis of P11-4 and P11-8 peptide fragments 
In order to prepare functionalised peptide building blocks the first step was to prepare the base 
peptide using manual SPPS.  P11-4 is acylated at the N-terminus but replacement of this unit 
can enable the installation of the required functional groups for GAG conjugation.  The initial 
design also envisaged addition of a fluorophore to the peptide chain to enable tracking of the 
molecule and aid analysis. 
The target product bore an N-terminal azido group separated from the peptide by a PEG spacer. 
A coumarin functionalised lysine residue has been added at the N-terminus of the core P11-4 
peptide to provide the required fluorescence (Fig 3.10). 
 
Fig 3.10ː Structure of P11-4 (top) and peptide 1 - functionalised P11-4 (bottom). 
This methylcoumarin labelled lysine residue has good photophysical properties with an 
excitation peak ~360nm which does not overlap with the excitation peak of the tryptophan side 
chain (λex ~284 nm), which meant UV detection could be employed to aid in the characterisation 
of the Pep/GAG conjugate. The appropriate Fmoc protected amino acid building block was also 
commercially available.    
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3.2.1.1 P11-4: Unidecamer or Dodecamer 
Previous research carried out by the Aggeli group at the University of Leeds, suggested that the 
optimal number of amino acids in a peptide chain for self-assembly was any odd number as this 
minimises the entropic penalty and maximises the enthalpic gain during self-assembly (Aggeli 
et al., 2001).  The addition of the coumarin molecule in peptide 1 extends the formal peptide 
chain to 12 amino acids due to the coupling of the labelled lysine. In case this disfavoured 
incorporation of the peptide into a P11-4 array an alternative design was also targeted where 
the fluorophore was installed after the PEG spacer preserving the length of the self-assembling 
sequence, as shown in Fig 3.11 and 3.12. The alternative would be synthesized in the same 
manner as the original. 
 
Fig 3.11ː Structure of functionalised P11-4 or “P12-4” – dodecamer. 
 
Fig 3.12ː Structure of functionalised P11-4 – unidecamer. 
Various reaction conditions and reagents were employed to optimise the synthesis of the 
functionalised P11-4 molecule, and reactions were optimised by synthesising both peptides 1 
and 2 using both manual and automated Fmoc SPPS. The various attempts are summarised in 
Table 3.1. 
  
Peptide 1 
Peptide 2 
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Reaction 
No 
Resin Coupling 
Reagents 
Coupling 
Time 
(min) 
Manual or 
Automated 
Success Cleavage 
Mixture 
Comments Decision for future 
reactions 
1 PEGA 
Rink 
Amide 
HCTU / DIPEA 180 Manual  TFA: 
Phenol: 
Ethanediol: 
Anisole  
(92.5: 2.5: 
2.5: 2.5) 
MS-MS analysis 
showed the 
presence of P11-4 but 
unsuccessful for 
functionalised 
peptide 
Reduction of coupling 
time and change 
cleavage mixture.  
2 PEGA 
Rink 
Amide 
HCTU / DIPEA 60 Manual  TFA: TIPS: 
DCM 
(95: 2.5: 
2.5) 
Unknown reason 
why synthesis failed 
– MS showed no 
peptide species 
present 
Use automated 
synthesizer, based on 
research reporting 
increased success 
(Collins et al., 2012) 
3 PEGA 
Rink 
Amide 
HCTU / DIPEA 60 Automated 
(microwave 
assisted except for 
R - intramolecular 
lactam formation - 
Collins et al., 2012) 
 TFA: TIPS: 
DCM 
(95: 2.5: 
2.5) 
Deletions of amino 
acids was detected 
in MS of crude 
product, as shown in 
Fig 37 
Investigation into 
loading success testing 
4 Novagel 
Rink 
Amide 
Oxyma Pure / 
DIC 
60 Automated (base 
P11-4 sequence) / 
Manual 
(functionalisation 
steps) 
 TFA: TIPS: 
DCM 
(95: 2.5: 
2.5) 
Successful – LC-MS 
as clean as the 
previous method but 
complete synthesis 
N/A 
5 NovaSyn© 
TG Sieber 
Oxyma Pure / 
DIC 
60 Automated (base 
P11-4 sequence) / 
Manual 
(functionalisation 
steps) 
 TFA: TIPS: 
DCM 
(95: 2.5: 
2.5) 
Successful but yield 
was low – 11 mg – 
2.4% 
N/A 
Table 3.1:  A summary of the various methods and conditions employed in the attempt to successfully synthesize the peptide fragment – other than method 5, all methods were 
employed for peptides 2 and 3. 
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As noted in Table 3.1 for reaction 3, the synthesis was partially successful, showing the presence 
P11-4 and a rather clean mass spectrum probably due to the increased purity achieved by the 
automated approach. The cleaner mass spectrum allowed further analysis to be carried out 
which showed the presence of 3 additional peptides besides P11-4 which were shorter than P11-
4. Each shorter peptide was missing a C-terminal section indicating incomplete loading of the 
resin with the first amino acid – Fmoc-Gln (Trt)-OH.  The mass spectrum is shown in Fig 3.13. 
This was the consequence of incomplete loading of the resin and not blocking the unreacted 
groups thus resulting in multiple C-terminal amino acids. 
 
Fig 3.13ː Mass spectrum analysis indicating that sequential deletion of amino acids during the P11-4 synthesis 
which resulted from incomplete loading of the resin with the initial amino acid – Gln. 
This observation led to investigation of alternative loading conditions resins and coupling 
reagents, where the different resins used are shown in Fig 3.14. When loading tests were 
carried out using PEGA Rink Amide Resin and HCTU/DIPEA, with each completed loading cycle 
monitored by a Kaiser test, the average number of loading cycles required for complete loading 
was 5 ± 1.  
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Fig 3.14: The structures of the two different resins mainly employed – PEGA Rink Amide and Novagel® Rink 
Amide resins. 
An alternative resin –Novagel Rink Amide, was chosen which had a larger loading capacity (0.65 
mMol/g) than the PEGA Rink Amide (0.2-0.5 mMol/g) and did not require activation but came 
in a dry form which made accurate weighing out and preparation i.e. swelling easier. As 
illustrated in Fig 3.14, the linker in each type of resin was the same but the solid polymeric 
support was different. The average number of loading cycles when the same test as above was 
carried out was 4±1. Whilst this was an obvious improvement it still meant the loading period 
was ≥ 2days so alternative coupling reagents were investigated. 
The results of these alternatives – HOBt.nH2O/DIC and Oxyma Pure/DIC and the results above 
are summarised in Table 3.2 below. 
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Resin Reagents No Loading Cycles 
PEGA Rink Amide HCTU/DIPEA 5 ± 1 
Novagel Rink Amide HCTU/DIPEA 4 ± 1 
Novagel Rink Amide HOBt.nH2O/DIC 4 ± 1 
Novagel Rink Amide Oxyma Pure/DIC 2 ± 0 
 
Table 3.2ː Average loading cycles required to achieve complete loading for different combinations of resins and 
coupling reagents. 
On the basis of these results Rink Amide Novagel was employed in future reactions and loaded 
using DIC/ OxymaPure as activating agent. Using these conditions for loading both 
functionalised peptides 1 and 2 were successfully assembled and cleaved from the resin, 
although in modest yield (4.3 % and 3.9 % respectively) 
Mass spectrometry and LC-MS analysis indicated functionalization was successful so the 
functionalised peptides was cleaved and taken forward to purification via HPLC, where the mass 
spectra are shown in Fig 3.15.  In the figure below, the highlighted species are the doubly 
charged species. The carboxylated species was due to the incomplete deprotection of the Boc 
group from the Trp residue, as illustrated in the figure below.  
 
 
 
Fig 3.15ː Mass spectra of both functionalised P11-4 in crude form, A – P11-4 and B – “P12-4” where the highlighted 
peptide peak in B had the Trp residue carboxylated.  This residual CO2 group was removed by treatment with 
AcOH and lyophilisation.  
A 
B 
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UV-directed reverse phase HPLC was employed to purify the crude peptide with a C18 peptide 
column and a gradient of 10-30% 0.1% NH3 aqueous solution (to keep the peptide from self-
assembling) as solvent A and CH3CN as solvent B and fractions detected at 254nm and 280nm 
(absorbance of the tryptophan side chain). On a test run, a UV absorption peak at 17.4min was 
collected and analysed by LC-MS which indicated the presence of the functionalised P11-4, with 
the UV trace and LC-MS spectrum shown in Fig 3.16. On full scale purification, the collected 
fraction showed little during LC-MS analysis. This was predicted to be because of the DMSO 
added to aid dissolution of the crude peptide for HPLC as 254nm is the absorption peak for 
DMSO. This issue of solubility of the crude product was reinforced when inspection of the vials 
of the crude mixture showed the formation of a colourless precipitate, which analysis by LC-MS 
showed to be functionalised P11-4.  
 
 
Fig 3.16ː Mass spectra showing the test scale (top) and full scale (bottom) purification attempts of the 
functionalised P11-4 peptides via UV directed RP HPLC. 
Given the loss of material on HPLC, an alternative system was used. A UV-directed Biotage 
Isolera One system was employed using a RediSep Rf High Performance GOLD HP C18 50g 
column. This column also separates by reverse phase interactions but with this system manual 
loading of the column can be carried out ensuring the full dissolution of the crude peptide and 
its addition to the column. LC-MS analysis of the collected fractions, shown in Fig 3.17, indicated 
relatively clean purification of the crude peptide which was sufficiently pure to use in further 
investigations. 
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Fig 3.17ː Mass spectrum of the purification attempt of functionalised P11-4 via chromatography on a UV-directed 
Biotage instrument, where the peptide peak is highlighted. 
3.2.1.2 Effects on self-assembly and morphology 
Both P11-4 variants – peptides 1 and 2, were tested to investigate the effect of having an odd 
or even consecutive amino acid sequence on the self-assembly. Both variants were tested under 
different conditions which mimicked physiological conditions: – 1) two different buffer 
solutions with varying concentrations of various salts, mainly Na+ - 130 mM to 230 mM which 
mimic the limits of Na+ content found within articular cartilage (Urban, 1994), 2) two different 
molar ratios to dope base P11-4 -  64:1 and 32:1 (P11-4: Variant) which were based on calculations 
of fibril dimensions and concentrations and the dimensions of native aggrecan from AFM 
measurements (Ng, 2003).  
The effect on morphology was investigated through dimensional analysis of electron 
micrographs, examples of which are shown in Fig 3.18. The width and length of individual fibrils 
were measured from electron micrographs using image analysis software – ImageJ. The 
dimensions are shown in Fig 3.19 for various conditions. 
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Fig 3.18: TEM Micrographs of two different isomers of P11-4-CS at different molar ratios within P11-4 hydrogels 
(~6 mM). A) P11-4 + P11-4-PEG-Lys (Mca)-Hex-CS 32-1 Ratio 230 mM Na+ buffer, 4000x magnification B) P11-4 + P11-
4-PEG-Lys (Mca)-Hex-CS 64-1 Ratio 230 mM Na+ buffer, 6000x magnification C) P11-4 + P11-4-Lys (Mca)-PEG-Hex-
CS 32-1 Ratio 230 mM Na+ buffer, 5000x magnification c) P11-4 + P11-4-Lys (Mca)-PEG-Hex-CS 64-1 Ratio 230 mM 
Na+ buffer, 4000x magnification, scale bar – 500 nm. 
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Fig 3.19: The different fibril dimensions, A) effect on fibril length for the different variants at 130 mM and 230 
mM Na+ concentrations, B) effect on fibril width for different variants at 130 mM and 230 mM Na+ 
concentrations. Error bars: ± standard deviation, n = 100.  
The measured lengths and widths showed no significant differences between the control – P11-
4 230 mM Na+ and the various alternative conditions when analyzed by a one-way ANOVA 
statistical test (α = 0.95).  
The lack of significant difference in terms of morphological dimensions and ability to self-
assemble, led to the decision to follow historical research and use the unidecameric – peptide 
1 structure. During this work it was also discovered that the addition of the coumarin moiety 
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significantly complicated the synthesis as well as making the material much more expensive to 
produce with little benefit in overall analysis.  The target peptide was hence redesigned. 
3.2.1.3 Final peptide structure 
The new structure of the intended peptide –peptide 3, is shown in Fig 3.20.  
 
Fig 3.20: Structure of P11-4-PEG-Hex-N3. 
In order to increase the yield of product, a different resin was used – NovaSyn© TG Sieber resin 
which is more acid labile and enables a two-step cleavage process.  This enabled release of the 
peptide from the support before cleavage of the side chain protecting groups. This can prevent 
self-assembly of the peptide within the resin matrix during the cleavage which can dramatically 
decrease the yield of product. The different cleavage procedure for the Sieber resin compared 
to the Rink Amide resins is shown in Fig 3.21. 
 
 
Peptide 3 
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Fig 3.21: The differences between the two types of resin: (top) requires low TFA content to cleave the peptide 
from the solid support whilst leaving the side groups protected (bottom) high TFA content to cleave the peptide 
causes the side groups to be deprotected as well as cleaving the solid support. 
An analytical HPLC trace and accurate mass MS trace was obtained to check the purity of the 
functionalized peptide which is shown in Fig 3.22. 
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Fig 3.22:  A) Analytical HPLC trace B) Accurate mass MS trace for synthesized peptide 3 (P11-4-PEG-Hex-N3), with 
the 1+ and 2+ species shown.  
The successful synthesis and purification of the peptide 3 (P11-4-PEG-Hex-N3) meant an 
alternative peptide – peptide 4, was synthesized using a similar approach with an alternative 
net charge – P11-8-PEG-Hex-N3 (+2 net charge), shown in Fig 3.23 with the analytical HPLC and 
accurate mass MS trace shown in Fig 3.24. 
With successful routes to the peptide established large scale synthesis was still challenging and 
so the decision was made to outsource the bulk synthesis of these materials to Cambridge 
Bioscience who provided 300 mg of each of the two conjugates.  
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Fig 3.23: Structure of synthesized peptide 4 (P11-8-PEG-Hex-N3). 
 
 
Fig 3.24: Structural determination of peptide 4 (P11-8-PEG-Hex-N3) with A) Analytical HPLC trace B) Accurate mass 
MS trace. 
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3.2.2 Chondroitin Sulfate conjugate synthesis  
3.2.2.1 Reductive amination method 
The synthetic pathway, shown in Fig 3.25, was used to synthesize a linker which could be used 
to functionalize chondroitin sulfate to arm it for click conjugation to the peptide.   4-
Ethynylbenzylalcohol 1 was reacted with N-hydroxyphthalimide 2 under Mitsunobu conditions 
to form the substituted phthalimide 3.  Cleavage of the phthalimide with hydrazine gave the 
desired alkynyl substituted hydroxylamine which was isolated as the hydrochloride salt 4  
   
Fig 3.25ː Synthetic pathway of alkynyl substituted hydroxylamine linker as hydrochloride salt. 
Reductive amination reactions were attempted under a variety of conditions with the general 
synthetic scheme shown in Fig 3.26. 
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Fig 3.26: General scheme for reductive animation synthetic pathway. 
The intended method of purifying the final chondroitin sulfate fragment was via gel-permeation 
chromatography (GPC), where the aim of this was to remove the smaller reagents from the 
large Chondroitin sulfate containing products. This purification method was difficult for larger 
scale reaction >50mg due to the large amounts of DMSO/H2O, so dialysis was employed as an 
alternative to purify the crude mixture. By using dialysis tubing with a molecular weight cut off 
of 14kDa then all of the chondroitin sulfate, whether reacted or unreacted would remain and 
the smaller molecules would diffuse into the surrounding water where aliquots could be tested 
using TLC (visualized with KMnO4 and H2SO4 in MeOH) to investigate complete removal of the 
reagents from the mixture. FTIR and LC-MS indicated the presence of the corresponding 
functional groups in chondroitin sulfate and the lack of other reagents in the purified product. 
In conclusion, purification via dialysis was successful with the estimated final yield of the 
functionalized chondroitin sulfate being ~70%. 
3.2.2.2 Oxime formation method 
The excessive conditions to reductively aminate the CS residue led to investigations as to 
whether the covalent bond required reducing from the oxime to the hydroxylamine. Numerous 
glycobio-conjugates have been prepared using oxime formation (Gori and Longhi, 2016, Krall et 
al., 2016). The highly reactive aminooxy functional group meant aniline catalyzed ligation could 
be carried out in the similar fashion as an oxime ligation. Fig 3.27.  
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Fig 3.27: Synthetic pathway of chondroitin sulfate conjugate via the aniline catalysed oxime ligation route. 
The issue with the ligation method was difficulty removing the aniline or P-phenyldiamine 
catalysts following the reaction. Aniline was present following dialysis even following a toluene 
wash in order to encourage preferential separation and the PPD removal was not possible due 
to oxidation of the PPD as clearly seen by the intensely coloured nature of the product.  
3.2.3 P11-4-CS conjugate: Click reaction optimization  
Click chemistry was utilized to covalently link the functionalized peptide and CS fragments. A 
Cu-catalyzed azide-alkyne click (CuAAC) reaction was chosen due to the relatively high tolerance 
of reaction conditions and fast rate of reaction. The generic reaction scheme is illustrated in Fig 
3.28. Various conditions were tested to obtain the highest possible complete conjugation to 
counter difficulties in purifying any CS containing species.  To make the initial testing as simple 
as possible 2-ethynylbenzyl alcohol 1 was used as an analogue for the CS fragment to allow the 
reactions to be monitored via LC-MS. The various conditions are shown in Table 3.3.  
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Fig 3.28: Generic reaction scheme of CuAAC reaction linking functionalized peptide with either 4-
Ethynylbenzylalcohol 1, aminooxy 4 or functionalized CS 5 under various conditions. 
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Attempt Solvent pH [Pep] [Benzyl] [TCEP] [TBTA] [CuSO4] [Na-
ascorbate] 
Time 
(hr) 
Other 
 
Success 
1 H2O 7 0.3 mM 0.15 mM - - 1 mM 10 mM 90 Order of addition was: 1) 
Benzyl, 2) Pep, 3) CuSO4 
then 4) Na-ascorbate 
Yes 
(~20%) 
2 H2O 7 0.3 mM 0.15 mM - - 0.03 mM 0.3 mM 24 Order of addition was: 1) 
Benzyl, 2) Pep, 3) CuSO4 
then 4) Na-ascorbate 
No 
3 H2O 7 0.3 mM 0.15 mM - - 0.045 mM 0.45 mM 24 Order of addition was: 1) 
Benzyl, 2) Pep, 3) CuSO4 
then 4) Na-ascorbate 
No 
4 H2O 7 0.3 mM 0.15 mM - - 0.06 mM 0.6 mM 24 Order of addition was: 1) 
Benzyl, 2) Pep, 3) CuSO4 
then 4) Na-ascorbate 
No 
5 H2O 7 0.3 mM 0.15 mM - - 0.075 mM 0.75 mM 24 Order of addition was: 1) 
Benzyl, 2) Pep, 3) CuSO4 
then 4) Na-ascorbate 
No 
Table 3.3: Various conditions investigated for the CuAAC reaction between P11-X-PEG-Hex-N3 and alkyne-CS fragments. 
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6 H2O 7 0.3 mM 0.15 mM - - 0.15 mM 15 mM 24 Order of addition was: 1) 
Benzyl, 2) Pep, 3) CuSO4 
then 4) Na-ascorbate 
No 
7 H2O 7 20µM 30 µM 1 mM 100 µM 1 mM -  - No 
8 H2O 7 20µM 30 µM 1 mM 100 µM 1 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
No 
9 H2O 7 1 mM 1 mM 1 mM 1 mM 1 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
No 
10 PBS 7.4 1 mM 1 mM 1 mM 1 mM 1 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
Yes 
(~40-
50 %) 
11 10 mM 
NaPO4 
buffer 
7.4 1 mM 1 mM 1 mM 1 mM 1 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
Yes 
(~40 %) 
Table 3.3: Various conditions investigated for the CuAAC reaction between P11-X-PEG-Hex-N3 and alkyne-CS fragments. 
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(wait 2min), 4) TBTA then 
5) Benzyl 
12 100 mM 
NaPO4 
buffer 
7.4 1 mM 1 mM 1 mM 1 mM 1 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
Yes 
(~60 %) 
13 100 mM 
NaPO4 
buffer 
7.4 1 mM 5 mM 1 mM 1 mM 1 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
Yes 
(~80 %) 
14 100 mM 
NaPO4 
buffer 
7.4 0.5 mM 0.5 mM 0.5 mM 0.5 mM 0.5 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
Yes 
(~10 %) 
15 100 mM 
NaPO4 
buffer 
7.4 1 mM 1 mM 2 mM 2 mM 2 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
Yes 
(~30 %) 
Table 3.3: Various conditions investigated for the CuAAC reaction between P11-X-PEG-Hex-N3 and alkyne-CS fragments. 
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16 100 mM 
NaPO4 
buffer 
7.4 1 mM 5 mM 2 x 2 
mM 
2 x 2 
mM 
2 x 2 mM - 1 Order of addition was: 1) 
Pep, 2) TCEP, 3) CuSO4 
(wait 2min), 4) TBTA then 
5) Benzyl 
Yes 
(~80 %) 
17 100 mM 
NaPO4 
buffer 
7.4 1 mM 1 mM - 1 mM 1 mM 1 mM 1 Order of addition was: 1) 
Pep; 2) Alkyne, 3) Na-
ascorbate; 4) TBTA then 
5) CuSO4 
Yes 
(~80-
90 %) 
Table 3.3: Various conditions investigated for the CuAAC reaction between P11-X-PEG-Hex-N3 and alkyne-CS fragments.
 
 
111 
 
 
The simple analogue allowed monitoring of the reaction through LC-MS and 1H NMR with the 
success being judged by the relative percentage of product vs the alkyne and azide starting 
materials. The product triazole was small enough that the product could be clearly seen on the 
LC-MS trace. In Fig 3.29, the LC-MS trace for the most successful conditions are shown – 2 
equivalents of alkyne, 1 equivalent of peptide, TBTA as ligand for the copper, TCEP as reducing 
agent and CuSO4.5H2O as the copper source.  The increase in mass on triazole formation is clearly 
visible. One issue which arose using the TBTA: TCEP system was the short lifetime of activity the 
in situ Cu (I) species had of ~1hr, where the issue was exacerbated by the limited solubility of 
the system as well where after ~2hrs a white precipitate formed which on investigation turned 
out to be TBTA which had precipitated over time. 
 
Fig 3.29: Mass spectra for starting peptide 3 (P11-4-PEG-Hex-N3) material (top) and click reaction product 
conjugate 1 with ethynyl benzyl alcohol (bottom) under reaction 13 conditions.  
As an alternative method of monitoring, 1H NMR was used to monitor the formation of the 
characteristic triazole proton at ~8ppm. The spectrum of a test reaction is shown in Fig 3.30.  
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Fig 3.30: The 1H NMR spectrum of the product of an ethynyl benzyl alcohol – P11-4-PEG-Hex-N3 click reaction – 
conjugate 1 using reaction 13 conditions. The characteristic triazole proton peak is ~8 ppm.  
Using the optimal conditions the aminooxy alkyne 4, also reacted successfully. Key spectra from 
the LC-MS analysis are shown in Fig 3.31.  
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Fig 3.31: Mass spectra for starting peptide 3 (P11-4-PEG-Hex-N3) material (top) and click reaction product 
conjugate 3 with aminooxy intermediate 4 (bottom) under reaction 13 conditions. 
The same conditions worked for the aminooxy intermediate showing ~ 75% conversion, almost 
matching the ~80% conversion observed for the benzyl starting material. The final step to 
investigate was to check whether the click reaction conditions worked for the CS fragment. This 
reaction was much harder to monitor as the polydisperse and exceedingly large product that 
would result is not amenable to normal analytical methods.  The highly sulfated CS resists 
electrospray ionization and NMR spectra are extremely complex.  A number of different 
analytical methods were used to infer success. The reaction was monitored in the same manner 
as previous analogues with the starting peptide 3 (P11-4-PEG-Hex-N3) concentration measured 
by LC-MS.  During the reaction all the free peptide 3 disappeared from the reaction mixture 
which was consistent with a successful click reaction to form the desired conjugate which was 
invisible in the LC-MS.   The LC-MS trace is shown in Fig 3.32. The formation of the triazole proton 
formation was also analyzed using 1H NMR. The 1H NMR spectrum is shown in Fig 3.33.  
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Fig 3.32: UV trace of conjugate 5 (P11-4-PEG-Hex-(triazole)-CS) reaction before (above) and after (bottom) 
completion. There was no presence of the starting peptide material indicating the reaction has gone to 
completion with the UV peak at 1.9 min having disappeared. 
 
Fig 3.33: 1H NMR trace comparing peptide 3 (P11-4-PEG-Hex-N3), conjugate 3 (P11-4-PEG-Hex-Benzyl) and 
conjugate 5 (P11-4-PEG-Hex-CS), with the characteristic triazole proton ~8 ppm. 
The low amount of triazole proton compared to the CS protons in the spectra made this analysis 
challenging but through using a large number of scans it was possible to identify the triazole 
proton which was apparent in the 1H NMR spectrum of both conjugate 1 and conjugate 5 but 
not the spectrum of peptide 3 as highlighted in Fig 3.33. The aromatic peaks around 7-7.5 ppm 
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correspond to the aromatic protons on the peptide from the tryptophan and phenylalanine side 
groups, as the 1H NMR spectrum of peptide 3 shows similar aromatic peaks, but the missing 
protons seen in the conjugate spectra come from the protons on the benzyl group located within 
the linker.  
The final method of characterization of the click product was to use size-exclusion 
chromatography with multi angle laser light scattering (SEC-MALLS) to measure the shift in 
retention time based on different molecular weights. The SEC-MALLS UV and light scattering (LS) 
trace for CS and conjugate 5 (P11-4-PEG-Hex-CS) is shown in Fig 3.34 In both traces a significantly 
different retention time was observed suggesting that indeed the click reaction has occurred 
successfully. 
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Fig 3.34: SEC-MALLS trace – UV trace (top) and LS trace (bottom) with CS (blue) and conjugate 5 (P11-4-PEG-Hex-
CS) (orange).  
With the validation and characterization of conjugate 5 (P11-4-PEG-Hex-CS) the next step was to 
use the alternative peptide 4 (P11-8-PEG-Hex-N3) to create a net positively charged peptide-GAG 
conjugate. The same conditions were used for the click reaction. LC-MS once again showed 
complete disappearance of starting peptide and 1H NMR showed appearance of a proton at the 
correct chemical shift for a triazole. Fig 3.35 and Fig 3.36.  
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Fig 3.35: UV trace of conjugate 6 (P11-8-PEG-Hex-CS) reaction before (above) and after (bottom) completion. 
There was no presence of the starting peptide material indicating the reaction has gone to completion with the 
UV peak at 1.5 min having disappeared. 
 
Fig 3.36: 1HNMR trace comparing peptide 4 (P11-8-PEG-Hex-N3), conjugate 4 (P11-8-PEG-Hex-Benzyl) and conjugate 
6 (P11-8-PEG-Hex-CS), with the characteristic triazole proton ~8ppm. 
SEC-MALLS was used again to compare the shift in molecular weights of the conjugate 6 (P11-8-
PEG-Hex-CS) and CS to indicate the click reaction was a success. The SEC-MALLS traces for both 
the UV and LS detectors are shown in Fig 3.37. 
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Fig 3.37: SEC-MALLS traces for conjugate 6 (P11-8-PEG-Hex-CS) (red) compared to CS only (blue). UV trace (top) 
and LS trace (bottom). 
3.2.4 Cu cytotoxicity  
The one possible issue with using CuAAC for a biomedical applications is the cytotoxicity of any 
residual Cu (I) and Cu (II) in biological systems if it is not removed during purification. The Cu 
content of the reaction mixture (for the maximum Cu (II) – CuSO4 concentration used in the click 
reaction), subsequent dialysis fluid and final dialysis mixture were measured through flame 
atomic absorption spectroscopy (FAAS).  The system was calibrated based on a calibration 
gradient from prepared known concentration of CuSO4 – 0-12 ppm, shown in Fig 3.38. The initial 
concentration of CuSO4 used in the click reaction was 1 mM with a volume of 1 ml and the final 
concentration of the product once removed from the dialysis tube (~1 ml) was 0.009 mM, 
indicating that over 99% of the Cu species had been removed through dialysis.  
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Fig 3.38: Amount of Cu (II) present (mM) in consecutive rounds of dialysis as determined by FAAS using a calibration 
gradient. 
The effect of the residual Cu concentrations were then investigated through an extract 
cytotoxicity test using 2 cells lines – Baby Hamster Kidney (BHK) cells and murine fibroblast 
(L929) cells. The copper species selected were CuSO4 to represent a Cu (II) species and CuCl to 
represent a Cu (I) species with each species concentration ranging from 0.001 – 5 mM. The cell 
lines were incubated in the presence of each Cu species for 48 hr and then an ATP-lite assay was 
performed to measure the cell viability after exposure. The results from the extract cytotoxicity 
tests are shown in Fig 3.39.  
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Fig 3.39: Extract cytotoxicity results for residual Cu (I) and Cu (II) concentrations using BHK and L929 cell lines. 
(Uppermost) BHK cells exposed for 48 hr to CuSO4 at various concentrations. (Upper middle) BHK cells exposed 
for 48 hr to CuCl at various concentrations. (Lower middle) L929 cells exposed for 48 hr to CuSO4 at various 
concentrations. (Lowermost) L929 cells exposed for 48 hr to CuCl at various concentrations.     = Significant 
difference to negative control (Media) (α = 0.95). 
The results of the extract cytotoxicity showed that with the maximum residual Cu amount 
detected with FAAS (0.009 mM) was not cytotoxic to either BHK or L929 cell lines at the 
maximum potential concentration of CS conjugate that the cell lines could be exposed to, as the 
amount of product extracted following dialysis was ~50 mg in 1 ml (0.26 μg of Cu or 0.004 mM) 
which was a greater concentration than the maximum concentration possible for the hydrogels 
– 30 mg ml-1 (0.15 μg of Cu or 0.002 mM ). This validated that 3 rounds of dialysis was sufficient 
to remove an adequate amount of Cu from the click product mixture but to be sure an additional 
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2 rounds of dialysis were carried out to ensure the amount of residual Cu was definitely below 
the concentration deemed to be cytotoxic.  
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3.3 Discussion 
3.3.1 Functionalised peptide synthesis 
The work presented in this chapter provides methods and evidence for the first reported 
successful synthesis of a self-assembling peptide-CS conjugate through utilising the reducing end 
of the polysaccharide. The first aim was to synthesize a peptide containing an azide functionality 
which also had a propensity to self-assembly under certain conditions such as pH, ionic strength 
and concentration. The propensity to self-assemble was based around the amino acid sequences 
chosen: P11-4 – QQRFEWEFEQQ and P11-8 – QQRFOWOFEQQ. These are sequences previously 
reported by the Aggeli group at the University of Leeds (Bell, 2006, Maude et al., 2011). The 
difficulties reported in this chapter was both the synthesis of these core peptide sequences, and 
the post modification of these, in terms of coupling a biocompatible linker and introducing a 
functional group which could be transformed into the azide motif. The final synthesis of the core 
peptide sequence arose from difficulties with the initial loading of the resins and sequential 
coupling reactions from inappropriate coupling reagents. The subsequent modification 
increased the length of the synthesized peptide chain which may have contributed in 
conjunction with the peptides self-assembling properties, to make the overall synthesis and 
purification difficult. These difficulties were overcome by changing the initial resin used from a 
PEGA Rink Amide resin to a Novagel Rink Amide resin (Pipkorn, 2000, Stetsenko and Gait, 2000). 
The rationale for this change was to make the preparation and swelling of the resin easier, 
because it came in a dry form compared to the PEGA Rink Amide resin which came in a swollen 
form. The LC-MS data indicated this change meant the synthesis was successful according to the 
LC-MS data for the crude mixture following cleavage from the resin. Further difficulties were 
encountered purifying the crude products either through mass/UV directed reverse phase HPLC 
or UV directed Biotage purification which resulted in low recoveries. The problems were 
believed to be due to the peptides self-assembling during cleavage and aggregating onto the 
resin beads as well as self-assembling when they were re-solubilised following ether 
precipitation. Small amounts of peptide 1 and 2 (P11-4-(PEG-Lys(Mca)/Lys(Mca)-PEG)-Hex-N3) 
were produced which allowed the investigation into whether the order of the linker and 
fluorophore residues made a significant difference to the ability of the peptide to self-assemble. 
This investigation indicated there was no significance between the two different variants in 
terms of micro-structure and dimensional measurements or critical concentration for self-
assembly using a 1-way ANOVA statistical test (α=0.05). As the sequence was not critical and the 
Mca residue had been of little value in the analysis of the reaction the peptide structure was 
simplified by removal of the fluorescent residue.  
 
 
124 
 
 
The final resin change from Novagel Rink Amide to the TG Sieber resin was to overcome the 
difficulties and low yields experienced during purification. The resin had a lower loading capacity 
(0.1-0.25 mMol/g) with a dual stage cleavage mechanism, where the peptide can be cleaved 
from the resin using 1% TFA, leaving the side groups protected until it is exposed to a 95% TFA 
mixture (Sieber, 1987). The lower loading reduced the potential of unfavourable interactions 
between growing peptide chains within the resin bead by having a lower loading capacity and 
the side groups still being protected to minimise non-covalent side group interactions. This dual 
stage process reduced aggregation within the resin matrix.  The LC-MS data showed this change 
allowed purification to be carried out to an acceptable level with multiple milligrams produced.  
However, with the scale required to continue the project the decision was taken to outsource 
the peptide synthesis to Cambridge BioScience which guaranteed purity and supply, with the 
company synthesizing both azido functionalised P11-4 and P11-8 variants – peptides 3 and 4 on a 
300mg scale.  
3.3.2 Modified chondroitin sulfate synthesis 
The functionalisation of chondroitin sulfate was based on derivatising the reducing end of the 
chondroitin polysaccharide chain instead of the more conventional hydroxyl and amino side 
group functionalisation more commonly employed with GAG functionalisation. 
The two different methods (oxime formation and reductive amination) for functionalisation 
reported in this chapter were based around a similar synthetic route with only the conjugation 
of the alkyne containing motif with the chondroitin sulfate polymer differing. The reductive 
amination method used excess amounts of reducing agent to force the reaction, towards the 
amine product which is a stable bond and resistant chemical cleavage e.g. hydrolysis. The one 
disadvantage of this method compared to the oxime formation method is the lack of a 
characteristic proton signal in NMR as with the oxime the imine proton ~7.5-8 ppm can be 
observed, as reported by Brand et al. (Brand et al., 2006). The oxime method was a more 
expedient method, requiring a maximum reaction time of ~ 24hrs compared to the 144hrs for 
the reductive amination method. The reaction could be monitored by the formation of the 
characteristic oxime peak as mentioned above, but the disadvantage this method had was the 
removal of the aniline or aniline substitute – P-phenyldiamine (PPD) which aggregated with the 
product or readily oxidised respectively (Wendeler et al., 2013, Meyer and Fischer, 2015). All 
attempts to remove the catalyst through phase separation, extraction, azotropic separation or 
precipitation failed with excessive amounts of the catalyst still present in the product as 
determined by LC-MS. This removal issue has been investigated and documented in published 
work, where it was found that PPD has various oxidation products with varying solubilities and 
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polarities making extraction difficult (Bai et al., 2010, Aeby et al., 2009, Solis et al., 1976), which 
was one of the deciding factors in using the reductive amination method for the project, as well 
as the fact the reductive amination method being able to be scaled up to multi-gram 
scale(Meyer and Fischer, 2015).  
3.3.3 P11-4-CS conjugate: Click reaction optimization 
In this chapter, various modifications of the classic CuAAC reaction have been reported, which 
have been reported previously by many groups. The difference here is the application of the 
click reaction in terms of covalently linking a relatively small peptide with a propensity to self-
assembly with a poly-anionic polysaccharide. The difficulties encountered with optimising the 
click reaction came down to the massive differences in molecular weight of the two components 
– peptide ~ 2kDa, CS ~48kDa. The high molecular weight of the CS made monitoring the click 
reaction difficult so the reaction had to be optimised as much as possible using smaller 
analogues to check various conditions. This allowed monitoring through LC-MS and NMR 
techniques but due to the large discrepancies between the analogues and CS molecular weights 
meant that SEC-MALLS had to be employed to validate the final click reaction as well as the 
presence of the characteristic triazole proton signal ~8ppm in the 1H NMR spectrum 
(Appukkuttan et al., 2004). The various conditions investigated were relatively robust, in terms 
of the types of aqueous buffers the reaction was successful in, but all of the conditions were pH 
sensitive with successful reaction only when then pH was ~7-7.4, which matches the 
observations of various groups that have reported similar difficulties with polysaccharides  
(Elchinger et al., 2011, Appukkuttan et al., 2004). This may have been due to the peptides 
inherent self-assembling ability which could have interfered with the reaction by collapsing or 
aggregating intermolecularly causing the N3 group to become buried within the aggregate thus 
inhibiting the click reaction (Kakwere et al., 2011). The stoichiometry of the click reaction 
catalysts was also important as investigation into reactions with lower amounts of catalytic 
reagents were unsuccessful. The optimum ratio turned out to be a 1:1:1 for CuSO4: TBTA: Na-
ascorbate, with a 1:1 ratio of peptide: alkyne yielding ~80-90% conversion based on amount of 
peptide remaining following the click reaction. These conditions were originally described by 
Cielpla et al for their work on covalently linking fluorophores on to human and zebrafish cells 
(Ciepla et al., 2014). As mentioned previously, one issue with using TBTA was encountered when 
used in tandem with TCEP, due to the formation of a white precipitate after ~2hrs which was in 
fact TBTA. This issue with solubility has been noted by other groups using TBTA as a stabilizing 
ligand for the Cu (I) reactive species. (Lallana et al., 2011, Ciepla et al., 2014). This meant the two 
vastly different reagents had relatively little time to collide considering both of the propensities 
to inter and intramolecularly aggregate as well as the loss of the stabilising ligand for the Cu (I) 
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species, thus killing the catalytic reaction. Compared to this, the Na-ascorbate: TBTA system 
could be left overnight to go to completion before a precipitate formed ~ 36hrs, which was 
probably due to the stabilising effect the TBTA had on the in situ Cu (I) formation and stability. 
This greater duration window for the reaction meant the reagents could be scaled up 
significantly with no major loss of conversion, where the test scale reactions were carried out 
on 1-5mg while the full scale reactions were carried out on 10-50mg scales with no significant 
increase in unreacted azido-peptide. The only issue with using Na-ascorbate as the mild reducing 
agent in the click reaction is the sensitivity to light, where the CuSO4/Na-ascorbate/TBTA mixture 
turned a yellow-orange colour but if left exposed to light the mixture turned a cloudy white 
colour indicating the oxidation of the Na-ascorbate or the Cu (I) species. In order to overcome 
this issue the reaction was simply carried out in a vessel protected by foil. Over time, as the 
reaction progressed, the CS product did precipitate from the conjugate trying to self-assemble 
into fibrillar structures.  
3.3.4 Cu cytotoxicity 
The main concern with the type of click chemistry reported in this chapter is the presence of 
Cu (I) and Cu (II) which has previously been reported to be cytotoxic in biological systems. When 
the rationale for this project was with the aim of being injected into human patients, this meant 
the presence of excessive residual Cu after the click reaction and purification could be an issue. 
The results from the FAAS assay showed the residual Cu to be approximately 0.9% of the starting 
mass of Cu (II) indicating if the starting concentration was 1 mM the residual concentration for 
the same volume was approximately 9 μM. This concentration was then used to base the limits 
to which to expose the two different cell lines to, with the maximum being a huge excess – 5 
mM and the minimum being 0.001 mM, equalling the upper limit of the measured amount of 
residual Cu. The extract cytotoxicity results showed that both L929 and BHK cells survived in 
concentrations as high as 0.1 mM, so 10x the maximum residual Cu measured, where Lanke et 
al. reported observing a similar concentration being cytotoxic to BHK cells (Lanke et al., 2007). 
This result showed that the number of rounds of dialysis were sufficient to remove enough Cu 
from the peptide-CS conjugation product but as mentioned in section 3.2.4, the number of 
rounds of dialysis was increased to 5 x 1hrs rounds to ensure the residual Cu was not an issue in 
the future. 
3.4 Conclusion 
The aim was to synthesize and characterise a self-assembling peptide-CS conjugate through 
utilising click chemistry to form a covalent bond between peptide and GAG through the 
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formation of a triazole link. The peptide was based on a previously reported peptide sequence 
– P11-4 (QQRFEWEFEQQ) (Aggeli, 1997, Aggeli, 2001b, Carrick, 2007a, Carrick et al., 2007, Davies 
and Aggeli, 2011, Davies et al., 2006, Maude et al., 2012), but further modified to allow Cu 
catalysed click chemistry to be employed to covalently link it to an alkyne functionalised CS 
molecule. This is the first reported example of such a conjugate having been synthesized with 
the propensity to form macromolecular structures. Similar examples include hydrogels formed 
from crosslinked GAG molecules such as hyaluronate, chondroitin sulfate and gelatin (Hu, 2011) 
or using different polysaccharides such as chitosan (Tan et al., 2009). These are permanent 
hydrogels once formed, in contrast to the system reported in this chapter where the mechanism 
of hydrogel formation is through the reversible, equilibria controlled formation of a fibrillary 
network based on an anti-parallel β-sheet secondary structure. With these materials in hand the 
effects of the CS conjugates on peptide self-assembly could be investigated in terms of 
morphology and mechanical properties to identify the most appropriate gel combination to 
carry forward to investigate the effect within a tissue model.  
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Chapter 4 
Effect of peptidoglycan content on 
morphology and mechanical 
properties of hydrogels 
As discussed in Chapter 1, the aim was to investigate the physical properties of undoped and 
doped peptide hydrogels in terms of the different morphologies different compositions, with 
and without the synthesized P11-4/8-CS conjugate, formed and the rheological properties of 
each composition to identify and rationalise the results in terms of the effect that introducing 
CS into the self-assembling peptide network has upon these different properties.   
In this chapter I will identify and analyse the different morphologies through the use of 
transmission electron microscopy and graphical software. The observations of this will then be 
used, in conjunction with rheological experiments to measure the hydrogel mechanical 
properties, to establish and rationalise the “strongest” gels to take forward to in vitro testing in 
a whole condyle porcine osteoarthritic model.   
4.1 Introduction 
With methods established to prepare chondroitin sulfate functionalised peptides the next stage 
was to determine how these changes affected the self-assembling properties of the system. 
4.1.1 Self-assembling systems 
Self-assembly is the spontaneous association of smaller structures into larger, ordered arrays. 
There are two types of self-assembly: static and dynamic. Most research has been based around 
static systems whilst dynamic systems still remain poorly understood (Lee et al., 2001, 
Hosseinkhani et al., 2013). Static self-assembling systems are defined as ones that have reached 
local or global equilibrium through the process of self-assembly. This process may require energy 
but once formed the ordered structure is stable leading to a loss of free energy from the system. 
Dynamic self-assembling systems in contrast are ones that require the system to lose energy 
during the formation of an ordered structure before the system reaches a state of equilibrium 
(Lee et al., 2001, Hosseinkhani et al., 2013). This required loss of free energy, from non-covalent, 
specific interactions makes investigating dynamic systems far more complex than static systems 
with the amount of energy lost needing to be both controlled yet unconstrained such as 
controlling the temperature of the system through isothermal parameters e.g. room 
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temperature which would not limit the potential for self-assembly. These two different types of 
self-assembly can be further differentiated based on the scale over which self-assembly occurs: 
- molecular, nanoscale mesoscopic, macroscopic self-assembly can all be observed, with 
molecular and nanoscale being further classified as intramolecular and intermolecular. 
Intramolecular self-assembly, the best example of which is the process by which proteins fold in 
nature, occurs when a complex random structure adopts an ordered conformation. 
Intermolecular self-assembly occurs when molecules form supramolecular arrays through 
various associations. The functional properties of the array is dependent on the composition of 
the independent building blocks (Lee et al., 2001, Hosseinkhani et al., 2013).  
This study concerns the self-assembly of peptides, which can be described as a dynamic, intra 
and intermolecular, molecular/nanoscale system.  
4.1.2 Self-assembling peptide hydrogels 
Self-assembling peptides are short peptide chains that can undergo spontaneous ordered 
intramolecular and intermolecular organisation through non-covalent interactions such as 
hydrogen bonding and π- π interactions as well as the hydrophobic effect (Koutsopoulos, 2016). 
Such spontaneous organisation can be triggered by simple proximity to other molecules or 
through exposure to an external stimuli such as a change in pH, temperature or ionic strength.  
As previously discussed (Section 1.8), there are two principal types of self-assembling peptidic 
families based on either α-helical or β secondary structures. Compared to α-helical peptides, β 
structure forming peptides are quite diverse in the primary peptide sequence and the adopted 
secondary structure. The differences between the structures and self-assembly at the molecular 
level lead to different outcomes at the nano- and macro-scales.   
4.1.3 Methods of morphological analysis 
On the macro-scale β strand based arrays can produce hydrogels with different characteristics 
such as flocculate formation, nematic fluid or gel as shown in Fig 4.1 using the P11-X class of β-
sheet forming self-assembling peptides developed by the Aggeli group.  These hydrogels can 
also show a range of stiffness and opacity (Aggeli et al., 2001). 
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Fig 4.1: Stages of self-assembly and hydrogel formation for P11-X class of self-assembling peptides (Reproduced 
from Aggeli et al with permission from PNAS). 
At the nano-scale sequence variation can lead to different fibrillary construction, inter-
connectivity and dimensions. The study of self-assembling peptides uses a diverse toolkit of 
techniques to analyse the materials at these different scales including microscopic techniques 
such as transmission electron microscopy (TEM) and interaction based atomic force microscopy 
(AFM) through to rheological techniques to measure the physiochemical properties of 
hydrogels.  
Transmission electron microscopy is a microscopic technique enables the imaging of materials 
through the interaction of an electron beam as it passes through a sample. The sample is usually 
placed on a copper grid that can have varying mesh sizes to allow different sized spaces for the 
sample to reside on. For the field of self-assembling peptides, a staining agent is used to help 
act increase image contrast for the relatively thin nanostructures. The most common staining 
agent is uranyl acetate, which is very electron dense and scatters the electron beam based on 
how much stain is absorbed by the sample, which is known as negative staining. This technique 
allows intricate imaging of the fine, twisted, nanostructure which can be then used to measure 
dimensions ( e.g. width, length, pitch twist), as well as determine connectivity and branching of 
the fibrils. A basic schematic of how TEM works is shown in Fig 4.2.  
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Fig 4.2: A schematic of a typical transmission electron microscope  
4.1.4 Physical testing of hydrogels 
Hydrogels are defined as compositions of materials that form colloidal suspensions with water 
as the medium which have varying degrees of phase, opacity and stiffness. These various 
properties make testing the physical bulk properties of hydrogels a challenge but rheology can 
be used to measure the liquid and solid component properties both jointly and separately by 
measuring the storage or elastic modulus (G’) and loss or viscous modulus (G”).  The storage 
modulus reflects the “solid component” and the loss modulus the “liquid component” of the 
system. These two properties, in conjunction, describe the composition of the hydrogel and 
whether it is more “solid”-like (where it contains more solid particles) or more “liquid”-like 
(where it contains a greater proportion of water). Rheological experiments can be classified into 
two types of set ups: strain and stress controlled. In strain controlled experiments, the motor 
and transducer are independent and operate separately. The motor applies a particular strain 
to the sample and the sample response is measured as stress through the transducer. An 
example of this type of setup is shown in Fig 4.3. 
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Fig 4.3: A schematic representation of a strain controlled rheological experiment. 
In stress controlled experiments, the motor and transducer are linked so operate in a combined 
manner. The motor applies a set stress or torque to the sample with the displacement measured 
using a sensor. An example of this type of setup is shown in Fig 4.4. 
 
Fig 4.4: A schematic representation of a stress controlled rheological experiment. 
Another factor to consider with rheological experiments is the types of plates used to apply the 
stress or strain to the sample. There are three main types of plate setups: concentric cylinders, 
cone on plate and plate on plate. Each setup has a different range of viscosity limits so are 
tailored to certain samples, where plate on plate is the most commonly used for soft hydrogel 
samples. A simple representation of the three setups is shown in Fig 4.5. 
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Fig 4.5: The various configurations of measurement interfaces possible with rheological experiments 
The techniques mentioned above were utilized to investigate the micro and macroscopic 
physical properties of gels composing of P11-4 and P11-8 peptides (and functionalised variants) 
under a range of conditions.  The conditions investigated are summarized below in Table 4.1, 
where the different conditions in terms probed the effects of: 1) molar ratio between the base 
P11-4/8 peptide and either the free CS or covalently linked P11-4/8-CS conjugate, 2) the different 
ionic buffer solution in which the gels were made up in and, most importantly whether covalent 
linkage of the CS to the peptide produced a different response to simple mixing of the two 
materials. 
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Sample No Peptide CS Buffer Molar 
ratio 
[Peptide]  
mg ml-1 (~ 
mM) 
P11-4 only 230 mM 
Na+ 
1 P11-4 - 230 mM 
Na+ 
- 10 (6) 
P11-4 only 130 mM 
Na+ 
2 P11-4 - 130 mM 
Na+ 
- 10 (6) 
P11-4 + CS 32:1 
230 mM Na+ 
3 P11-4 Free 230 mM 
Na+ 
32:1 10 (6) 
P11-4 + CS 64:1 
230 mM Na+ 
4 P11-4 Free 230 mM 
Na+ 
64:1 10 (6) 
P11-4 + CS 32:1 
130 mM Na+ 
5 P11-4 Free 130 mM 
Na+ 
32:1 10 (6) 
P11-4 + CS 64:1 
130 mM Na+ 
6 P11-4 Free 130 mM 
Na+ 
64:1 10 (6) 
P11-4 + P11-4-CS 32:1 
230 mM Na+ 
7 P11-4 Covalently 
bound 
230 mM 
Na+ 
32:1 10 (6) 
P11-4 + P11-4-CS 64:1 
230 mM Na+ 
8 P11-4 Covalently 
bound 
230 mM 
Na+ 
64:1 10 (6) 
P11-4 + P11-4-CS 32:1 
130 mM Na+ 
9 P11-4 Covalently 
bound 
130 mM 
Na+ 
32:1 10 (6) 
P11-4 + P11-4-CS 64:1 
130 mM Na+ 
10 P11-4 Covalently 
bound 
130 mM 
Na+ 
64:1 10 (6) 
P11-8 only 230 mM 
Na+ 
11 P11-8 - 230 mM 
Na+ 
- 10 (6) 
P11-8 only 130 mM 
Na+ 
12 P11-8 - 130 mM 
Na+ 
- 10 (6) 
P11-8 + CS 32:1 
230 mM Na+ 
13 P11-8 Free 230 mM 
Na+ 
32:1 10 (6) 
P11-8 + CS 64:1 
230 mM Na+ 
14 P11-8 Free 230 mM 
Na+ 
64:1 10 (6) 
P11-8 + CS 32:1 
130 mM Na+ 
15 P11-8 Free 130 mM 
Na+ 
32:1 10 (6) 
P11-8 + CS 64:1 130 
mM Na+ 
16 P11-8 Free 130 mM 
Na+ 
64:1 10 (6) 
P11-8 + P11-8-CS 32:1 
230 mM Na+ 
17 P11-8 Covalently 
bound 
230 mM 
Na+ 
32:1 10 (6) 
P11-8 + P11-8-CS 64:1 
230 mM Na+ 
18 P11-8 Covalently 
bound 
230 mM 
Na+ 
64:1 10 (6) 
P11-8 + P11-8-CS 32:1 
130 mM Na+ 
19 P11-8 Covalently 
bound 
130 mM 
Na+ 
32:1 10 (6) 
P11-8+ P11-8-CS 64:1 
130 mM Na+ 
20 P11-8 Covalently 
bound 
130 mM 
Na+ 
64:1 10 (6) 
Table 4.1: Summary of the different samples, peptide type, CS introduction manner, buffer type, molar ratio and 
peptide concentration. 
P11-4/8 only gels composed of only the base peptide at a concentration of 10 mg ml-1, while P11-
4/8 + CS gels were gels comprising of the same quantity of base peptide as the previous gels but 
were doped with free CS at the two mentioned molar ratios. These gels were designed to 
represent a model where the CS was “suspended” within the gel matrix rather than covalently 
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linked. The P11-4/8-CS gels were gels again comprising of the same base peptide but doped with 
the covalently linked P11-4/8-CS conjugate rather than the free CS.  
4.2 Results 
4.2.1 Morphologies of different P11-4 gels at different ionic strengths 
The morphologies of the gels on the microscopic scale were imaged using TEM and the images 
analysed using ImageJ to measure the fibrillary lengths and widths. An example of how the 
fibrillary widths and lengths were measured on a micrograph is shown below in Fig 4.6.  
 
Fig 4.6: An example TEM micrograph to highlight how the fibril lengths and widths were measured – where the 
length was the persistence length and the width was the width of the fibril at the widest point (to avoid any 
variation in other unmeasured dimensions such as pitch twist). Scale bar – 500 nm. 
4.2.1.1 P11-4 only  
The morphology of P11-4 gels formed in the two different ionic strength physiological buffers 
(130 mM and 230 mM Na+) mentioned previously were analysed. A consistent concentration of 
peptide was used – 10 mg ml-1 (~5.85 mM) with the method of preparation, pH switching and 
testing standardized as detailed in Section 2.  Different TEM micrographs of P11-4 hydrogels are 
shown in Fig 4.7, for each different concentration. 
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Fig 4.7: TEM images of P11-4 (~6 mM) gels in different ionic strength buffers. A) 230 mM Na+ buffer, 4000x 
magnification, scale bar - 500nm. B) 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm.  
Analysis of the fibrillar lengths and widths of the gels at both buffer strengths (130 mM and 
230 mM) yielded the following dimensions presented in Table 4.2. 
Sample Length (nm) Width (nm) 
P11-4 only 230 mM Na+ 513 ± 105 37 ± 9 
P11-4 only 130 mM Na+ 423 ± 171 35 ± 10 
 
Table 4.2: The fibrillar lengths and widths for P11-4 only samples at two different ionic strength buffers (± S.D). 
Statistical analysis (α = 0.95) indicted there was no significant difference between the fibrillar 
dimensions at the two different salt concentrations. Visual analysis of the micrographs of the gel 
samples on the grids showed that the 230 mM Na+ samples were more defined in terms of fibrils 
rather than more open structured, ribbon like structures. The fibrils were more tightly bound 
and denser bundles were seen in the 230 mM Na+ samples compared to the 130 mM Na+ 
samples. Both gels appeared similar in terms of opacity and stiffness as shown in Fig 4.8. 
 
Fig 4.8: Image of P11-4 gels only at 230 mM Na+ (left) and 130 mM Na+ (right)  
A B 
Fibrillar 
bundles 
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4.2.1.2 P11-4 + CS  
The morphology of P11-4 was examined in the presence of CS at the same conditions as the 
previous samples. The same concentration of peptide was used – 10mgml-1 (~5.85mM) but two 
molar ratios of peptide to CS were employed (Pep: CS 32:1 and 64:1).  Different TEM 
micrographs of P11-4 + CS hydrogels are shown in Fig 4.9, for each different concentration and 
molar ratio.  
  
  
Fig 4.9: TEM images of P11-4 + CS (~5.85mM) gels in different ionic strength buffers. A) P11-4 + CS 32-1 Ratio 
230 mM Na+ buffer, 4000x magnification, scale bar - 500nm. B) P11-4 + CS 64-1 Ratio 230 mM Na+ buffer, 4000x 
magnification, scale bar - 500nm. C)  P11-4 + CS 32-1 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
D) P11-4 + CS 64-1 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
Analysis of the fibrillar lengths and widths of the gels at both molar ratios of CS (32:1 and 64:1 
(P11-4: CS) at both buffer strengths (130 mM and 230 mM) yielded the following dimensions 
presented in Table 4.3. 
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Sample Length (nm) Width (nm) 
P11-4+ CS 230 mM Na+ 32:1 694 ± 88 35 ± 7 
P11-4 + CS 230 mM Na+ 64:1 731 ± 93 37 ± 7 
P11-4+ CS 130 mM Na+ 32:1 881 ± 178 37 ± 9 
P11-4+ CS 130 mM Na+ 64:1 739 ± 130 34 ± 8 
 
Table 4.3: The fibrillar lengths and widths for P11-4 +CS samples at two different molar ratios and ionic strength 
buffers (± S.D). 
Again, statistical analysis (α=0.95) indicated there was no significant difference between the 
fibrillar dimensions at the two different concentrations. Visual analysis of the images of the gel 
samples showed that in the presence of the higher 230 mM Na+ buffer, the fibrillary network 
appeared to have more junction points as well as greater salt precipitation in and around the 
fibrils, which may be a result of the relatively high concentration of salt in the buffer from 
reduced solubility of the solution from the presence of the CS molecules which have a low 
solubility inherently due to the high molecular weight, the evidence for this hypothesis was the 
greater salt precipitation present in the higher CS ratio samples (32:1). The fibrils appeared 
defined and rigid in shape being relatively straight and consistent in thickness throughout the 
fibrillary length. In comparison, in the presence of the lower 130 mM Na+ buffer the fibrils 
appeared to be more defined but this could be due to the absence of salt precipitation making 
the image less blurred. When comparing all four samples, there was no significant difference 
between each in terms of fibrillary length showing that the variation of CS content and salt 
concentration  do not affect the ability of the non-covalent mixture of P11-4 and CS to self-
assemble into fibrillary networks. However when the samples in this group are compared to the 
controls – P11-4 only in both buffers, there is a significant difference in terms of fibrillar length, 
with the introduction of CS into the network seeming to cause the fibrils to elongate. The fibrillar 
widths in contrast have remained unchanged.  Both gels appeared similar in terms of opacity as 
shown in Fig 4.10. 
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Fig 4.10: Image of P11-4 + CS gels at 230 mM Na+ at both 32:1 (far left), 64:1 (left) molar ratios and 130 mM Na+ at 
both 32:1 (far right), 64:1 (right) molar ratios. 
4.2.1.3 P11-4 + P11-4-PEG-Hex-CS 
The morphology of P11-4 + P11-4-PEG-Hex-CS in which the CS is covalently linked to the P11-4 
molecule was studied in a similar way Different TEM micrographs of P11-4 + P11-4-PEG-Hex-CS 
hydrogels are shown in Fig 4.11, for each different concentration and molar ratio. 
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Fig 4.11: TEM images of P11-4 + P11-4-CS (~5.85mM) gels in different ionic strength buffers. A) P11-4 + P11-4-CS 32-1 
Ratio 230 mM Na+ buffer, 4000x magnification, scale bar - 500nm. B) P11-4 + P11-4-CS 64-1 Ratio 230 mM Na+ 
buffer, 4000x magnification, scale bar - 500nm. C) P11-4 + P11-4-CS 32-1 130 mM Na+ buffer, 4000x magnification, 
scale bar – 500nm. D) P11-4 + P11-4-CS 64-1 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
Analysis of the fibrillar lengths and widths of the gels at both molar ratios (32:1 and 64:1 (P11-4: 
P11-4-PEG-Hex-CS) at both buffer strengths (130 mM and 230 mM) yielded the following 
dimensions presented in Table 4.4. 
Sample Length (nm) Width (nm) 
P11-4+ P11-4-CS 230 mM Na+ 
32:1 
1083 ± 109 70 ± 13 
P11-4+ P11-4-CS 230 mM Na+ 
64:1 
931 ± 65 66 ± 13 
P11-4+ P11-4-CS 130 mM Na+ 
32:1 
941 ± 134 60 ± 12 
P11-4+ P11-4-CS 130 mM Na+ 
64:1 
945 ± 137 61 ± 6 
Table 4.4: The fibrillar lengths and widths for P11-4 + P11-4-CS samples at two different molar ratios and ionic 
strength buffers (± S.D). 
ANOVA analysis again (α =0.95) indicted there was no significant difference between the 
fibrillary dimensions under the different conditions concentrations. Visual analysis of the TEM 
images once again showed that with the higher buffer concentration the images were partially 
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masked by background salt precipitation but that again there appears to be more junction points 
and more closely packed fibrils in the network compared to samples formed at the lower buffer 
concentration. The major difference compared to the previous sample group (P11-4 with added 
CS) is a significant change (α =0.05) in fibrillary width. This could be due to the fact the CS chains 
are now covalently bound to the fibrils but rather than project outwards from the central 
fibrillary core, the chains could be collapsing and wrapping around the fibrils, making the widths 
thicker. All the gels appeared similar in terms of opacity as shown in Fig 4.12. 
     
Fig 4.12: Images of P11-4 + P11-4-CS gels at 230 mM Na+ at both 32:1 (far left), 64:1 (left) molar ratios and 130 mM 
Na+ at both 32:1 (right), 64:1 (far right) molar ratios. 
A comparison of the different fibrillary lengths and widths of each sample reveal distinct 
differences between the different samples and between groups. The data is shown below in Fig 
4.13.  
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Fig 4.13: Comparison of the different fibrillar lengths and widths for each different P11-4 sample. A) Fibrillar 
lengths of each P11-4 sample. B) Fibrillar widths of each P11-4 sample. (Error bars = ± S.D). 
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4.2.2 Morphologies of different P11-8 gels at different ionic strengths 
The morphology of the P11-8 gels, including the suspension and integration manner 
incorporation of CS groups, were tested at the same conditions and concentrations as those 
with P11-4 gels. 
4.2.2.1 P11-8 only 
 Different TEM micrographs of P11-8 hydrogels are shown in Fig 4.14, shown for each different 
concentration. 
  
Fig 4.14: TEM images of P11-8 (~5.85mM) gels in different ionic strength buffers. A) 230 mM Na+ buffer, 4000x 
magnification, scale bar - 500nm. B) 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
Analysis of the fibrillar lengths and widths of the gels at the two respective ionic concentrations 
(130 mM and 230 mM Na+) yielded the following results shown in Table 4.5. 
Sample Length (nm) Width (nm) 
P11-8 230 mM Na+ 611 ± 148 34 ± 11 
P11-8 130 mM Na+ 606 ± 83 35 ± 7 
 
Table 4.5: The fibrillar lengths and widths for P11-8 only samples at two different ionic strength buffers (± S.D). 
One-way ANOVA analysis (α =0.05) indicted there was no significant difference between the 
fibrillar dimensions at the two different concentrations. The showed very little difference 
between the two different buffer concentrations with the fibrils looking similar in terms of 
definition, packing and propensity to form junction points. This net positively charged peptide 
seems to form slightly longer fibrils compared to the negatively charged P11-4 peptide gels. There 
was no significant difference between the two buffer concentrations in fibrillary length and 
width. Both gels appeared similar in terms of opacity as shown in Fig 4.15. 
A B 
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Fig 4.15: Image of P11-8 gels only at 230 mM Na+ (left) and 130 mM Na+ (right) 
4.2.2.2 P11-8 + CS 
Different TEM micrographs of P11-8 self-assembled in the presence of CS are shown in Fig 4.16, 
shown for each different concentration and molar ratio. 
          
   
Fig 4.16: TEM images of P11-8 + CS (~5.85mM) gels in different ionic strength buffers. A) P11-8 + CS 32-1 Ratio 
230 mM Na+ buffer, 4000x magnification, scale bar - 500nm. B) P11-8 + CS 64-1 Ratio 230 mM Na+ buffer, 4000x 
magnification, scale bar - 500nm. C)  P11-8 + CS 32-1 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
D) P11-8 + CS 64-1 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
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Analysis of the fibrillar lengths and widths of the gels at the two respective ionic concentrations 
(130 mM and 230 mM Na+) and two different molar ratios (32:1 and 64:1) resulted in the 
following fibrillary lengths and widths shown below in Table 4.6. 
Sample Length (nm) Width (nm) 
P11-8 + CS 230 mM Na+ 32:1 652 ± 182 49 ± 11 
P11-8 + CS 230 mM Na+ 64:1 574 ± 166 34 ± 10 
P11-8 + CS 130 mM Na+ 32:1 610 ± 116 46 ± 14 
P11-8 + CS 130 mM Na+ 64:1 654 ± 100 41 ± 11 
 
Table 4.6: The fibrillar lengths and widths for P11-8 +CS samples at two different molar ratios and ionic strength 
buffers (± S.D). 
One-way ANOVA analysis (α =0.05) indicted there was no significant difference between the 
fibrillar dimensions at the two different buffer concentrations. Visually, the images no significant 
difference in terms of definition, rigidity and propensity to form junction points. There was also 
no significant between the different samples in terms of fibrillar length and width, and there 
was also no significant difference between this sample group – P11-8 + CS and the control group 
– P11-8 only. All gels appeared similar in terms of opacity and ability to form self-supporting gels, 
as shown in Fig 4.17. 
 
Fig 4.17: Image of P11-8 + CS gels at 230 mM Na+ at both 32:1 (far left), 64:1 (left) molar ratios and 130 mM Na+ at 
both 32:1 (right), 64:1 (far right) molar ratios. 
4.2.2.3 P11-8 + P11-8-PEG-Hex-CS 
The influence of covalently linking the CS to the P11-8 molecule was then investigated. Different 
TEM micrographs of P11-8 + P11-8-PEG-Hex-CS hydrogels are shown in Fig 4.18, shown for each 
different concentration and molar ratio. 
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Fig 4.18: TEM images of P11-8 + P11-8-CS (~5.85mM) gels in different ionic strength buffers. A) P11-8 + P11-8-CS 32-1 
Ratio 230 mM Na+ buffer, 4000x magnification, scale bar - 500nm. B) P11-8 + P11-8-CS 64-1 Ratio 230 mM Na+ 
buffer, 4000x magnification, scale bar - 500nm. C)  P11-8 + P11-8-CS 32-1 130 mM Na+ buffer, 4000x magnification, 
scale bar – 500nm. D) P11-8 + P11-8-CS 64-1 130 mM Na+ buffer, 4000x magnification, scale bar – 500nm. 
Analysis of the fibrillar lengths and widths of the gels at the two respective ionic concentrations 
(130 mM and 230 mM Na+) and two different molar ratios (32:1 and 64:1) revealed the fibrillary 
lengths and widths shown below in Table 4.7. 
Sample Length (nm) Width (nm) 
P11-8 + P11-8-CS 230 mM Na+ 
32:1 
642 ± 94 55 ± 8 
P11-8 + P11-8-CS 230 mM Na+ 
64:1 
633 ± 171 79 ± 19 
P11-8 + P11-8-CS 130 mM Na+ 
32:1 
690 ± 170 62 ± 13 
P11-8 + P11-8-CS 130 mM Na+ 
64:1 
653 ± 104 64 ± 12 
Table 4.7: The fibrillar lengths and widths for P11-8 +P11-8-CS samples at two different molar ratios and ionic 
strength buffers (± S.D). 
Statistical analysis (α =0.95) showed no significant differences within the sample group, 
indicating the different self-assembly conditions (CS doping ratio and salt concentration) had no 
significant effect on the morphology of the fibrils formed when each different condition was 
compared with one another. Visual analysis of the micrographs showed the presence of 
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excessive salt as seen in previous sample containing CS. There were indications of other 
nanostructures, such as nano needles, being formed as well as fibrils. The fibrils were less rigid 
than observed in the P11-4 series of gel samples, but rather than the formation of junction points 
the fibrils seemed to aggregate through lateral association rather than entwinement. All gels 
appeared cloudy and opaque in physical appearance and were self-supporting, indicating the 
formation of nematic gels as shown in Fig 4.19. 
       
Fig 4.19: Images of P11-8 + P11-8-CS gels at 230 mM Na+ at both 32:1 (far left), 64:1 (left) molar ratios and 130 mM 
Na+ at both 32:1 (right), 64:1 (far right) molar ratios. 
The comparison of the different self-assembly conditions and samples is shown below in Fig 
4.20. This highlights the differences between the fibrillar lengths and widths of the groups and 
samples. 
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Fig 4.20: Comparison of the different fibrillar lengths and widths for each different P11-8 sample. A) Fibrillar 
lengths of each P11-8 sample. B) Fibrillar widths of each P11-8 sample. (Error bars = ± S.D). 
The fibrillar length and widths of each group are summarised in Table 4.8 below, where 
significant differences are highlighted (α = 0.95). 
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Sample Length (nm) Width (nm) 
P11-4 only 230 mM Na+ 513 ± 105 37 ± 9 
P11-4 only 130 mM Na+ 423 ± 171 35 ± 10 
P11-4+ CS 230 mM Na+ 32:1 694 ± 88 35 ± 7 
P11-4 + CS 230 mM Na+ 64:1 731 ± 93 37 ± 7 
P11-4+ CS 130 mM Na+ 32:1 881 ± 178 37 ± 9 
P11-4+ CS 130 mM Na+ 64:1 739 ± 130 34 ± 8 
P11-4+ P11-4-CS 230 mM Na+ 
32:1 
1083 ± 109 70 ± 13 
P11-4+ P11-4-CS 230 mM Na+ 
64:1 
931 ± 65 66 ± 13 
P11-4+ P11-4-CS 130 mM Na+ 
32:1 
941 ± 134 60 ± 12 
P11-4+ P11-4-CS 130 mM Na+ 
64:1 
945 ± 137 61 ± 6 
P11-8 230 mM Na+ 611 ± 148 34 ± 11 
P11-8 130 mM Na+ 606 ± 83 35 ± 7 
P11-8 + CS 230 mM Na+ 32:1 652 ± 182 49 ± 11 
P11-8 + CS 230 mM Na+ 64:1 574 ± 166 34 ± 10 
P11-8 + CS 130 mM Na+ 32:1 610 ± 116 46 ± 14 
P11-8 + CS 130 mM Na+ 64:1 654 ± 100 41 ± 11 
P11-8 + P11-8-CS 230 mM Na+ 
32:1 
642 ± 94 55 ± 8 
P11-8 + P11-8-CS 230 mM Na+ 
64:1 
633 ± 171 79 ± 19 
P11-8 + P11-8-CS 130 mM Na+ 
32:1 
690 ± 170 62 ± 13 
P11-8 + P11-8-CS 130 mM Na+ 
64:1 
653 ± 104 64 ± 12 
Table 4.8: Summary of the different fibrillar lengths and widths (nm) for each different peptide sample from both 
the P11-4 and P11-8 series (± S.D).  
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4.2.3 Mechanical properties of P11-4 gels at different ionic concentrations 
The mechanical properties of the gels was measured using rheology in terms of G’ (elastic 
modulus) and G” (viscous modulus) through firstly measuring and identifying the linear 
viscoelastic region (LVER) of the sample by carrying out a strain-controlled amplitude sweep 
from 0-100% shear strain at two different frequencies – 1Hz and 20Hz. The LVER strain rate was 
then used to carry out a strain controlled frequency sweep from 1-20Hz to measure the G’ and 
G” of each sample.  
An illustrated example using P11-4 only 230 mM Na+ is shown in Fig 4.21 which illustrates the 
analysis of the amplitude sweep data in order to choose the LVER region and how the region 
was similar at both 1 Hz and 20 Hz.  
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Fig 4.21: An example illustrating the LVER region from two amplitude sweeps: 1 Hz (left) and 20 Hz (right), where 
the plateau region is apparent.  
The two graphs above: 1 Hz (left) and 20 Hz (right) amplitude sweeps were carried out to identify 
the LVER as mentioned above. This is the region where the gel behaves as both a viscous and 
elastic substance but the two components can be separated sufficiently to measure the 
individual moduli. The LVER region is identifiable by a region when in a stress-controlled 
experiment the sample exhibits a resistance to strain, or a plateau region is observed, up to a 
certain limit. Once this limit has been reached, either the viscous or elastic component becomes 
more dominant upon which the plateau region is no longer observed due to the strain response 
becoming non-linear.  
In this sample, the LVER region has been highlighted to reside between 0-0.2% shear strains, so 
0.15% shear strain was selected at which to carry out a frequency sweep to measure the 
viscoelastic properties or G’ and G” as mentioned above, of the sample. The frequency sweep 
between 1-20 Hz is shown below for P11-4 only 230 mM Na+ in Fig 4.22, where the shear strain 
was controlled at 0.15%.  
LVER Region 
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Fig 4.22: An example of which value indicates the G’ and G” moduli, which are obtained from the frequency 
sweeps at the selected strain chosen from the amplitude sweeps for the LVER region of the sample. 
The relatively linear response to the change in frequency indicated that the LVER region was 
selected correctly due to the equal response in both the G’ and G” moduli and no crossover of 
these moduli indicating again the LVER was correctly selected. The G’ and G” moduli values can 
be taken directly from the graph, which were G’ – 25.2 ± 7.3 kPa, G” – 2.0 ± 0.7 kPa. 
The rheological analysis was performed for each combination of peptide, CS additive and salt 
concentration discussed above (Table 4.1) For each sample the corresponding shear strain 
regions were different and the selected shear strain for the frequency sweeps were different. 
The various parameters and results are summarised in Table 4.9 below. Raw data is available in 
Appendix 3. 
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Sample LVER Region (%) Shear Strain (%) G’ (kPa) G” (kPa) 
P11-4 only 
230 mM Na+ 
0 – 0.2 0.15 25.2 ± 7.3 2.0 ± 0.7 
P11-4 only 
130 mM Na+ 
0 - 0.2 0.15 15.4 ± 3.1 1.4 ± 0.3 
P11-4 + CS 32:1 
230 mM Na+ 
0.05 - 0.2 0.15 19.2 ± 0.6 1.8 ± 0.2 
P11-4 + CS 64:1 
230 mM Na+ 
0.05 - 0.1 0.08 7.3 ± 1.8 0.9 ± 0.2 
P11-4 + CS 32:1 
130 mM Na+ 
0.0 5- 0.3 0.25 11.6 ± 6.3 1.8 ± 0.9 
P11-4 + CS 64:1 
130 mM Na+ 
0.05 - 0.2 0.15 5.9 ± 3.8 0.7 ± 0.3 
P11-4 + P11-4-CS 
32:1 230 mM 
Na+ 
0.05 - 0.3 0.23 234.8 ± 12.6 25.9 ± 3.0 
P11-4 + P11-4-CS 
64:1 230 mM 
Na+ 
0.05 - 0.3 0.23 63.1 ± 34.3 7.6 ± 3.9 
P11-4 + P11-4-CS 
32:1 130 mM 
Na+ 
0.05 - 0.3 0.27 277.5 ± 8.1 36.1 ± 3.2 
P11-4 + P11-4-CS 
64:1 130 mM 
Na+ 
0.05 - 0.2 0.15 95.0 ± 6.8 12.2 ± 0.8 
Table 4.9: Summary of the G’ and G” values of the P11-4 series of hydrogels, along with the parameters used to 
obtain the values from the frequency sweep. 
4.2.3.4 P11-4 series comparison 
A comparison of the G’ and G” values obtained for each sample indicated a significant increase 
in gel strength when the CS was introduced by covalent conjugation to the peptide, with the 
results shown in Fig 4.23 below. 
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Fig 4.23: A comparison of the G’ and G” values for each of the P11-4 samples, with the moduli axis in a log scale to 
show the relative magnitudes. 
4.2.4 Mechanical properties of P11-8 gels at different ionic concentrations 
The physical mechanical properties of the P11-8 gels were tested in the same manner as the P11-
4 gels were. The different parameters and results are summarised in Table 4.10 below. 
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Sample LVER Region (%) Shear Strain (%) G’ (Pa) G” (Pa) 
P11-8 only 
230 mM Na+ 
0.05 – 0.2 0.15 100.4 ± 7.4 9.4 ± 1.0 
P11-8 only 
130 mM Na+ 
0.05 – 0.2 0.1 100.1 ± 7.7 10.1 ± 0.8 
P11-8 + CS 32:1 
230 mM Na+ 
0.05 – 0.35 0.3 20.4 ± 1.0 2.2 ± 0.2 
P11-8 + CS 64:1 
230 mM Na+ 
0.05 – 0.35 0.3 15.2 ± 1.3 1.8 ± 0.1 
P11-8 + CS 32:1 
130 mM Na+ 
0.05 – 0.35 0.3 30.4 ± 2.2 3.6 ± 0.3 
P11-8 + CS 64:1 
130 mM Na+ 
0.05 – 0.35 0.3 15.9 ± 0.9 1.6 ± 0.1 
P11-8 + P11-8-CS 
32:1 230 mM 
Na+ 
0.05 – 0.25 0.22 153.7 ± 15.4 21.9 ± 1.0 
P11-8 + P11-8-CS 
64:1 230 mM 
Na+ 
0.05 – 0.3 0.25 140.8 ± 9.5  16.3 ± 1.9 
P11-8 + P11-8-CS 
32:1 130 mM 
Na+ 
0.05 – 0.3 0.24 54.2 ± 4.1 5.7 ± 0.4 
P11-8+ P11-8-CS 
64:1 130 mM 
Na+ 
0.05 – 0.3 0.24 43.7 ± 4.7 5.4 ± 0.9 
Table 4.10: Summary of the G’ and G” values of the P11-8 series of hydrogels at 10 mg ml-1, along with the 
parameters used to obtain the values from the frequency sweep. 
4.2.4.4 P11-8 series comparison 
A comparison of the different samples in the P11-8 series showed a significant decrease in gel 
strength when the CS was introduced through the non-covalent manner, and no significant 
change when introduced in the covalent manner, where the results are shown below in Fig 4.24 
below. 
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Fig 4.24: A comparison of the G’ and G” values for each of the P11-8 samples, with the moduli axis (y-axis) in a log 
scale to show the relative magnitudes. 
4.2.5 P11-4 Series at an increased concentration (30 mg ml-1 or ~18mM) 
The results reported above were at a peptide concentration of ~5.8mM or 10 mg ml-1, which 
was just above the concentration reported by the Aggeli group at which P11-4 formed a self-
supporting nematic gel ~4mM. At the lower end of this region of macroscopic states, subtle 
changes in environment or conditions could cause phase separation to occur overtime which 
was not desirable for the application of the project so the mechanical properties at the higher 
end of the concentration region was also explored by using 30 mg ml-1 ~ 18mM peptides. The 
results from increasing the peptide concentration from ~6 -18 mM is illustrated below in Table 
4.11. 
Sample LVER Region (%) Shear Strain (%) G’ (Pa) G” (Pa) 
P11-4 only 
130 mM Na+ 
(30 mg ml-1) 
0.05 - 3 0.27 143.5 ± 21.9 20.6 ± 2.9 
P11-4 + CS 32:1 
130 mM Na+ 
(30 mg ml-1) 
0.05 – 0.3 0.28 207.0 ± 13.7 20.2 ± 2.2 
P11-4 + P11-4-CS 
32:1 130 mM 
Na+ (30 mg ml-1) 
0.05 – 0.35 0.31 434.6 ± 51.3 58.7 ± 10.2 
Table 4.11: Summary of the G’ and G” values of the P11-4 series of hydrogels at 30 mg ml-1, along with the 
parameters used to obtain the values from the frequency sweep. 
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4.2.5.4 P11-4 series comparison including 30 mg ml-1 samples 
The increased peptide content samples were included in the previous comparative graph for the 
G’ and G” values where a significant increase across all three “groups” was observed compared 
to the relative 10 mg ml-1 samples in each group. The pattern though, was that the introduction 
of CS into the P11-4 system showed a significant increase each time, where the non-covalent 
introduction of CS gave a gel that was significantly stronger than just P11-4 only at 30 mg ml-1 
and the covalent introduction of CS gave even further significant increase in gel strength. The 
results of the comparison are shown below in Fig 4.25. 
 
 
 Fig 4.25: A comparison of the G’ and G” values for each of the P11-4 samples including the 30 mg ml-1 samples, A) 
the moduli axis in a numerical scale, B) with the moduli axis in a log scale to show the relative magnitudes.  
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4.2.6 P11-8 Series at an increased concentration (30 mg ml-1 or ~18mM) 
Similarly, the P11-8 series was investigated at the 30 mg ml-1 concentration regime to investigate 
whether the increased peptide content altered the mechanical properties of the subsequent 
gels. Again, these results are summarised and reported in Table 4.12 below. 
Sample LVER Region (%) Shear Strain (%) G’ (Pa) G” (Pa) 
P11-8 only 
130 mM Na+ 
(30 mg ml-1) 
0.05 - 35 0.3 205.1 ± 14.6 23.3 ± 1.1 
P11-8 + CS 32:1 
130 mM Na+ 
(30 mg ml-1) 
0.05 – 0.4 0.35 207.8 ± 19.9 31.5 ± 2.3 
P11-8 + P11-8-CS 
32:1 130 mM 
Na+ (30 mg ml-1) 
0.05 – 0.35 0.3 101.6 ± 8.5 13.5 ± 0.9 
Table 4.12: Summary of the G’ and G” values of the P11-8 series of hydrogels at 30 mg ml-1, along with the 
parameters used to obtain the values from the frequency sweep. 
4.2.6.4 P11-8 series comparison including 30 mg ml-1 samples 
The increased peptide content samples were included with the previous data for the G’ and G” 
values where a significant increase across all three “groups” was observed compared to the 
relative 10 mg ml-1 samples in each group. However, compared to the P11-4 series, there was no 
pattern in terms of changing gel strengths. The peptide only and non-covalent CS introduction 
samples were not significantly different, and the covalent introduction of CS showed a significant 
decrease compared to the peptide only sample (Fig 4.26). 
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Fig 4.26: A comparison of the G’ and G” values for each of the P11-8 samples including the 30 mg ml-1 samples, A) 
the moduli axis in a numerical scale, B) with the moduli axis in a log scale to show the relative magnitudes. 
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4.3 Discussion and Conclusion 
4.3.1 Morphologies of different P11-4 gels at different ionic concentrations 
Analysis of the different morphologies of the P11-4 series of gels produced under different 
conditions gave interesting results. The fibrillary widths and lengths of P11-4 in the two different 
buffer strengths showed no significant difference but compared to the fibrils produced in the 
presence of CS the fibrils were small, up to ~ 50% smaller when compared to the conjugate 
doped samples ( P11-4: P11-4-CS). When CS was introduced into the system, firstly in a non-
covalent, suspension manner (P11-4 + CS) and secondly the covalently bound conjugate manner 
(P11-4: P11-4-CS), a trend was observed in terms of fibrillar length and width. The introduction 
via in a non-covalent fashion caused the formation of longer fibrils when compared to the P11-4 
only controls but the fibrillary widths were not significantly different, indicating the presence of 
CS in the system promoted self-assembly through the formation of longer tape and in turn 
ribbon structures rather than the formation of fibres. This hypothesis was based on the 
mechanism of 1-D hierarchical self-assembly, where the fibrillary length is dependent on ribbon 
length whilst fibrillary width is dependent on the inter-ribbon spacing. The presence of a 
polyanionic species, such as CS, is probably acting as a template along which the β-strands can 
align through electrostatic and non-covalent interactions which could be lowering the εtape 
energy as represented in Eq 1. 
(𝑬𝒒 𝟏)       𝜀𝑡𝑎𝑝𝑒 =  𝜀𝑐𝑘𝐵𝑇 + 𝜀𝛽𝑘𝐵𝑇  
Eq 1: The equation for the energetics behind tape formation, where 𝜀𝑐𝑘𝐵𝑇  represents the tape scission energy 
and 𝜀𝛽𝑘𝐵𝑇 represents the β-sheet tape formation energy, at kBT. 
The large, undefined lengths of the CS molecules could allow simultaneous promotion of the 
formation of multiple tapes which are then stabilised during ribbon formation through non-
covalent and coulombic interactions by the CS molecules as well. This promotion of tape 
formation would cause the lengthening of the tapes, hence eventually through 1-D hierarchical 
self-assembly the lengthening of the fibrils (PNAS, Aggeli, 2001) (Nyrkova, Eur Phys J B, 2000). 
The introduction of CS via the covalently bound method caused the formation of longer and 
thicker fibrils when compared to both the P11-4 only controls and the non-covalent group (P11-4 
+ CS). The fibrils were nearly twice as long and thick as the peptide only controls while 20% 
longer and 200% thicker as the non-covalent group samples. These data indicated that the 
permanent incorporation of the CS molecules into the fibrillar network through the triazole 
linker, had a stabilising effect on the self-assembly. There was probably a negative repulsive 
effect of incorporating the CS into the fibrillar structure which may have resulted from the 
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similar net charges on both the CS and P11-4 molecules. The repulsive forces between the two 
molecules probably lead to a greater inter-ribbon spacing distance but the net positive effect of 
the dense negative charge of the sulfate groups on each CS molecule drew counter-ions such as 
Na+ and Ca2+ present in the buffer. These counter-ions screened the negative charge of the 
sulfate groups through coulombic interactions which led to minimising excessive repulsion 
between CS – P11-4 and P11-4 – P11-4 molecules. The net effect of this screening could be thicker 
fibrils through the greater inter-ribbon spacing occurring but no detriment to the ability to form 
fibrils, in conjunction with the templated promotion of tape formation as hypothesized above 
could explain the thicker and longer fibrils observed in the conjugate doped system samples 
(Aggeli et al., 2001, Carrick, 2007a, Nyrkova et al., 2000).  
The presence of GAGs – including CS has been previously reported by various researchers 
investigating amyloid studies to promote fibril formation (Cai et al., 1993, Citron et al., 1994, 
Fraser et al., 1992, Hilbich et al., 1991, Jarrett et al., 1993, Jarrett and Lansbury, 1993, Lomakin 
et al., 1996, McLaurin and Chakrabartty, 1996, McLaurin et al., 1998, McLaurin et al., 1999, Terzi 
et al., 1995). The P11-X family of peptide are classed as “amyloid like” due to the cross β structure 
of the fibril and so similar effects could well occur in this synthetic system. McLaurin et al 
reported that in the presence of CS, the amyloid peptide Aβ 40 formed fibrils which showed 
lateral aggregation but in the absence of CS no aggregation was observed beyond forming short 
thin fibrils. This was reinforced by the observation that a similar peptide - Aβ 42, the elongated 
version of Aβ 40, showed fibril thickening in the presence of GAGs (Castillo et al., 1999, McLaurin 
et al., 1999). McLaurin et al hypothesised that the GAGs act as a scaffold for fibril formation 
through enhancing β-sheet conformer formation and stabilising fibrils through lateral 
association in the latter stages of self-assembly. Furthermore, the group also reported that the 
presence of sulfate groups may be involved with promoting fibril formation by observing 
decreased fibril formation in the presence on desulfated GAGs (Castillo et al., 1999, McLaurin et 
al., 1999). Further evidence to support the hypothesis of CS promoting fibril formation in the 
P11-4 system was the observation by McLaurin et al that CS was the most effective GAG at 
promoting nucleation and lateral association of Aβ fibrils which they theorise may be due to CS 
having sulfate groups on only one face and having the ideal distribution of sulfate groups to 
promote fibril formation (McLaurin et al., 1999).  
4.3.2 Morphologies of different P11-8 gels at different ionic concentrations 
In comparison to P11-4, no similar trend was observed in the P11-8 series in terms of the 
sequential growth of the fibrils through the differing introduction of CS into the system. All three 
groups: - P11-8 only controls, non-covalent samples – P11-8 + CS and covalently bound samples – 
 
 
161 
 
 
P11-8 + P11-8-CS, showed no significant difference in terms of fibrillar length and width as 
observed with the P11-4 series. This could be possibly due to the opposite net charges between 
the polyanionic CS and the net positive charged P11-8 peptide, resulting in an electrostatic 
attraction which may not promote and/or stabilise further self-assembly from β-strands to 
tapes. There is obviously no detrimental effect on self-assembly as the lengths and widths are 
not significantly different in the presence of CS.   
4.3.3 Mechanical properties of different P11-4 gels at different ionic concentrations 
The measured mechanical properties of the P11-4 gels as obtained through rheological 
experiments correlated well with the dimensional analysis of TEM micrographs. The presence of 
CS within P11-4 samples in simply a non-covalent suspension manner had no significant effect on 
the G’ and G” of the samples compared to the peptide only samples indicating the CS did not 
cause any significant increase in gel strength. There was no significant difference in regards to 
the ratio of G” to G’ again indicating the composition of the different gels (in terms of being 
more solid or liquid like) are not significantly different. These data indicate that while the 
presence of CS in the system caused the formation of longer fibrils, this did not translate into an 
effect on gel strength and composition.  
When compared to the covalently conjugated samples, there was a significant change in gel 
strength. The G” and G’ measurements for each of the covalent samples were significantly 
higher than any of the other samples. This indicated the covalent gels were significantly 
stronger, although the ratio of G” to G’ was similar to the P11-4 only and P11-4 + CS samples and 
hence the composition of the covalent gels were comparable in terms of solid and liquid like 
behaviour. These comparable properties indicate the only possible explanation for the higher 
G” and G’ values was due to the effect of the covalently introducing CS into the fibrillar network. 
This observation was backed up from the TEM analysis where longer, thicker fibrils were 
observed in the covalently incorporated CS gels. The increased dimensions signified the 
formation of stronger networks. CS only controls demonstrated that with the lack of the self-
assembling peptide network, a CS solution at either molar ratio or buffer concentration behaved 
like a pure liquid with very low G” and G’ values but the ratio of G” to G’ was far smaller again 
reinforcing the liquid like behaviour observed.  
4.3.4 Mechanical properties of different P11-8 gels at different ionic concentrations 
Similarly, in the P11-8 series, covalently incorporating CS into the fibrillar network gave rise to 
greater G” and G’ values but significant difference between peptide only and P11-8-CS were only 
observed when the 230 mM Na+ buffer was used to make up the gel samples. The hypothesis 
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for this was the increased sodium content screened the electrostatic interaction between the 
negatively charged CS and positively charged P11-8. This was the opposite behaviour to that 
observed with the P11-4 series where the increased ionic strength of the buffer probably 
screened the electrostatic repulsion between the like charged CS and P11-4 molecules. Unlike 
the P11-4 series, where every covalent system sample showed significant different to the peptide 
only control group, only the covalent samples with 230 mM Na+ buffer showed significant 
difference, indicating the introduction of the CS covalently into the fibrillar network maybe not 
as favourable with the oppositely charged species of P11-8 and CS which could be due to the 
longer range of electrostatic attraction compared to the shorter range of electrostatic repulsion 
which could have led to greater disruption of the fibrillar network. 
4.3.5 Mechanical properties of different P11-4 gels at different ionic concentrations 
at 30 mg ml-1  
The increased peptide content caused an increase in the measured G’ and G” values for P11-4 
only samples, causing an increase by nearly an order of magnitude – 9.2x. This observed increase 
in gel strength is explained by previously reported data on P11-4 by the Aggeli group, where due 
to the concentration dependent mechanism of self-assembly, the increased peptide content 
causes the formation of thicker fibrils/fibres which promotes the gel to become more “solid-
like” thus having increased elastic and viscous moduli. Interestingly, unlike in the 10 mg ml-1 
regime, the presence of CS caused an even greater increase in gel strength – a further 1.4x. This 
observation further reinforces the hypothesis that the CS acts and stabilises fibril nucleation and 
growth as observed with amyloid fibrils. But the most interesting observation, was the further 
enhancement of gel strength of the covalent P11-4: P11-4-CS samples when in the 30 mg ml-1 
regime. At 10 mg ml-1, the measured G’ and G” values were already larger than any measured 
value indicating these were the strongest gels but at 30 mg ml-1 the gels are even stronger with 
a further 2.1x increase on the P11-4 + CS sample mentioned above, or a 1.8x increase on the 10 
mg ml-1 covalent sample.  
These measured gel moduli have never been reported for a reversible system incorporating 
biopolymeric materials, and are higher than some reported permanently cross-linked synthetic 
polymeric materials such as acrylamide or poly-vinyl alcohol (PVA) where Oyen (Oyen, 2014) and 
Pal et al (Pal et al., 2009) reported dynamic moduli were in the order of 104 Pa (Pal et al., 2009). 
Biopolymer hydrogels such as agrose and gelatin hydrogels were investigated by Zuidema et al, 
where the dynamic moduli reported there were in the order of 103 Pa (Zuidema et al., 2014). 
The reported dynamic moduli for the covalent peptide: peptide-CS gels are 1-2 orders of 
magnitude larger than these covalently cross-linked hydrogels indicating the incorporation of 
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the CS permanently into the fibrillar network has a significant stabilising effect on the hydrogel 
structure.  
4.3.6 Mechanical properties of different P11-8 gels at different ionic concentrations 
at 30 mg ml-1  
When the P11-8 samples were increased to 30 mg ml-1, there was a significant increase in 
dynamic moduli between the P11-8 only at 10 mg ml-1 and 30 mg ml-1. This again matches 
previously reported data by the Aggeli group, where increasing the peptide content, the fibrillar 
structure becomes more rigid and thicker thus increasing the gel strength. The influence of 
doping the gel with CS showed an increase in dynamic moduli but it was not a significant 
increase, but the influence of doping the gel with the covalently bound CS –peptide conjugate 
did show a significant effect, but the opposite to that observed for P11-4, the dynamic moduli 
decreased to a similar value measured for the base P11-8 only gels at 10 mg ml-1.  
4.3.7 Conclusion 
The effect of introducing CS into two different peptide systems in two different fashions showed 
stark differences. In the similarly charged system of P11-4 and CS at 10 mg ml-1 or ~ 6mM, 
introducing the CS non-covalently resulted in a significant change in the fibrillar length but no 
significant change in fibrillar width compared to the peptide only samples and the gels showed 
no significant change in dynamic moduli at any molar ratio or buffer strength. However, when 
CS was incorporated by using a covalently linked peptide-CS conjugate, a significant change in 
both fibrillar length and width was observed alongside large changes in the dynamic moduli of 
the hydrogels which increased significantly across all molar ratios and buffer strengths. When 
the peptide content was increased to 30 mg ml-1, a significant increase of dynamic moduli was 
observed for the base peptide only, whilst introducing the CS in non-covalently at this 
concentration gave a significant increase in dynamic moduli compared to the peptide alone, 
again, the covalent manner of introduction gave further significant increases above every other 
measured gel yield a hydrogel with an elastic modulus measured at 0.48MPa.  
In the oppositely charged system of P11-8 and CS at 10 mg ml-1 or ~ 6mM, introducing the CS in 
both the non-covalent and covalently bound manner resulted in no significant change in either 
the fibrillar length or width and it caused a significant decrease in the dynamic moduli indicating 
a destabilising effect on the fibrillar network. In comparison, the covalently introduced CS 
manner caused a significant increase in dynamic moduli in the 230 mM Na+ buffer samples for 
both molar ratios indicating the increased sodium content screened and overcame the 
destabilising effect of the opposite charges of the P11-8 and CS, probably caused by electrostatic 
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attraction. When the peptide content was increased to 30 mg ml-1, significant increases in 
dynamic moduli for the P11-8 only and non-covalent P11-8 + CS samples were observed but for 
the covalent sample a significant decrease occurred compared to the other 30 mg ml-1 samples. 
This indicated the increase P11-8 content had some stabilising effect on the gel but it was 
countered by the increased P11-8-CS conjugate to some degree.  
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Chapter 5 
Assessment of functionalised self-
assembling peptides in a GAG 
depleted cartilage model 
Following the characterisation of the self-assembling peptide gels, their ability to restore the 
resistance to deformation properties of an early stage GAG depleted osteoarthritic cartilage 
model was investigated through qualitative and quantitative measurement of the resistance to 
deformation properties of both native and GAG depleted tissue through indentation and 
material testing, while confirmation of self-assembly within the tissue was achieved through the 
use of confocal microscopy.  
5.1 Introduction 
5.1.1 Osteoarthritic cartilage models 
5.1.1.1 Choice of animal model 
Within the field of tissue engineering and regenerative medicine, it is necessary to have models 
of tissue exhibiting the biomechanics and biology of the affected tissue being investigated. In 
research directed towards understanding and developing treatments for osteoarthritis there is 
a requirement for various models, depending on the hypothesis being evaluated and in which 
to test treatments in vitro and in vivo. Various animals have been used for in vivo testing and 
their (osteo)chondral tissues used in vitro. Commonly murine, laprine, and canine models are 
used, but when the experiment requires testing intervention under appropriate physiological 
loads, i.e. loads suitable for human anatomy, larger species are employed and ovine, porcine, 
caprine, bovine and equine as well human tissue are usually employed (Ahern et al., 2009, 
Fermor et al., 2015a, Fermor et al., 2015b, Wayne et al., 1998).  
The rationale for the use of larger species of animal for physiological loading is mainly due to 
the thickness of the cartilage, the maximum load capacity of the skeletal structure, abundancy 
of the tissue and the ethical considerations behind using the species. When live animal models 
are required other factors come into play, such as cost of housing, feeding and medical care for 
the subjects. In this chapter only in vitro animal tissue models will be employed. The pros and 
cons of the animal tissue used in vitro is summarised in Table 5.1 below. 
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Species Pros Cons 
Ovine Large availability and low 
cost of sourcing tissue 
Variability in cartilage 
thickness makes modelling 
difficult. Slow rate of skeletal 
maturation 
Porcine Large availability and low 
cost of sourcing tissue. 
Similar anatomy of the knee 
joint to the human knee  
Slightly thinner cartilage than 
human cartilage 
Bovine Large availability and low 
cost of sourcing tissue 
Different collagen 
orientation within cartilage 
compared to human 
cartilage.  Significantly 
thinner cartilage layer 
Table 5.1: Pros and cons of tissue types commonly used in in vitro testing. The pros and cons of each different 
tissue is summarised in terms of practicality and cost effectiveness.  
The three larger animal species (bovine, porcine, ovine, caprine) each have their benefits 
depending on the intended design of the in vitro experiment. Sheep is a commonly used species 
for cartilage animal models due to the availability and low cost of sourcing tissue. The 
disadvantage of this tissue is the variability in cartilage thickness which often has grade III/IV 
(ICRS) lesions extending into the subchondral bone. The rate of skeletal maturity is relatively 
slow which in conjunction to the other disadvantages causes some limitations when the tissue 
is used as a model. The goat is another commonly used species for cartilage models which is 
similar in terms of cost and availability and has a less variable cartilage thickness which makes it 
suitable for small defect modelling. Pigs are not as commonly used as sheep and goats but due 
to having a larger thickness of cartilage, porcine tissue can be utilized for large to full thickness 
defect research due to having a similar defect composition to that observed in human tissue in 
terms of proportions of damage to the cartilage and subchondral layers respectively. A larger 
proportion of damage is observed in the subchondral region in sheep and goat tissue. Cows are 
also used for cartilage models due to having a similar availability as to the others and show a 
similar cartilage thickness as porcine tissue (Ahern et al., 2009, Fermor et al., 2015b, Fermor et 
al., 2015a). 
Whilst the thicknesses of porcine and bovine tissue most closely match that of human tissue, 
Rieppo et al reported huge differences between the cartilage histologies in terms of composition 
and striations throughout the cartilage regions. The superficial zone thickness was similar across 
the three species but the organisation and content of the collagen throughout each species 
differed. In human tissue, birefringence measurements showed a significantly higher level of 
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collagen in the superficial and deep zones as compared to porcine and bovine tissue. The 
collagen levels increase linearly throughout the deep zone reaching a maximum close to the 
cartilage-bone interface whilst in porcine and bovine tissue a plateau region is observed at half-
thickness. In both porcine and bovine tissue, a lower anisotropy level was observed at the 
cartilage-bone interface indicating less organisation compared to human tissue, whereas in the 
middle or translational zone a higher thickness with a higher anisotropy was noticed in porcine 
tissue compared to human and bovine tissue which had similar appearances. Besides differences 
in histology, differences in proteoglycan content are observed between the three tissues, where 
a lower content was observed in the superficial zone of human tissue compared to bovine and 
porcine samples. The increase in proteoglycan content throughout the total cartilage thickness 
differs between the different tissues. In porcine tissue the maximum content occurs 
approximately one sixth through the total depth whilst in human and bovine tissue a monotonic 
increase occurs when the animal is skeletally mature. The proteoglycan content increases as the 
animal matures thus a compromise has to be made between maximum proteoglycan content 
and maturation time. A small decrease in proteoglycan content, as well as other maturation of 
structurally important materials such as collagen, can cause changes in the properties of the 
tissue such as resistance to compression. 
These differences highlight the limitations of using animal models to predict how human tissue 
functions when osteoarthritic, but also the different choices that have to be made when 
considering which tissue/species to use to base the model on in the first place.  
5.1.1.2 Model development and disease simulation 
Another consideration when using animal models is how to samples which can mimic the human 
diseased state, as trying to obtain tissue already in the diseased state of interest is exceedingly 
difficult. For osteoarthritic models, various methods to create a diseased state have been 
employed ranging from use of enzymatic digestion (with enzymes such as chondroitinases and 
proteases such as papain) through to techniques such as ultrasound or mechanical degradation 
(Grenier et al., 2014, Benam et al., 2015, Johnson et al., 2016). These different methods have 
been used to create different levels of degradation and defects throughout the tissue, as each 
technique has a different level of intensity and penetration.  
As described in Chapter 1, there are differing severities of disease progression and damage 
observed in osteoarthritic cartilage, so the method employed to simulate the disease state is 
also dependent on the severity of damage required due to aforementioned differing levels of 
intensity and penetration.  
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In this chapter, the animal model of choice was porcine tissue due to the ease of obtaining 
samples and the similarities in mechanical strengths of the articular cartilage region on the knee 
between human and porcine tissue. Whilst the thickness of cartilage in porcine tissue is slightly 
thinner compared to human cartilage (1.5 mm compared to 2.35 mm average thickness), the 
only animal tissue with a thicker cartilage layer is equine tissue at 1.75 mm, but porcine tissue 
is far more abundant and cost effective (Ahern et al., 2009). This is hence one of the reasons 
behind choosing this tissue for the model of osteoarthritic knee developed by Andres Barco 
(Barco, 2017). The average GAG content of porcine tissue in the femoral condyles is higher than 
that found within humans but because the aim of the experiment was to deplete the GAGs from 
the tissue this increased content was not an issue in choosing porcine tissue for the model 
(Hosseininia et al., 2013, Fermor et al., 2015a). 
5.2 Results  
5.2.1 Severe osteoarthritic model validation 
An early stage osteoarthritic model with total loss of GAGs was chosen for the testing reported 
in this chapter. The model was developed by Andres Barco of the Ingham group using a series a 
process summarised in Fig 5.1.  
 
Fig 5.1: Flowchart illustrating the GAG depleting procedure. The procedure involved SDS and PBS washes at 
varying lengths, whilst being agitated at 240 rpm, 37 °C. 
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The rationale behind using this model was that while in an early stage osteoarthritic model the 
level of GAGs are barely diminished and that the total loss of GAGs within cartilage is associated 
with severe late stage OA, the minimal loss of GAGs would have meant any measurement of 
changes in biomechanics would have been inaccurate and difficult to measure to any degree of 
precision so by totally depleting the GAG concentration of an otherwise early stage OA model 
meant any change in the biomechanics of the tissue could be measured with precision and 
accuracy with an acceptable level of sensitivity.  Histological and immunohistochemical analysis 
was carried out to confirm that a total GAG depleted tissue model was produced in accordance 
with the previously developed method.  
5.2.1.1 Histological validation of GAG depleted cartilage model 
Safranin O Fast Green, selectively reveals the location of proteoglycans within tissue by staining 
them red while proteoglycan depleted tissue appears green.    Staining of paraffin embedded 
native and GAG depleted cartilage tissue sections shows that treatment with 0.1 % (w/v) SDS 
effectively removes all proteoglycans from the tissue (Fig 5.2).  
  
  
Fig 5.2: Safranin O and fast green stained sections of native and GAG depleted porcine cartilage. Top left (A) – 
native healthy medial cartilage. Top right (B) – GAG depleted medial cartilage. Bottom left (C) – native healthy 
lateral cartilage. Bottom right (D) – GAG depleted lateral cartilage. Scale bar = 500 µm.  
A B
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The micrographs indicated the successful generation of a GAG depleted porcine cartilage model 
with the total absence of GAGs following the SDS and PBS washes. The 5-10 µm layer of blue at 
the cartilage surface in the native micrographs are probably due to the various washes carried 
out during the staining protocol. The superficial zone surface of the GAG depleted samples are 
defined and little damaged compared to the native healthy samples indicating the process did 
not damage the cartilage sample during the various agitation steps which had to be relatively 
rigorous to ensure full penetration of the SDS and PBS washes and sufficient movement of the 
solutions to wash out any GAGs from the tissue samples.  
5.2.1.2 Immunohistochemical validation of GAG depleted cartilage model 
Immunohistochemical analysis of both native healthy and GAG depleted tissue was carried out 
as described in section 2. The procedure employed a CS selective antibody and results in a brown 
staining of the tissue when CS is present. The micrographs, shown below in Fig 5.3, indicated 
near total loss of CS selectively in the GAG depleted sample (right hand images, B and D, in Fig 
5.3) compared to the native tissue (left hand images, A and C, in Fig 5.3). This reinforced the 
data from the histology images also showing that the treatment of the tissue with 0.1 % SDS 
(w/v) and PBS washes removed the majority of the GAGs from the tissue, including CS.  
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 ,     
Fig 5.3 : Immunohistochemical micrographs of native and GAG depleted cartilage. CS selective staining for native 
and GAG depleted samples indicating the presence of CS where the dense brown colouration is located. A) Native 
medial sample. B) GAG depleted medial sample. C) Native lateral sample. D) GAG depleted lateral sample. Scale 
bar = 500 μm. 
5.2.1.3 Quantitative validation of GAG depleted cartilage model 
One issue with histological and immunohistochemical testing is that it does not give truly 
quantitative results as these tests only provide qualitative images of the tissue.  Biochemical 
assays can be used to quantify the amounts of materials such as chondroitin sulfate using 
sulphate in the dimethymethylene blue (DMMB) colorimetric assay.  In the DMMB assay 
example the dye binds to sulphate groups in the molecule causing and produces a change in 
emission, shifting the wavelength towards a maximum at 525 nm> The assays were performed 
on desiccated tissue as detailed in Chapter 2.  The average GAG content (n=3) measured for 
native tissue was 267.8 ± 13.4 μg mg-1 whilst the SDS depleted tissue had a measured average 
GAG content (n=3) of 63.9 ± 3.2 μg mg-1, indicating a 76% decrease in GAG content following 
SDS treatment. The reduction in GAG content was significant (p<0.05, Students T-Test) as shown 
in Fig 5.4 below. 
A B
 
 A 
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Fig 5.4: Quantification of GAG content of native and GAG depleted cartilage. Data is shown as the mean (n=6) ± 
95% CL. * indicates significant (p<0.05, Students T-test). 
5.2.1.4 Detection of residual SDS using a Stains-All assay 
To assess whether there was any residual SDS present in the GAG depleted model cartilage, a 
photometric assay was carried out using a carbocyanine based dye which had the commercial 
name Stains-All, illustrated in Fig 5.5. 
 
Fig 5.5: Structure of Stains-All dye. 
The results are shown in Fig 5.6 with the medial and lateral samples separated. 
Quantitative analysis of SDS in each wash showed that no additional SDS could be detected 
following PBS wash 4 (Fig 5.6). This suggested that SDS was sufficiently removed from the 
treated cartilage during the processing to not be regarded as an issue with future testing. 
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Fig 5.6: Quantitative measurements of average SDS levels in various washes of medial (Top) and lateral (Bottom) 
tissue samples (n=3). Wavelength read at 447nm. Results are the mean readings (n=3) ± 95 % CL, where 
significance (p<0.05) is indicated by *. 
The data presented indicated that in the medial samples on average over 99.8 ± 0.17% of SDS 
was removed by the final PBS wash, while the lateral samples had over 99.7 ± 0.14% removed 
by the final wash. A peptide hydrogel was prepared, as previously described for hydrogels in 
Chapter 4 except using 0.1% SDS solution instead of the sodium buffers, to investigate whether 
these levels of residual SDS would interfere with self-assembly, but as shown in Fig 5.7, a 
hydrogel formed in the presence the residual SDS.  
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Fig 5.7: Images of P11-4 only hydrogels (10mgml-1) in the presence of SDS at 0.1 % starting SDS concentration.  
These results, as well as the physical formation of a gel at the measured concentrations, 
indicated the removal steps during the GAG depletion process were sufficient.  
The next step was to confirm whether the monomeric peptide solutions firstly penetrated the 
tissue following injection and secondly whether the self-assembling peptides formed hydrogels 
in situ.  
5.2.3 Confirming self-assembly in the tissue 
Confirmation as to whether the injected peptide gels had self-assembled within the tissue was 
required to be able to definitively associate any changes in bio-mechanical properties with the 
presence of the gels rather than some interaction between the tissue and the monomeric 
solutions. The challenge was to image the self-assembled gels within the tissue without 
disrupting the self-assembly.  In order to image the materials various fluorescently labelled 
molecules were employed.  For example small quantities of fluorescently labelled peptide could 
be doped into the self- assembling mixture and employed to visualise the location of the peptide 
within the tissue. Unfortunately direct fluorescence microscopy was unsuccessful due to 
artificial creation of fibril like structures which were indiscernible from folds within the tissue 
section that caused increased fluorescence to be observed, as shown in Fig 5.8.  
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Fig 5.8: Fluorescence micrograph of peptide injected tissue. Gel was P11-4:P11-4-CS 32:1 (P11-4-Fluorescein doped 
150:1) injected GAG depleted tissue. 
The advantage of having doped the gels with fluorescent molecules was being able to use 
confocal microscopy which enabled larger sections to be cut and z stacking performed to show 
the penetration of the fluorescent material throughout the cartilage tissue. However, the 
greatest advantage confocal microscopy had over other techniques was being able to carry out 
a fluorescence recovery after photo bleaching (FRAP) type experiments to indicate the diffusion 
rate of the fluorophore within the tissue.  
5.2.3.1 Confocal imaging 
In order to show the diffusion rate of a small molecule, a solution of free fluorescein was injected 
into the tissue and FRAP experiments performed. Selected micrographs are shown below in Fig 
5.9, with the pre-bleaching, bleached and post bleaching points highlighted. 
 
Questionable 
region of self-
assembled 
peptide 
Background 
fluorescence 
of cartilage 
tissue and/or 
fluorescence 
from peptide 
gel 
Potential fold 
of cartilage 
tissue from 
processing 
 
 
176 
 
 
   
  
 
Fig 5.9: Confocal images of fluorescein only control within articular porcine cartilage and FRAP recovery data. A) 
Pre-bleaching micrograph with the positive control circled in blue, while the negative control circled in red.  B) 
Positive control area has been photo-bleaching using 100% power for 488nm laser. C) Post-bleaching shows 
recovery of fluorescence after ~50 ms. Graph represents fluorescence recovery rate of over 100 ms following 
photo bleaching of control area. Scale bar = 50 μm. 
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The images showed that the fluorescein was rapidly able to diffuse (25 ms) from the non-
bleached tissue surrounding the positive control area, thus restoring fluorescence within the 
control area by 76 %. This recovery rate represented a non-self-assembled state and showed 
rapid diffusion of a small molecule through the tissue. This ability to recover was used as the 
negative control for the peptide samples to indicate whether gels had formed or the peptides 
were still in a monomeric solution.  
The P11-4 only sample, doped with fluorescein labelled P11-4 (Fig 5.10) doped in a ratio of 1:150 
fluorescein-P11-4:P11-4, showed no recovery when FRAP was carried out, indicating a self-
assembled state within the tissue. The images below in Fig 5.11 highlight the lack of recovery in 
the bleached area. 
 
Fig 5.10: Structure of fluorescein labelled P11-4 used in the FRAP experiments.  
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Fig 5.11: Confocal micrographs of P11-4 only controls injected within articular porcine cartilage and FRAP recovery 
data. A) Pre-bleaching micrograph with the positive control circled in blue, while the negative control circled in 
red.  B) Positive control area has been photo-bleaching using 100% power for 488nm laser. C) Post-bleaching 
shows some recovery of fluorescence after ~50 ms. Graph represents fluorescence recovery rate of over 100 ms 
following photo bleaching of control area. Scale bar = 20 μm. 
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The lack of recovery in the P11-4 only sample indicated the peptide bound fluorophore had 
significantly lower diffusion rates in the tissue which was attributed to the formation of a gel 
within the tissue. A similar observation was noted in the P11-4-CS sample, when lack of 
fluorescence recovery was witnessed within the same timescale ~ 50 ms. The micrographs are 
shown below in Fig 5.12, again the negative bleaching control shown to highlight the loss of 
fluorescence was through control rather than background bleaching of the sample.  
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Fig 5.12: Confocal images of P11-4-CS control within articular porcine cartilage and FRAP recovery data. A) Pre-
bleaching micrograph with the positive control circled in blue, while the negative control circled in red.  B) 
Positive control area has been photo-bleaching using 100% power for 488nm laser. C) Post-bleaching shows 
recovery of fluorescence after ~50 ms. Graph represents fluorescence recovery rate of over 100 ms following 
photo bleaching of control area. Scale bar = 50 μm. 
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A fluorescently labelled CS sample, as shown in Fig 5.13, was introduced to the tissue to 
investigate the diffusion rate of the much larger (~48 kDa) material through the tissue.   
 
Fig 5.13: Fluorescein labelled CS molecule used in the FRAP experiments. 
In comparison to the peptide containing samples, the fluorescently labelled CS only control 
showed 25 % recovery after 25 ms compared with 1-2 % recovery after 25 ms for the peptide 
containing samples, as shown in Fig 5.14. This observation indicated the CS was not bound in a 
self-assembled matrix within the tissue but due to the large size of the molecule the recovery 
time was significantly longer than observed with the fluorescein only control. However the fact 
that even this large macromolecule diffuses more rapidly than the fluorescently labelled P11-4 
demonstrates that the peptide has formed very large self-assembled aggregates within the 
tissue. 
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Fig 5.14: Confocal images of fluorescently labelled CS only control within articular porcine cartilage and FRAP 
recovery data. A) Pre-bleaching micrograph with the positive control circled in blue, while the negative control 
circled in red.  B) Positive control area has been photo-bleaching using 100% power for 488nm laser. C) Post-
bleaching shows recovery of fluorescence after ~50 ms. Graph represents fluorescence recovery rate of over 
100 ms following photo bleaching of control area. Scale bar = 50 μm. 
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5.2.2 Mechanical testing of osteoarthritic tissue model 
5.2.2.1 Indentation testing 
Once the animal model was validated to be sufficient in terms of mimicking severe 
osteoarthritic, GAG depleted cartilage and the ability of the peptides to penetrate and self-
assemble within the tissue had been confirmed the mechanical properties of the tissue were 
measured.  A range of conditions, as shown in Table 5.2, were used in these experiments to 
provide information about how the different peptides, loading of CS (either conjugated to the 
peptide or otherwise) and peptide concentration affected the mechanical response.   
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Tissue 
Condition 
Acronym 
Used 
(M/L) 
Peptide Ratio 
(CS:Peptide) 
Buffer Other 
Native 
(Healthy) 
H - - - - 
Native 
(Healthy) 
HN - - - Needle 
Only 
Native 
(Healthy) 
HS - - 130mM Na+ 
buffer 
Sham 
solution 
injection 
SDS treated – 
GAG depleted 
S - - - - 
SDS treated – 
GAG depleted 
S + CS - 1:32 130mM Na+ 
buffer 
Fluorescent 
labelled CS  
SDS treated – 
GAG depleted 
S + P P11-4 (10 mg 
ml-1 or ~6mM) 
1:32 130mM Na+ 
buffer 
Fluorescent 
labelled 
P11-4 (1:150 
P11-4_F:P11-
4) 
SDS treated – 
GAG depleted 
S + P114 
30 
P11-4 (30 mg 
ml-1 or 
~18mM) 
- 130mM Na+ 
buffer 
Fluorescent 
labelled 
P11-4 (1:150 
P11-4_F:P11-
4) 
SDS treated – 
GAG depleted 
S + P11-CS 
30 
P11-4 (30 mg 
ml-1 or 
~18mM) 
1:32 130mM Na+ 
buffer 
Fluorescent 
labelled 
P11-4 (1:150 
P11-4_F:P11-
4) 
SDS treated – 
GAG depleted 
S + P11-8-
CS 30 
P11-8 (30 mg 
ml-1 or 
~18mM) 
1:32 130mM Na+ 
buffer 
Fluorescent 
labelled 
P11-8 (1:150 
P11-8_F:P11-
8) 
Table 5.2: The different control groups tested using the indentation rig to measure the effects of deformation 
observed within native and depleted cartilage samples. 
5.2.2.2 Cartilage thickness measurements 
The thickness of the cartilage covering each condyle was measured using a set up as described 
in Chapter 2, where a needle probe was inserted into the cartilage surface and the compressive 
load was measured against the relative displacement of the probe. By analysing the compressive 
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load as the probe moves through the sample, the regions of transition from air to cartilage and 
cartilage to subchondral bone can be observed and from this the thickness of the cartilage can 
be determined.  
The thickness was calculated from the intersection point of the two linear fits which represented 
the resistance forces for the cartilage and bone resistances. A representation of the data analysis 
corresponding to the different regions of the cartilage during the experiment is shown in Fig 
5.15. 
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Fig 5.15: Typical schematic of cartilage thickness measurement (Top) and real data interpretation (Bottom). A 
representation of the data analysis and the corresponding regions of the cartilage sample (top). The thickness of 
the cartilage layer is calculated from the interception point from the gradients chosen where the boundaries of 
the cartilage are – the example shown is for a medial sample where the calculated cartilage thickness = 2.01 mm. 
The data differed from the idealised model shown in the schematic but with experience the 
curves could be analysed through by the method shown in the real data graph. 
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The measured thickness for both the medial and lateral condyles, for both the native and SDS 
treated samples can be seen below in Table 5.3 along with literature values for the different 
regions. 
Sample Region Measured (mm) Literature (mm) Reference 
Native Medial 1.97 ± 0.11 2.00 ± 0.25 (Fermor et al., 
2015a) 
Native Lateral 1.67 ± 0.39 1.57 ± 0.43 (Ahern et al., 
2009, Wayne 
et al., 1998, 
Fermor et al., 
2015a) 
SDS treated Medial 2.05 ± 0.14 N/A N/A 
SDS treated Lateral 1.76 ± 0.35 N/A N/A 
Table 5.3: The measured and literature values for both medial and lateral cartilage thicknesses, with SDS treated 
measured samples also shown (n=12) where the results are presented as the mean ± 95% CL (p<0.05 student T-
test)  
The measured thicknesses for the native tissue matched previous measurements from literature 
made by different techniques such as CT scanning, thus validating the measurements, and were 
not significantly (p<0.05) different from the SDS treated tissue, which were slightly thicker.  
5.2.2.3 Deformation during indentation tests 
Tissue deformation was measured using an indentation rig. A 20.5 g 2.5 mm diameter circular 
indenter was used to apply a 0.22 MPa load to the surface of the cartilage sample. As described 
in section 2.6.2, the relative displacement of the load cell was measured over the period 1hr at 
a 10Hz scan rate. The data was then plotted as a time course over the hour in seconds to show 
the total deformation of the tissue for each experimental condition. The data is shown in Fig 
5.16, where the medial and lateral condyles are shown on separate graphs.  
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Fig 5.16: Summary of mean deformation data after 1hr. Deformation was shown over 1hr (3600s) for each control 
group separated for the two condyles – medial samples (top) and lateral samples (bottom) with data 
representing mean (n=3) ± 95% CL. Labels – M = Medial, L = Lateral, H = Native (Healthy), S = SDS GAG depleted, 
HN = Native needle only, HS = Native Sham injection, S + P = GAG depleted + P11-4-CS 10 mgml-1 injected, S + CS = 
GAG depleted + CS only injected, S + P11-4 30 = GAG depleted + P11-4 30 mgml-1 only, S + P11-4-CS 30 = GAG 
depleted + P11-4-CS 30 mgml-1, S + P11-8-CS 30 = GAG depleted + P11-8-CS 30 mgml-1. 
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Upon analysing the rate of deformation by measuring the first and second derivatives of each 
curve, there were no discernible differences so to better represent the total deformation of each 
sample as simple bar chat would suffice, as shown in Fig 5.17. 
 
 
Fig 5.17: Percentage deformation at equilibrium end point. The data shows the percentage deformation once the 
tissue has reached an equilibrated state ~ 1hr. The data is split into two data sets, medial (top) and lateral 
(bottom) samples, with the mean values (n=3) ± 95 % CL shown, where significance (p<0.05, Student T-test) is 
indicated by *. Labels – M = Medial, L = Lateral, H = Native (Healthy), S = SDS GAG depleted, HN = Native needle 
only, HS = Native Sham injection, S + P = GAG depleted + P11-4-CS 10 mgml-1 injected, S + CS = GAG depleted + CS 
only injected, S + P11-4 30 = GAG depleted + P11-4 30 mgml-1 only, S + P11-4-CS 30 = GAG depleted + P11-4-CS 
30 mgml-1, S + P11-8-CS 30 = GAG depleted + P11-8-CS 30 mgml-1. 
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The normalised deformation for the healthy tissue showed that there was no significant 
difference between the medial and lateral condyles, 7 ± 1% and 8 ± 2% respectively which was 
also observed for the GAG-depleted samples, 32 ± 2% and 35 ± 3% respectively. The treated 
samples though, showed significant differences (P < 0.05) in certain groups. The peptide: 
conjugate (10 mgml-1) injected samples, the average deformation observed in the medial 
samples was ~24 ± 2% whilst in the lateral samples it was ~44 ± 11 %. The huge variation in 
deformation was partially attributed to the larger variation in cartilage thickness observed in 
lateral samples.  
The amount of deformation for each sample indicated the presence of either peptide alone or 
the peptide: conjugate systems decreased the amount of deformation. The recovery of 
resistance to deformation, i.e. the percentage reduction in deformation compared to the SDS 
GAG depleted sample as a maximum and the native sample as the benchmark minimum, was 
calculated and the results are illustrated in Table 5.4. 
Medial Sample Deformation Restoration (%) Entry Number 
SDS + P11-4-CS M 46.7 ± 1.5 1M 
SDS + CS M 29.3 ± 6.7 2M 
SDS + P11-4 30 mg ml-1 M 45.7 ± 3.9 3M 
SDS + P11-4-CS 30 mg 
ml-1 M 
59.3 ± 3.4 4M 
SDS + P11-8-CS 30 mg 
ml-1 M 
80.3 ± 0.9 5M 
 
Lateral Sample Deformation Restoration (%) Entry Number 
SDS + P11-4-CS L -4.3 ± 11.3 1L 
SDS + CS L 39.3 ± 6.8 2L 
SDS  + P11-4 30 mg ml-1 L 58.4 ± 2.3 3L 
SDS + P11-4-CS 30 mg 
ml-1 L 
68.2 ± 2.5 4L 
SDS + P11-8-CS 30 mg 
ml-1 L 
69.7 ± 2.5 5L 
Table 5.4: Summary of restoration of deformation resistance in various controls groups. The data shown is split 
into two data sets – medial (top) and lateral (bottom)where the data is the mean restoration (n=3) ± 95 % CL. 
(p<0.05, student T-test) 
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In both the medial and lateral samples, the presence of chondroitin sulfate (Table 5.4, Entry 2M 
and 2L) alone gave some restoration but when covalently bound to either P11-4 (Table 5.4, Entry 
1M, 4M, and 4L) or P11-8 (Table 5.4, Entry 5M and 5L) the amount of restoration was significantly 
higher, except in the case of P11-4-CS at 10 mg ml-1 (Table 5.4, Entry 1L) when injected into the 
lateral sample which showed no significant difference compared to the SDS treated degenerated 
sample. When the concentration of the base peptide was increased from 10 to 30 mg ml-1, a 
comparable, non-significantly different, rate of restoration was noticed between the P11-4 only 
30 mg ml-1 (Table 5.4, Entry 3M and 3L) and P11-4-CS 10 mg ml-1 sample (Table 5.4, Entry 1M and 
1L). But between the covalently bound P11-4-CS and P11-8-CS samples there was significantly 
greater restoration of deformation resistance in both the medial and lateral samples. P11-8-CS 
30 mg ml-1 (Table 5.4, Entry 5M and 5L) performed ~20% better at reducing the amount of 
deformation in the medial samples compared to P11-4-CS 30 mg ml-1 (Table 5.4, Entry 4M and 
14), whilst in the lateral samples there was no observable difference. 
When the amount of deformation was converted to the restoration based on maximum 
deformation being the measured value for SDS samples then the percentages changed. In the 
6 mM P11-4: P11-4-CS (Table 5.4, Entry 1M) in the medial condyle, the percentage restoration 
was not significantly different from the 18 mM P11-4 only (Table 5.4, Entry 3M) percentage 
indicating the presence of the CS covalently bound to the peptide matrix had an equal effect as 
the stronger peptide only gel but which lacked the osmotic effect from the inclusion of CS. When 
the concentration was increased for the conjugate sample - P11-4: P11-4-CS at 18 mM (Table 5.4, 
Entry 3M and 3L), then the percentage restoration significantly increased, with an average 
restoration of 63% across the whole knee (average between medial and lateral condyles) 
indicating the stronger gel network as well as the presence of CS within the network had a 
significant benefit on restoring the biomechanical properties of the tissue. However, the biggest 
percentage restoration was from the positively charged peptide - P11-8: P11-8-CS at 18 mM (Table 
5.4, Entry 5M and 5L), where an average percentage restoration of 75 % was observed, which 
was significantly higher than that for the P11-4 equivalent. This result was not expected based 
on the rheological data presented in Chapter 4, but one hypothesis for this result was that due 
to being a slower self-assembling system and “weaker” gel, then the monomeric gel was able to 
penetrate further into the tissue through an increased lifetime before fully self-assembling to 
form a gel in situ. 
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5.3 Discussion and conclusion 
5.3.1 GAG depleted cartilage model 
A GAG depleted porcine cartilage model was produced using 0.1 % SDS followed by PBS washes 
as previously developed by a PhD student – Andres Barco. The model was validated through 
histological and immunohistochemical staining as well as photometric assays which showed, the 
near-complete removal of GAGs in from the depleted cartilage tissue. The chosen model was 
aimed at cartilage which had damage equivalent to Grade 1 lesions (as rated by ICRS score) 
where a progressive loss of GAGs has started. This was based on the opinion of the researcher 
that this was the initial trigger point of degradation of cartilage towards severe osteoarthritis 
(Matzat et al., 2013, Felson and Hodgson, 2014), rather than trying to mimic the hypothesis that 
osteoarthritic cartilage formed through damage to the collagen network throughout the 
extracellular matrix of cartilage (Hosseini et al., 2013, Madry et al., 2016). However the level of 
GAG loss in these early stage lesions did not have detectable changes in terms of biomechanics 
when tested with the indentation methodologies so the severely GAG depleted cartilage model 
allowed changes in biomechanics following the treatment with SAP-GAG conjugates to be 
detectable and quantifiable.   
When each sample was analysed by a DMMB photometric assay, the measured GAG loss was ~ 
80% which, whilst less than the visual estimation from the images, matched reported estimates 
of severe osteoarthritic cartilage by various groups. In order to confirm that all the SDS (which 
was used to deplete GAGs in the cartilage and may prevent the self-assembly of functionalised 
peptides in situ) had been removed the level of residual SDS remaining in the cartilage after GAG 
depletion step was determined.  It was confirmed that that over 99% of the SDS had been 
removed by the PBS washes used in the model generation and that any residual low levels of 
SDS which may remain within the tissue does not disrupt self-assembly of the peptide. All of 
these results reinforced that the model was suitable to be taken forward for mechanical testing. 
5.3.3 Confirming self-assembly within the tissue 
The development of a successful method to show, with good accuracy, whether or not the self-
assembling peptides and conjugates actually succeeding in self-assembling within the tissue 
following injection was an important milestone for the project. This method was not only useful 
for this area of research   into cartilage tissue but could be also be employed for other tissue 
types where self-assembling peptides have used such as hard tissue like bone or soft tissue such 
as vascular samples. 
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The cartilage injected with fluorescein only, or fluorescein covalently bound to chondroitin 
sulphate showed free diffusing fluorophore when a specific area of cartilage was photo 
bleached. In contrast, the cartilage injected with fluorescein doped peptide or peptide-CS 
conjugate showed no recovery of fluorescence in the positive control bleached areas. This 
indicated that the fluorophore was entrapped within the peptide matrix which could only be 
possible when the peptide had formed a self-supporting hydrogel within the tissue, thus 
providing indication that the peptide hydrogels had self-assembled within the GAG depleted 
cartilage following injection in a monomeric solution. 
5.3.2 Mechanical testing of GAG depleted tissue model 
Indentation testing indicated that the SDS treatment caused significant (p<0.05) 500 fold 
increase in the percent deformation of cartilage compared to the native samples.  The effect of 
simply piercing the cartilage with a 30 G needle showed no significant increase in indentation 
compared to the healthy control, yet when the native tissue was injected with a simple PBS 
solution, a significant increase in deformation was observed. This may have been due to a 
disruption of the ionic environment inside the cartilage as well as causing a change in the 
concentration of GAGs within the injected area. When the concentration of GAGs within the 
cartilage is altered, there are reported observations of detrimental changes in biomechanical 
properties (Zhu et al., 1993, Jin and Grodzinsky, 2001, Partington et al., 2013, Griffin et al., 2014). 
Injection of CS only into the model produced a decreased deformation but it was not significant 
although (p<0.05) with more sample repeats the significance of the difference may have been 
confirmed, When any peptide sample was injected at either ~6 or 18 mM, (with the exception 
of one sample – P11-4: P11-4-CS 6 mM in the lateral condyle), the sample showed significantly 
reduced percent deformation of the SDS treated tissue. The data from the indentation testing 
indicated that the conjugation of CS to the peptide produced increased restoration of 
deformation resistance to the tissue following severe depletion of GAGs from within the tissue. 
This was in comparison to the peptide and CS only samples which showed a remarkably lower 
restoration percentage indicating that covalent linkage of the CS to the self-assembling matrix 
produces a significant beneficial effect. A small difference was noticed between the negatively 
charged P11-4 and positively charged P11-8 gel samples. As mentioned previously the rheological 
data presented in chapter 4 predicted that the P11-4-CS samples would produce the greater 
restoration but from the indentation data it was in fact the P11-8-CS samples that produced the 
greatest restoration.  
In the P11-4 system, the P11-4-CS at 18 mM concentration at 32:1 molar ratio in 130 mM Na+ 
buffer showed the greatest restoration within that series and in the P11-8 system it was P11-8-CS 
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at 18 mM concentration at 32:1 molar ratio in 130 mM Na+ buffer which showed the greatest 
restoration not just within the P11-8 series but also the whole experiment. These results have 
shown for the first time significant (p<0.05) restoration of the biomechanical properties of 
porcine cartilage which was a model for severe GAG depleted osteoarthritic cartilage.  
5.3.4 Conclusion 
In this chapter, a GAG depleted porcine cartilage model was successfully reproduced and 
validated. The model was used to assess the efficacy of CS conjugated self-assembling peptide 
gels to restore the resistance to deformation of articular cartilage. P11-8-CS at 18 mM was the 
most successful peptide at restoring the resistance to deformation of cartilage following 
injection. FRAP showed this effect was indeed related to the in situ self-assembly of the peptide 
rather than through some unknown interaction between the tissue matrix, hydrogel matrix and 
CS polymer. This data suggests that this could be taken forward as a clinical product used during 
arthroscopy to restore the mechanical behaviour of early OA GAG depleted cartilage.  
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Chapter 6 
Discussion, future work and 
conclusion 
6.1 General Discussion 
The hypothesis upon which this study was based was that stable restoration of GAGs into disease 
depleted tissue would restore its biomechanical properties; however previously reported data 
suggested that simply injecting a CS solution into cartilage tissue did not show a significant effect 
probably because the CS is simply pushed out of the material under load. However, it was 
postulated that if the CS could be entrapped within a matrix that ensured the CS would not be 
displaced when the tissue was subjected to physiological loading. The beneficial effects of GAG 
replacement could still be realised. The idea to entrap the CS within a self-assembling peptide 
matrix meant that the CS could be introduced within a monomeric peptide solution to achieve 
penetration of the tissue following injection, however simply suspending the CS within the 
matrix may not be sufficient to entrap the CS following loading. Instead a system was designed 
which would covalently link the CS to the self-assembling peptide  such that an aggrecan like 
structure would be formed upon self-assembly that could potentially entrap the CS within the 
matrix in a more permanent manner and prevent any displacement following loading of the 
tissue as observed in native undamaged cartilage tissue. 
The project was divided into three areas as represented by the three results chapters – 1) 
synthesis of a self-assembling peptide-CS conjugate covalently linked through a triazole motif 
created using click chemistry, 2) evaluation  of the self-assembling properties of hydrogels 
composed of varying degrees of doping of base self-assembling peptide with the peptide-CS 
conjugates and subsequent  selection of  the most appropriate conditions which gave the 
strongest hydrogels to take forward to further testing ex vivo and 3) evaluation the 
biomechanics of a GAG depleted early stage OA porcine cartilage model and determination of 
whether injecting the peptide-CS doped hydrogels had an effect on restoring the resistance to 
deformation of the cartilage tissue. In the synthetic chapter, the issues encountered came from 
both the propensity of the self-assembling peptide to aggregate whilst still bound to the resin 
or during purification which had to be solved to enable sufficient material to be produced.  The 
polydispersity and molecular weight of the CS as well as the regioselective approach to 
functionalising the CS by reductively aminating the reducing end of the polysaccharide also led 
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to significant synthetic and analytical challenges. The number of amino acid residues in the self-
assembling peptide would have usually entailed an easy synthesis for a relatively small peptide 
but the inherent nature to self-assembly meant that while the synthesis itself was difficult only 
in terms of ensuring the correct resin and loading/coupling conditions were employed to achieve 
the highest possible yield, the purification was the main issue to overcome. The difficulty arose 
from the issues with solubility of the self-assembling peptide following cleavage from the resin 
and lyophilisation. In order to purify the crude mixture, ideally a small volume with the highest 
concentration possible would be employed but the self-assembling peptides aggregated and 
precipitated from solution due to the high local concentration. The use of pH switching the crude 
mixture as well as addition of DMSO to ensure the peptides stayed in a monomeric state meant 
that dissolution could be achieved in a reasonable volume but once loaded and run through a 
reverse phase column the peptides then had nucleation sites to aggregate upon on the C18 
functionalised silica within either the HPLC or Biotage columns (Orbach, 2009, Boyle and 
Woolfson, 2011, Boyle and Woolfson, 2012). Again pH switching the water and acetonitrile used 
to carrying out the purification meant that the intrinsic nature of the self-assembling peptides 
to aggregate was overcome sufficiently to actually purify the crude mixtures, but the problem 
then lay with the final yields which were not high enough for the intended future experiments 
(Cui, 2010a, Stupp, 2010). This meant the decision to outsource the synthesis to Cambridge 
Bioscience was taken which ensured a sufficient amount of azido-P11-4/8 was obtained to carry 
out the click reaction at scales necessary to produce enough material to carry out the self-
assembling studies reported in Chapter 4 and the biomechanical studies reported in Chapter 5. 
Click chemistry has been employed to selective conjugate small chemical probes or molecules 
to large biomolecules on a cells surface (Kolb et al., 2001, Binder and Sachsenhofer, 2007, 
Uttamapinant et al., 2012). However the relatively small functional alkyne group on the CS 
fragment combined with the azide group on the self-assembling peptide fragment, which could 
potentially be hidden within the self-assembled structures, meant that the rate of reaction was 
impeded greatly thus the need for robust click reaction conditions was required. Hence CuAAC 
was selected rather than a metal free approach such as SPAAC (Elchinger et al., 2011). The 
relative size and natural origin of the CS, which again was due to the impossibility of synthesizing 
a CS polymer in the lab, meant that characterising the products of these reactions was difficult. 
The random sulfation  along with the polydispersity of the CS also complicated issues as 
techniques such as ion exchange chromatography would have potentially led to complex 
purification mixtures, thus also making analysis via this method potentially difficult as well 
(Cumpstey, 2013, Elchinger et al., 2011). The characteristic proton produced following CuAAC 
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reactions was identifiable in 1H NMR following suppression of the water and hydroxyl signals of 
the CS, which in conjunction with SEC-MALLS to measure the relatively small change in molecular 
weight of the CS following successful conjugation meant the reaction and production of a self-
assembling peptide–CS conjugate could be demonstrated. (Cumpstey, 2013) 
The successful production of the CS-peptide conjugate was further reinforced from the results 
of the self-assembly studies using this material where changes in morphology and rheological 
properties of the resulting gels were observed. The introduction of covalently linked CS into the 
self-assembling peptide fibrillar matrix of the negatively charged P11-4 peptide system caused a 
significant increase in fibrillar length and width compared to simply suspending the CS within 
the peptide matrix in a non-covalent fashion or using undoped peptide. However no significant 
change was observed for the positively charged P11-8 peptide system. These observations could 
be explained by the electrostatic repulsion between the sulfate and glucuronic acids groups on 
the CS and the net negative charge on the P11-4 peptide leading to less steric hindrance during 
self-assembly which meant the peptide could integrate into the base fibrillar structure more 
successfully than the corresponding P11-8 system where electrostatic attraction between the 
positively charged peptide and the poly-anionic CS chain could have led to inhibitory interaction 
during self-assembly leading to no significant change in fibrillar length and width compared to 
the other controls. As mentioned in Chapter 4, the effect of CS on fibril formation has been 
studied but not in the field of tissue engineering but rather amyloid research due to the known 
propensity of GAGs to promote self-assembly of naturally occurring peptides involved in 
conditions such as Alzheimer’s disease (Fraser et al., 1992, McLaurin et al., 1999).  
The incorporation of CS into hydrogels has been previously studied but rather than incorporated 
into reversible systems such as the one reported in this study, biopolymers such as chitosan or 
gelatin and other GAGs such as hyaluronic acid (Tan et al., 2009, Hu, 2011, Li et al., 2016) or 
synthetic polymers like PLLA or PCL (Pal et al., 2009, Zhao et al., 2013, Eslahi et al., 2016) have 
been investigated. These hydrogels have mainly been employed as scaffolds for cell-based 
therapies rather than structural supports for cartilage tissue. These routes employed the side 
chains of the polysaccharides rather than the reducing end of the polymer to form linkage sites 
for permanent cross-linking of the polymers to occur, thus forming permanent hydrogels, rather 
than reversible ones such as the ones used in this study. This design meant that non-selective 
functionalisation occurred meaning no control over the nanostructures formed was achievable. 
In contrast in this study where the nanostructure is more tightly controlled and is based around 
forming an aggrecan-like structure.  
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As mentioned previously, studies have been performed that involved injecting a CS solution into 
osteoarthritic cartilage with the aim to either 1) restore the biomechanics and osmotic gradient 
within the tissue (Marshall, 2000, Brief et al., 2001, Oegema et al., 2002, Van Blitterswijk et al., 
2003, Kapoor et al., 2016) or 2) act as a lubricant during articulation (Creamer et al., 1994, Basalo 
et al., 2007b, Ayhan et al., 2014). The issue with both of these hypotheses was the temporary 
nature of the treatment in terms of clinical applicability. The restoration of the biomechanics 
and osmotic gradient within the tissue through simply injecting the CS into the tissue is a 
temporary solution due to the lack of permanent fixation of the CS within the tissue (Bali, 2001). 
During articulation of the joint, fluid motion throughout the tissue would cause movement of 
the CS with the potential expulsion of the CS when the tissue is put under physiological loads 
which are inherently variable. Studies have shown, as mentioned in Chapter 1, that CS is involved 
in the lubrication of articular joints during motion but other components have also been shown 
to be involved and the overall effect from CS injection was not significant compared to the effect 
of other components (Basalo et al., 2007b, Katta et al., 2009). This raises the question whether 
it is a single component or the cumulative effect of various components that are involved in 
lubricating the joint during articulation. However, the results from this study have shown that 
when the CS was incorporated into a hydrogel matrix, formed through the spontaneous 
assembly of peptide chains, in a covalently linked manner, a restoration of the inherent 
resistance to deformation of GAG depleted cartilage approaching 75 % in one combination. This 
approach differs from other techniques showing similar levels of restoration in that it involves 
the simple injection of a solution under physiological conditions in situ. Other techniques include 
surgical methods, which are damage limitation attempts following the already onset of 
osteoarthritic damage to the articular cartilage (Sarzi-Puttini et al., 2005, Perera et al., 2012, 
Thiede et al., 2012, Makris et al., 2015); stem cell based methods which while having shown 
promise in recent years, complete control of the differentiation of stem cells into the 
appropriate cell type and encourage the correct production of the complex structures which 
cartilage contains has still not been achieved to a level to overcome the use of surgical methods. 
The results reported from this study highlight a potentially cost effective, easy to administer, 
minimally invasive method that could prevent the onset or further degradation of osteoarthritis 
within the cartilage tissue. This study is also the first reported attempt at synthesizing a peptide-
CS conjugate which has then been studied to evaluate the best candidate to take forward to ex 
vivo testing using an osteoarthritic cartilage model and the effects the corresponding hydrogels 
had on the biomechanics of the tissue.  
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6.2 Detailed approach to future work 
The multi-disciplinary nature and requirement for ex vivo testing during this project meant that 
many questions remained uninvestigated. This allows future work to be potentially carried out 
on this research in terms of understanding the basic science behind the peptide-GAG interaction 
more specifically to gain an insight into what about the peptide-GAG conjugate causes the 
changes in morphology and increased gel strength of the hydrogels. Further biocompatibility 
studies need to be carried out to confirm unequivocally whether any aspect of the peptide-GAG 
conjugate synthesis is indeed cytotoxic through carrying out a contact cytotoxicity assay using 
mammalian cell lines as used in the extract cytotoxicity assay reported in this study.  Other than 
creep indentation and needle indentation testing, friction testing should be carried out to 
investigate whether the incorporation of the peptide-CS conjugate reduces the friction 
coefficient as reported previously when CS is simply injected into the cartilage tissue as an 
aqueous solution (Bell, 2006, Katta et al., 2009). A full assessment of the dispersion and 
penetration of the peptide-CS conjugate prior to self-assembly within the tissue needs to be 
carried out utilising confocal microscopy to see whether the monomeric solution remains 
monomeric for a sufficient timescale to penetration into the deep zone of the cartilage tissue. Z 
stack imagining of the injected tissue should enable this assessment of the penetration and 
dispersion following some optimisation of the process. The intended structure of the fibrillar 
assembly after incorporation of the peptide-CS conjugate into a hydrogel was that of native 
aggrecan found within cartilage tissue. The techniques used in this study did not have sufficient 
resolution to visualise individual CS chains, but employing atomic force microscopy would give 
an acceptable resolution to hopefully image individual CS chains and confirm whether the 
assembly resembles native aggrecan or some other structure.  
6.2.1 Effect of peptide-GAG interaction on self-assembly 
Investigating what about the structure of CS causes accelerated fibrillar growth of the P11-X 
series of peptides would be required to fully understand the interaction the hydrogels is having 
within the tissue upon injection. The amyloid-like promotion of fibril growth as well as increased 
gel properties needs to be investigated in terms of whether the effect is based on concentration 
or length of CS- is there a specific number of subunits of CS that promote the self-assembly or a 
combination of the length and concentration? This could be achieved through digesting the CS 
using chondroitinase in a controlled fashion to obtain smaller repeating units of the CS 
disaccharide and using different concentrations of each subunit, measure the rate of self-
assembly, morphology of fibrils produced and the gel properties of the formed hydrogels.   
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6.2.2 Contact cytotoxicty of peptide-GAG conjugate 
Whilst the cytotoxicity of the base peptides have been studied previously in house (Maude et 
al., 2011), and the cytotoxicity of residual copper resulting from the click reactions used within 
this study has been investigated in this project, whether the peptide-GAG conjugates are 
cytotoxic were not investigated within this study so a contact cytotoxicity assay would need to 
be carried out to confirm the conjugate did not impede cell growth or leeched cytotoxic 
molecules following self-assembly. The same cell lines as used in the extract cytotoxicity test 
reported in this study – BHK and L929 cell lines, a hydrogel would be formed and visual 
observation of whether the cells grew up to and on to the hydrogel or an exclusion zone formed 
around the hydrogel indicating cell death as well as potentially using an ATP-lite® assay to 
quantitatively measure the number of live cells within the well following incubation of the cells 
with the hydrogels for 48 h.  
6.2.3 Tribological testing 
Friction based testing would involves measuring the friction coefficient of a tissue sample by 
means of using a tribometer where the friction coefficient is measured when the tissue is slid 
across a surface. The friction coefficient of a tissue sample is specific to the composition and 
makeup of the tissue along with the intrinsic lubrication mechanism that lowers the friction 
found within the native environment of the tissue. The measurement of this friction coefficient 
would evaluate whether the incorporation of CS into the cartilage tissue caused any change in 
friction coefficient when entrapped, also whether any CS leaked over time modifying the friction 
coefficient.  
6.2.4 Analysis of peptide-GAG conjugate penetration within cartilage tissue 
Confirmation of whether the hydrogels actually self-assembled within the cartilage tissue was 
achieved using FRAP experiments through confocal microscopy, the amount of penetration 
achieved by the hydrogel when in a monomeric state prior to self-assembly however was not 
confirmed due to the difficulty in obtaining reliable and full depth z-stack images from confocal 
microscopy following harvest of the cartilage from the condyles after injection. Simply 
optimising the harvesting and z-stack imaging of the tissue would allow confirmation of the 
levels of penetration achieved following injection.  
6.2.5 Investigating the structure of the peptide-GAG conjugate upon self-assembly 
The intended structure of the peptide-GAG conjugate hydrogels was to resemble that of the 
aggrecan molecule found within cartilage naturally. TEM did not give sufficient resolution to 
visualise the CS chains in a brush-like arrangement when incorporated into the fibrillar network. 
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Atomic force microscopy (AFM) would give the required resolution to visual the CS chains, as 
native aggrecan has been visualised previously using AFM, but a functionalised mica surface was 
required to achieve this imagining. The investigation, optimisation and utilisation of a 
functionalised mica surface for the peptide-CS conjugate hydrogels and using either contact or 
tapping mode to investigate whether or not the conjugate does in fact produce an aggrecan-like 
structure when the CS chains do not collapse into the fibrillar network. 
6.3 Conclusion 
In conclusion, this study showed the successful restoration of certain biomechanical properties 
within an animal model which represented an early OA state. The study also represented the 
first successful example of a synthesized self-assembling peptide-GAG conjugate utilising 
reductive amination of the reducing end of the GAG and CuAAC to covalently link the peptide 
and GAG together in a manner that did not disrupt the self-assembly of the base peptide. The 
challenges encountered in achieving this were the disparity between classic methods of 
purification for peptide synthesis and that employed for polysaccharide synthesis, which was 
further compounded by the propensity of the peptides to self-assemble making all purification 
steps difficult. The incorporation of the conjugate into the matrix demonstrated significant 
increase in the material properties of the hydrogel in terms of strength, where in certain 
compositions the observed material properties were more commonly observed in non-
reversible covalently cross-linked polymer systems – in the order of MPa rather than kPa. The 
injection of these hydrogels in a monomeric manner into GAG depleted tissue, along with self-
assembly in situ showed restoration of resistance to deformation within the tissue – up to 80%, 
which has not been observed previously with a reversible soft matter system. The 
characterisation of the interaction between the hydrogel and the cartilage tissue needs to be 
further investigated however, as well as a more detailed analysis of the interaction between the 
base peptide and the peptide-CS conjugate in terms of the effect the permanent incorporation 
has on the self-assembling properties of the peptide. The future work aside, this study 
demonstrated that the hypothesis to permanently incorporate the CS within the GAG depleted 
tissue did restore the biomechanics of the tissue, highlighting that the entrapment of CS within 
the cartilage matrix using self-assembling peptides as a delivery and support system has the 
potential for an early stage intervention treatment for osteoarthritic cartilage. The success of 
this work overcame the challenge of delivering CS into the matrix directly and being able to 
enable the matrix to retain the CS during a loading cycle. The restoration reported in this study 
indicates there could be significant clinical interest for an intervention as effective, yet minimally 
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invasive as a simple injection into deteriorated articular cartilage. The advantage this method 
has over current treatments is the minimal recovery time along with potentially minimal periods 
of inactivity as well as the ability to repeat the treatment in the future countless times.  
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Chapter 8 
Appendices 
Appendix 1  
Table 1: Equipment 
Equipment Model Supplier 
Automatic Pipettes Gilson P2-P1000 Anachem Ltd 
Balances (Accuracy: 
0.01g/0.0001g) 
GR200/GX2000 Jencons PLC 
Bench top centrifuge 5415R Eppendorf 
Class II safety cabinet Heraeus 85 Kendro 
CO2 Incubator MCO-20AIC SANYO Biomedical Europe 
BV 
Cryostat CM3050S Leica 
Flame atomic absorption  
spectrophotometer 
Aanalyst 200 Perkin Elmer 
FT-IR spectrometer Spectrum 100S Perkin Elmer 
Freeze drier Modulyod-230 
Powerdry LL1500 
Benchtop BTP 82L 
Thermo Savant 
Thermo Heto 
VirTis 
Freezer (-20 °C) Electrolux 3000 Jencons PLC 
Fridge Electrolux 
ER8817C 
Jencons PLC 
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Fume cupboard/Fume hood - Whiteley 
Histology cassettes CMB-160-030R Thermo Fisher Scientific Ltd 
Histology water bath MH8515 Barnstead 
Hot plate E18.1 hotplate Raymond A Lamb 
Hot wax dispenser E66 was dispenser Raymond A Lamb 
Incubator Heraeus Jencons PLC 
Instron material testing 
machine 
3365 Instron 
Inverted confocal microscope LSM 510 META Zeiss 
Linear variable differential 
transformer (LVDT) 
RDP DS-200H Electrosence 
Liquid chromatography – mass 
spectrometer 
HCT-Ultra Bruker 
Liquid nitrogen Dewar BIO65 Jencons PLC 
Luminescence counter and 
liquid scintillation counter 
Packard TopCount 
NX 
Perkin Elmer 
Magnetic stirrer Stuart SB161 Scientific Laboratory 
Systems Ltd 
Mass Spectrometer MaXis Impact  Bruker 
Micro-plate 
spectrophotometer 
Multiscan 
Spectrum 1500 
Chameleon V 
Thermo Scientific 
Hidex 
Microscope (Inverted) Olympus IX71 Microscopes, Medical Diagnostics 
Systems and Olympus Patient 
Systems 
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Ltd 
Microscope (upright) Olympus BX51 Microscopes, Medical Diagnostics 
Systems and Olympus Patient 
Systems 
Ltd 
Microtome RM2125 RTR Leica Microsystems 
Neubauer 
haemocytometer 
MNK-420-010N Fischer scientific 
NMR spectrometer Avance 400 
Avance 500 
Bruker 
Bruker 
Orbital Shaker IKA KS130 basic Jencons PLC 
Oven (hot air)   
pH meter Jenway 3010 
Docu-pH 
CD720 
VWR International 
Satorus 
WPA 
Piezo-electric force  
transformer 
060-1896-02 Electrosence 
Pipette boy Acu Integra biosciences 
Plate Shaker IKA KS130 basic Jencons PLC 
Rheometer Pro Rheometer Malvern 
Slide holder E102 Raymond A Lamb 
Transmission electron 
microscope 
1400 JEOL 
Tissue Processor TP11020 Leica Microsystems 
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Vortexer Topmix FB15024 Fisher Scientific 
Water Bath Grant Jencons PLC 
Water purifier Option 7 ELGA 
Wax oven Windsor E18/31 Scientific Laboratory 
Supplies 
 
Table 2: Chemical Reagents 
Chemical/Reagent Cat No. Supplier 
1,2-Ethanediol 324558 Sigma-Aldrich 
1,9 dimethylene blue 34108-8 Sigma-Aldrich 
4-ethynylbenzyl alcohol 519235 Sigma-Aldrich 
6-Bromohexanoic acid 150452 Sigma-Aldrich 
Acetic acid (glacial) A/0400/PB17 Fisher Scientific 
Aniline 242284 Sigma-Aldrich 
Anisole 296295 Sigma-Aldrich 
ATPLite-M assay 6016941 Perkin-Elmer 
Chondroitin sulfate from shark 
cartilage 
C4384 Sigma-Aldrich 
Chondroitin sulphate B C-3788 Sigma-Aldrich 
DIAD 225541 Sigma-Aldrich 
Diaminoethanetetra-acetic acid 
disodium salt (EDTA) 
E/P140/65 Fisher Scientific Ltd 
Dimethyl sulfoxide (DMSO) D26650 Sigma-Aldrich 
Di-sodium hydrogen orthophosphate 
(anhydrous) 
1.06586.0500 Merck Millipore 
DPX mountant RRSP29 Atom Scientific 
Dulbecco’s minimal essential media 
(DMEM) 
D6546 Sigma-Aldrich 
Dulbecco’s PBS tablets BR0014 Oxoid 
Eosin Y 1.09844.1000 Merck Millipore 
Ethanol 10107 VWR International 
Ethanol E/0555DF/25 Fisher Scientific 
Fast green F7258 Sigma-Aldrich 
Fmoc-Arg(Pbf)-OH 852067 Novabiochem 
Fmoc-Gln(Trt)-OH 852045 
47674 
Novabiochem 
Sigma-Aldrich 
Fmoc-Glu(OtBu)-OH 852009 Novabiochem 
Fmoc-Lys(Mca)-OH 852095 Novabiochem 
Fmoc-NH-PEG-COOH 851037 Novabiochem 
Fmoc-Orn(Boc)-OH 852015 Novabiochem 
Fmoc-Phe-OH 852016 Novabiochem 
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Fmoc-Trp(Boc)-OH 852050 Novabiochem 
Foetal bovine serum (FBS) EU-000 Sera Lab 
Formic acid F-4166 Sigma-Aldrich 
Glasgow’s minimal essential media 
(GMEM) 
G5154 Sigma-Aldrich 
HCTU 04936 Sigma-Aldrich 
Hydrazine monohydrate 207942 Sigma-Aldrich 
Hydrochloric Acid H/1200/PB17 Fisher Scientific 
Hydrochloric acid (6 M) 2611.500 VWR International 
L-cycteine hydrochloride anhydrous C1276 Sigma-Aldrich 
L-Glutamine (200mM) G7513 Sigma-Aldrich 
Mayer’s Haematoxylin 
(Mayer's Haemalum) 
RRSP60 Atom Scientific 
N,N’-Diisopropylcarbodiimide D125407 Sigma-Aldrich 
N,N-Diisopropylethylamine 387649 Sigma-Aldrich 
N-hydroxy phthalimide H53704 Sigma-Aldrich 
NovaSyn® TG Sieber Resin 855013 Novabiochem 
Oxyma Pure 851086 Novabiochem 
P11-4-PEG-Hex-N3 - Cambridge Bioscience 
P11-8-PEG-Hex-N3 - Cambridge Bioscience 
Papain A3824,0100 Applichem 
PBS without Ca2/Mg2+ D8537 Sigma-Aldrich 
Penicillin (5000U/ml) / Streptomycin (5 
mg ml-1) 
P4458 Sigma-Aldrich 
Phenol 185450 Sigma-Aldrich 
Piperidine 411027 Sigma-Aldrich 
p-phenylenediamine P6001 Sigma-Aldrich 
Rink Amide Novagel™ Resin 855031 Novabiochem 
Rink Amide PEGA Resin 855016 Novabiochem 
Safranin O S305-2 or 
S305-3 
Raymond Lamb 
Scott’s tap water substitute 10x 
concentrate 
RRSP190 Atom Scientific 
Sodium Azide S2002 Sigma-Aldrich 
Sodium cyanoborohydride 156159 Sigma-Aldrich 
Sodium di-hydrogen orthophosphate 102454R VWR International 
Sodium formate 30142LN VWR International 
Sodium hydroxide S/4920/53 Thermo Fisher Scientific 
Ltd 
Sodium hydroxide (6 M) 102525P VWR International 
TFA 808260 Novabiochem 
TIPS 233781 Sigma-Aldrich 
Tris(2-carboxyethyl)phosphine 
hydrochloride 
C4706 Sigma-Aldrich 
Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine 
678937 Sigma-Aldrich 
Trypsin/EDTA T3924 Sigma-Aldrich 
Tryptone phosphate broth (TPB) T8782 Sigma-Aldrich 
Weigert Haemotoxylin 
Solution A 
  Solution B 
RRSP72-D 
RRSP73-D 
Atom Scientific 
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Xylene GPS1001-G Atom Scientific 
 
Appendix 2:  Rheological data 
P11-4 only  
130 mM Na+ buffer 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.2% shear strains, where 
0.15% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 15443.1 ± 3104.3 Pa, G” – 1431.4 
± 330.1 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.1.  
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Fig A2.1: Rheological sweeps for P11-4 130 mM Na+. A) Amplitude sweep 0.01 – 100% shear strain at 1Hz B) 
Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.15% shear strain – all at 37°C. 
P11-4 + CS 
230 mM Na+ buffer 32:1 P11-4: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.2% shear strains, where 
0.15% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 19198.3 ± 627.7 Pa, G” – 1770.0 
± 212.2 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.2.  
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Fig A2.2: Rheological sweeps for P11-4 + CS 32:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.15% shear strain 
– all at 37°C. 
230 mM Na+ buffer 64:1 P11-4: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.1% shear strains, where 
0.08% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 7343.2 ± 1756.9 Pa, G” – 862.5 
± 220.3 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.3.  
 
 
229 
 
 
0.00 0.02 0.04 0.06 0.08 0.10 0.12
0
1000
2000
3000
4000
5000
6000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Complex shear strain(%)
0.00 0.02 0.04 0.06 0.08 0.10 0.12
1000
2000
3000
4000
5000
6000
7000
8000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Complex shear strain(%)
0 5 10 15 20
1000
2000
3000
4000
5000
6000
7000
8000
9000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Frequency (Hz)
 
Fig A2.3: Rheological sweeps for P11-4 + CS 64:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.08% shear strain 
– all at 37°C. 
130 mM Na+ buffer 32:1 P11-4: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.25% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 11579.8 ± 6312.3 Pa, G” – 1843.3 
± 977.7 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.4.  
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Fig A2.4: Rheological sweeps for P11-4 + CS 32:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.25% shear strain 
– all at 37°C. 
130 mM Na+ buffer 64:1 P11-4: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.2% shear strains, where 
0.15% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 5952.3 ± 3816.2 Pa, G” – 707.5 
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± 289.3 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.5.  
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Fig A2.5: Rheological sweeps for P11-4 + CS 64:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.15% shear strain 
– all at 37°C. 
P11-4 + P11-4-CS  
230 mM Na+ buffer 32:1 P11-4: P11-4-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.23% shear strain was selected at which to carry out the frequency sweep at. The frequency 
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sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 234824.4 ± 12606.0 Pa, G” – 
25902.4 ± 3046.1 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.6.  
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Fig A2.6: Rheological sweeps for P11-4 + P11-4-CS 32:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.23% shear 
strain – all at 37°C. 
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230 mM Na+ buffer 64:1 P11-4: P11-4-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.23% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 63075.6 ± 34272.5 Pa, G” – 
7636.0 ± 3983.0 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.7.  
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Fig A2.7: Rheological sweeps for P11-4 + P11-4-CS 64:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.23% shear 
strain – all at 37°C. 
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130 mM Na+ buffer 32:1 P11-4: P11-4-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.27% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 277475.6 ± 8105.0 Pa, G” – 
36057.8 ± 3189.8 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.8.  
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Fig A2.8: Rheological sweeps for P11-4 + P11-4-CS 32:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.27% shear 
strain – all at 37°C. 
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130 mM Na+ buffer 64:1 P11-4: P11-4-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.2% shear strains, where 
0.15% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 95031.8 ± 44844.4 Pa, G” – 
12235.9 ± 5083.4 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.9.  
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Fig A2.9: Rheological sweeps for P11-4 + P11-4-CS 64:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.15% shear 
strain – all at 37°C. 
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130 mM Na+ buffer P11-4 30 mg ml-1 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.27% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 143447.5 ± 21984.0 Pa, G” – 
20576.4 ± 2857.9 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.10. 
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Fig A2.10: Rheological sweeps for P11-4 130 mM Na+ at 30 mg ml-1. A) Amplitude sweep 0.01 – 100% shear strain at 
1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.27% shear strain – all at 
37°C. 
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130 mM Na+ buffer P11-4 + CS 30 mg ml-1  
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.28% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 207008.9 ± 13692.5 Pa, G” – 
20181.8 ± 2161.4 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.11. 
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Fig A2.11: Rheological sweeps for P11-4 + CS 32:1 molar ratio 130 mM Na+ at 30 mg ml-1. A) Amplitude sweep 0.01 – 
100% shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.28% 
shear strain – all at 37°C. 
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130 mM Na+ buffer P11-4 + P11-4-CS 32:1 30 mg ml-1  
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.31% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 434555.9 ± 51345.0 Pa, G” – 
58665.7 ± 10214.6 Pa. The data from each amplitude sweep and the average frequency sweep 
is shown in Fig A2.12. 
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Fig A2.12: Rheological sweeps for P11-4 + P11-4-CS 32:1 molar ratio 130 mM Na+ at 30 mg ml-1. A) Amplitude sweep 
0.01 – 100% shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 
0.31% shear strain – all at 37°C. 
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P11-8 only  
230 mM Na+ buffer 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.2% shear strains, where 
0.15% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 25161.6 ± 7358.7 Pa, G” – 2041.7 
± 670.5 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.13.  
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Fig A2.13: Rheological sweeps for P11-8 230 mM Na+. A) Amplitude sweep 0.01 – 100% shear strain at 1Hz B) 
Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.15% shear strain – all at 37°C. 
130 mM Na+ buffer 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.2% shear strains, where 
0.1% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 15443.1 ± 3104.3 Pa, G” – 1431.4 
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± 330.1 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.14.  
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Fig A2.14: Rheological sweeps for P11-8 130 mM Na+. A) Amplitude sweep 0.01 – 100% shear strain at 1Hz B) 
Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.1% shear strain – all at 37°C. 
P11-8 + CS 
230 mM Na+ buffer 32:1 P11-8: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.3% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 19198.3 ± 627.7 Pa, G” – 1770.0 
± 212.2 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.15.  
 
 
242 
 
 
0 5 10 15 20 25
0
50000
100000
150000
200000
250000
300000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Complex shear strain(%)
0.00 0.05 0.10 0.15 0.20 0.25
0
5000
10000
15000
20000
25000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Complex shear strain(%)
0 5 10 15 20
2000
4000
6000
8000
10000
12000
14000
16000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Frequency
 
Fig A2.15: Rheological sweeps for P11-8 + CS 32:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.3% shear strain 
– all at 37°C. 
230 mM Na+ buffer 64:1 P11-8: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.3% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 7343.2 ± 1756.9 Pa, G” – 862.5 
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± 220.3 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.16.  
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Fig A2.17: Rheological sweeps for P11-8 + CS 64:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.3% shear strain 
– all at 37°C. 
130 mM Na+ buffer 32:1 P11-8: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.3% shear strain was selected at which to carry out the frequency sweep at. The frequency 
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sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 11579.8 ± 6312.3 Pa, G” – 1843.3 
± 977.7 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.18.  
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Fig A2.18: Rheological sweeps for P11-8 + CS 32:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.3% shear strain 
– all at 37°C. 
130 mM Na+ buffer 64:1 P11-8: CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.3% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 5952.3 ± 3816.2 Pa, G” – 707.5 
± 289.3 Pa. The data from each amplitude sweep and the average frequency sweep is shown in 
Fig A2.19.  
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Fig A2.19: Rheological sweeps for P11-8 + CS 64:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% shear 
strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.15% shear strain 
– all at 37°C. 
P11-8 + P11-8-CS  
230 mM Na+ buffer 32:1 P11-8: P11-8-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.25% shear strains, where 
0.22% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 234824.4 ± 12606.0 Pa, G” – 
25902.4 ± 3046.1 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.20.  
 
 
246 
 
 
0.00 0.05 0.10 0.15 0.20 0.25
0
50000
100000
150000
200000
250000
300000
350000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
" 
(P
a
)
Complex shear strain(%)
0.00 0.05 0.10 0.15 0.20 0.25
0
100000
200000
300000
400000
500000
600000
700000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' 
G
" 
(P
a
)
Complex shear strain(%)
0 5 10 15 20
20000
40000
60000
80000
100000
120000
140000
160000
180000
 Shear modulus (elastic component)(Pa)
 Shear modulus (viscous component)(Pa)
G
' G
"(
P
a
)
Frequency
 
Fig A2.20: Rheological sweeps for P11-8 + P11-8-CS 32:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.22% shear 
strain – all at 37°C. 
230 mM Na+ buffer 64:1 P11-8: P11-8-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.25% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
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independent. The average moduli obtained was as follows: G’ – 63075.6 ± 34272.5 Pa, G” – 
7636.0 ± 3983.0 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.21.  
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Fig A2.21: Rheological sweeps for P11-8 + P11-8-CS 64:1 molar ratio 230 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.25% shear 
strain – all at 37°C. 
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130 mM Na+ buffer 32:1 P11-8: P11-8-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.24% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 277475.6 ± 8105.0 Pa, G” – 
36057.8 ± 3189.8 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.22.  
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Fig A2.22: Rheological sweeps for P11-8 + P11-8-CS 32:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.24% shear 
strain – all at 37°C. 
130 mM Na+ buffer 64:1 P11-8: P11-8-CS 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.3% shear strains, where 
0.24% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 95031.8 ± 44844.4 Pa, G” – 
12235.9 ± 5083.4 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.23.  
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Fig A2.23: Rheological sweeps for P11-8 + P11-8-CS 64:1 molar ratio 130 mM Na+. A) Amplitude sweep 0.01 – 100% 
shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.24% shear 
strain – all at 37°C. 
P11-8 130 mM 30 mg ml-1 
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.3% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 205046.7 ± 14572.2 Pa, G” – 
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23325.1 ± 1099.5 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.24. 
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Fig A2.24: Rheological sweeps for P11-8 130 mM Na+ 30 mg ml-1. A) Amplitude sweep 0.01 – 100% shear strain at 
1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.3% shear strain – all at 
37°C. 
P11-8 + CS 130 mM 30 mg ml-1  
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.4% shear strains, where 
0.35% shear strain was selected at which to carry out the frequency sweep at. The frequency 
sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
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independent. The average moduli obtained was as follows: G’ – 207813.3 ± 19964.5 Pa, G” – 
31477.3 ± 2257.0 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.25. 
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Fig A2.25: Rheological sweeps for P11-8 + CS 32:1 molar ratio 130 mM Na+ at 30 mg ml-1. A) Amplitude sweep 0.01 – 
100% shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 0.35% 
shear strain – all at 37°C. 
P11-8 + P11-8-CS 130 mM 30 mg ml-1  
The two amplitude sweeps indicated the LVER laid between 0.05 – 0.35% shear strains, where 
0.3% shear strain was selected at which to carry out the frequency sweep at. The frequency 
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sweep was carried out in triplicate to ensure the measured moduli was sample preparation 
independent. The average moduli obtained was as follows: G’ – 101644.4 ± 8543.0 Pa, G” – 
13542.7 ± 953.3 Pa. The data from each amplitude sweep and the average frequency sweep is 
shown in Fig A2.26. 
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Fig A2.26: Rheological sweeps for P11-8 + P11-8-CS 32:1 molar ratio 130 mM Na+ at 30 mg ml-1. A) Amplitude sweep 
0.01 – 100% shear strain at 1Hz B) Amplitude sweep 0.01 – 100% shear strain at 20Hz C) Frequency sweep 1-20Hz at 
0.3% shear strain – all at 37 
